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Plasmodium falciparum malaria kills almost half a million people every year, 
many of whom are children living in Africa. Rosetting is a pathological 
phenomenon which is associated with all types of severe malaria and occurs 
when two or more uninfected erythrocytes adhere to an erythrocyte infected 
with the mature form of the P. falciparum parasite. It is thought that these 
rosettes may cause obstruction of the microvasculature leading to the 
serious complications seen in severe malaria. Understanding the molecular 
mechanisms of rosetting could therefore lead to the development of new 
adjuvant therapies for severe disease. The overall aims of this work were to 
reassess the evidence for previously described host erythrocyte rosetting 
receptors, explore new methods of investigating rosetting mechanisms, 
including generating knockdown/out erythrocytes from CD34+ 
haematopoietic stem cells and immortalised erythroid precursors, and to 
identify novel rosetting receptors. 
 
This thesis begins by reassessing the evidence that the glycosaminoglycans, 
heparan sulfate (HS) and chondroitin sulfate (CS) are involved in rosetting. 
Contrary to previously published work, results from experiments using 
carefully validated enzymes to cleave HS or CS did not support the 
hypothesis that HS or CS are important host receptors for rosetting across 
the six P. falciparum strains tested. In addition, I found no evidence to 
suggest that HS or CS are actually present on mature erythrocytes, though 
HS was detected on early bone marrow-derived erythrocyte precursors. 
 
Secondly, I investigated the use of induced pluripotent stem cells (iPSC) and 
cells cultured from adult bone marrow CD34+ stem cells (cRBC) as a tool to 
produce knockdown erythrocytes using RNA inference techniques. The 
cRBC appeared, both morphologically and by receptor profiling with flow 
cytometry, to be a good approximation of reticulocytes. However, 
unexpectedly, the  cRBC derived erythrocytes were only able to form 
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rosettes with two of the four parasite lines tested. Further study into the 
subtle differences in receptor expression levels between cRBC and 
peripheral erythrocytes suggested that Band 3 could be a potential novel 
rosetting receptor. This hypothesis was supported by the results of rosette 
disruption experiments which showed that antibodies to the Wrightb antigen, 
carried on Band 3, were capable of significantly disrupting rosettes of mature 
erythrocytes across all parasites strains tested.  
 
Finally, I used a new, immortalised erythroid precursor line, the “EJ” cells, 
developed by the Duraisingh laboratory at Harvard university, to further 
investigate the role of Band 3 and the Wrightb antigen in rosetting. Band 3, 
glycophorin A (GYPA) and CR1 knockout EJ cells, created using 
CRISPR/Cas9 technology, were tested for rosetting ability with six parasite 
lines. As the Wrightb antigen requires both Band 3 and GYPA to properly 
form, both these knockout EJ cells also lacked Wrightb. Compared to 
wildtype EJ cells, GYPA and Band 3 knockout EJ cells had reduced 
rosetting. However, the rosetting rates were similar between the two 
knockout lines, suggesting that neither the presence of GYPA or Band 3 
alone can rescue the poor rosetting phenotype in the absence of Wrightb.  
 
In summary, I have found that while there is little evidence to support the 
involvement of HS or CS in rosetting, the Wrightb antigen carried on Band 3 
may be an important, strain-transcending rosetting receptor and could 
represent a useful therapeutic target to reduce rosetting. In addition, I have 
developed new techniques for investigating rosetting receptors using a novel 
erythroid precursor line. The EJ cells also have great potential for the 
development of a rosetting screen to identify other candidates to help reduce 




II. Lay abstract 
 
There are over 200 million cases of malaria every year and almost half a 
million deaths, most of which are in children living in Africa. While the 
majority of children who get malaria suffer a ‘flu-like’ illness from which they 
recover well, around one in ten will develop severe, life-threatening 
symptoms. It is therefore important to discover what is different about these 
severe cases compared to the uncomplicated ones. A particular feature 
which is seen more commonly in severe malaria is that when a red blood cell 
is infected with the malaria parasite, it develops sticky projections on the 
outside of the cell, which allow it to latch onto other red blood cells which 
have not yet been infected. This causes clumps of infected and uninfected 
cells to form and these clumps are called rosettes. Rosettes are thought to 
cause obstructions in the tiny blood vessels throughout the body, leading to 
the life-threatening symptoms of severe malaria. At present, none of the 
current medications used to treat malaria are able to break apart these 
rosettes and there is an urgent need to better understand how rosettes 
develop in order to design new treatments specifically for severe malaria.  
 
For my thesis, I was particularly interested in the tiny structures on the 
uninfected red blood cells that the parasite infected cells use to latch on. I 
began by studying two structures called heparan sulfate and chondroitin 
sulfate, which other researchers had suggested might be important. I found 
that removing these structures, with chemicals known as enzymes, made no 
difference to how well the red cells formed rosettes. I also found that the red 
blood cells which flow around our body probably do not have any heparan 
sulfate or chondroitin sulfate on their cell surface. This suggests that neither 
of these structures are important for rosetting. 
 
I then decided to develop another method for investigating which structures 
are important for rosetting, by generating ‘designer’ red blood cells, allowing 
me to choose which structures were present on the cell surface. To begin 
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with, I used cells from adults who had donated their bone marrow. 
Unexpectedly, I found that red blood cells grown from these cells did not form 
rosettes very well. By comparing them to ‘normal’ red blood cells, I realised 
that they had less of a specific structure called Band 3, one part of which is 
called Wrightb. If I blocked Wrightb on ‘normal’ red blood cells, I discovered I 
was able to break apart rosettes in lots of different types of malaria.  
 
I then worked with scientists from Harvard University to grow immature forms 
of red cells which had the instructions for making Wrightb  cut out from their 
genetic code, using a new technique known as CRISPR/Cas9 genome 
editing. This means that these cells do not have any Wrightb on their cell 
surface. When I tested the Wrightb-free cells with different malaria parasites I 
found they were not able to form rosettes very well, which suggests that 
Wrightb is indeed key for rosetting in malaria. This is fantastic news, as it 
means that Wrightb could be a useful target for medications designed to 
reduce rosetting in severe malaria. The next phase of my research is to 
further investigate how the malaria parasite uses Wrightb to form rosettes, 
and whether we can design a therapy to reduce the burden of severe malaria 
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1. Chapter I: Introduction 
  
 2 
1.1 The worldwide burden of malaria  
 
There are over 200 million cases of malaria worldwide every year and at 
least 435,000 deaths (WHO, 2018) (Figure 1-1). The vast majority of these 
deaths are due to Plasmodium falciparum and 93% occur in African 
countries, with children under 5 years of age accounting for 61% of the total 
mortality (WHO, 2018). While great progress has been made over the past 
decade in reducing the number of cases and deaths, recent World Health 
Organization (WHO) Malaria Reports warn that “progress has stalled,” and 
we are “off course” to meet the WHO targets of reducing the morbidity and 
mortality of malaria worldwide (WHO, 2017, WHO, 2018). There are multiple 
reasons behind this (WHO, 2018), including parasite resistance to anti-
malarial drugs, mosquito resistance to insecticides, reduced funding, and 
high incidence countries struggling to reduce case numbers (WHO, 2018). In 
some cases this is due to conflict or challenging political situations, and also 
the emergence of new threats such as Ebola, which decimated the 
population of health care professionals in a number of African countries and 






Figure 1-1 The global burden of malaria. A Annual incidence of P. falciparum malaria in 2017, clinical 
cases per 1000 population. B The mortality of malaria worldwide per 100,000 people. Maps modified 
from the Malaria Atlas Project, available under the Creative Commons Attribution 3.0 Unported 
License. http://map.ox.ac.uk. 
 
There are five main Plasmodium species which cause disease in humans; P. 
falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi (Ashley et al., 
2018). The latter, P. knowlesi, is a zoonotic malaria, the natural host being 
macaque monkeys, and is of increasing concern particularly in Malaysia and 
South East Asia where it causes severe disease and death (Singh et al., 
2004, Barber et al., 2013, Barber et al., 2017). However, the total number of 










falciparum, P. vivax contributes most to the clinical burden of disease 
accounting for around 3.5% of worldwide cases (approximately 7.5 million), 
though this varies greatly by region from 0.3% of cases in Africa to 74.1% in 
South America (WHO, 2018). But infection with P. falciparum is far and away 
the greatest cause of malaria related mortality and morbidity worldwide 
accounting for over 95% of cases and almost all deaths (WHO, 2018). The 
remainder of this introduction and thesis will therefore concentrate on P. 
falciparum. 
 
1.2 Plasmodium falciparum life cycle 
 
The malaria parasite is transmitted by the female Anopheles mosquito, which 
injects sporozoites intradermally during a human blood meal (Figure 1-2) 
(White et al., 2014). The incubation period from infection to symptoms is 
roughly 12-14 days, representing 5-8 days in the liver, followed by 6-8 days 
multiplying through the blood stage (White et al., 2014). 
 
 
Figure 1-2 The life cycle of P. falciparum, taken from (White et al., 2014). 
 
The sporozoites pass briefly into the blood before invading the hepatocytes 
of the liver where they multiply to produce around 10,000 merozoites (the 
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liver stage). The merozoites emerge from the hepatocytes to enter the blood 
stage where they seek out erythrocytes to invade. There are a number of 
invasion pathways, including utilizing the host receptors Glycophorin A (Bei 
et al., 2010), Glycophorin B (Mayer et al., 2009) and Glycophorin C (Maier et 
al., 2003, Mayer et al., 2006), Complement receptor 1 (Tham et al., 2010), 
Basigin (Crosnier et al., 2011), CD55 (Egan et al., 2015) and possibly Band 3 
(Goel et al., 2003). Once inside the erythrocyte, over the next 48 hours, the 
merozoite matures (Figure 1-3) through the ring stage, into trophozoites 
which then undergo schizogony to produce between 8-36 merozoites (Garg 
et al., 2015). These new merozoites then burst out of the erythrocyte, 
destroying it, and begin the cycle again with fresh, uninfected erythrocytes. 
  
 
Figure 1-3 Maturation of P falciparum in the erythrocyte. Adapted from (Ashley et al., 2018) 
 
While there are many potential targets for intervention throughout the life 
cycle of P. falciparum, the work contained in this thesis concentrates on the 
blood stage, specifically after the parasite has invaded the erythrocyte and 
matured sufficiently to express the parasite derived ligands, PfEMP1, RIFIN 
and STEVOR (discussed in detail below).  
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1.3 Clinical presentation and treatment of severe P. 
falciparum malaria  
 
1.3.1 Clinical features of severe malaria 
 
Despite the huge incidence and unacceptably high absolute number of 
deaths, it is important to note that the majority of people living in endemic 
countries who become infected with P. falciparum malaria do not experience 
life-threatening disease. Most experience an unpleasant, ‘flu-like’ illness with 
fever, chills, muscle aches, headaches and/or diarrhoea (Ashley et al., 2018). 
The WHO has developed clinical and laboratory definitions of severe malaria, 
shown in Table 1-1, and there are other scores and techniques, which can 
further subclassify specific syndromes such as the Blantyre Coma Score 
(Molyneux et al., 1989) and assessing for malarial retinopathy to diagnose 
cerebral malaria (Taylor et al., 2004).  
Broadly speaking, there are three main syndromes of severe malaria which 
affect children; cerebral malaria (CM), severe malarial anaemia (SMA) and 
respiratory distress/metabolic acidosis (RD/A (White et al., 2014, Maitland, 
2015, Marsh et al., 1995). In adults, pregnancy-associated malaria and 
kidney failure are also important (White et al., 2014). Overlap between the 
syndromes does occur and is predictive of an increase in mortality; a large 
study of children with severe malaria found 43% of children with a 
combination of reduced consciousness, acidosis and renal impairment 
(defined by a blood urea nitrogen >20mg/dl) died, compared to 6-7% of those 
with only one of these features (von Seidlein et al., 2012). 
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Table 1-1 Clinical and laboratory feature of severe malaria in children and adults. The abbreviation in 
bold indicate the associated severe malaria syndrome. Based on (2014) and (WHO, 2012) 





Impaired consciousness (GCS<11, BCS<3) 
CM 
Common Fairly common 
Respiratory distress/acidotic breathing 
RD/A 
Common Fairly common 
Seizures 
CM 




Shock Less common Less common 
Pulmonary oedema Unusual Less common 
Abnormal bleeding Unusual Less common 
Jaundice Less common Common 
Laboratory features 
Severe anaemia  
SMA 
Common 
(Hb < 5g/dl/Hct 
<15%) 
Less common 
(Hb < 7g/dl/Hct 
<20%) 
Hypoglycaemia (Glucose <2.2) Common Fairly common 
Acidosis 
RD/A 
Common Fairly common 
Hyperlactataemia 
RD/A 
Common Fairly common 
Renal impairment (creatinine > 265µM or 
urea > 20mM)  
Unusual Common 
Hyperparasitaemia (>10%) Fairly common Less common 
Other features of severe malaria (not part of WHO definition) 
Duration of illness 1-2 days 5-7 days 
Resolution of coma 1-2 days 2-4 days 
Invasive bacterial co-infection Common Uncommon 
GCS= Glasgow Coma Score, BCS = Blantyre Coma Score, Hb= haemoglobin, Hct= 
haematocrit, CM= feature of cerebral malaria, RD/A= feature of respiratory distress/acidosis, 
SMA= feature of severe malarial aneamia 
 
The incidence of severe malaria is difficult to estimate, in part due to the 
undocumented cases which never present to healthcare service (WHO 
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2014), but also due to inter-country variability in whether uncomplicated 
and/or severe cases are managed as inpatients (Camponovo et al., 2017). 
Taking into account these ‘hidden’ cases, the WHO estimates there are 
around 2 million cases of severe malaria annually, around 1% of the total 
(WHO 2014). However, this estimate is of all cases, both adult and children, 
while the incidence specifically in the paediatric population is likely to be 
much higher. Gonçalves et al. (Gonçalves et al., WHO 2014) conducted a 
large, prospective study following 882 children in Tanzania from birth and 
found that 81.1% had at least one episode of P. falciparum and of these, 
11.6% had at least one episode of severe malaria, according to the WHO 
classification. Interestingly, many of these severe cases occurred after at 
least one uncomplicated malaria infection, and 15 children had more than 
one episode of severe disease (Gonçalves et al., WHO 2014). There were 11 
malaria related deaths; giving an overall mortality of those who had at least 
one malaria infection of 1.5%, and for those with severe malaria of around 
10% (Gonçalves et al., WHO 2014), similar rates to those seen in other 
studies of treated severe malaria (Dondorp et al., 2010, Manning et al., WHO 
2014, Ndila et al., 2018). The prospective design of this study is particularly 
useful as many other estimates of severe disease rely on assessing a subset 
of children who have been admitted to hospital and are therefore likely to be 
suffering from more severe symptoms. For example, Okiro et al. studied 
clinical admission data from 17 communities in 7 different malaria endemic 
countries and found that 4% of admitted children were suffering from cerebral 
malaria, and 17% from severe malarial anemia (Okiro et al., 2009). Earlier 
estimates by Snow et al. demonstrated the influence of different transmission 
intensities on the clinical presentation of severe malaria in a study comparing 
a relatively low transmission area, Kilifi in Kenya, with a high transmission 
area, Ifakara in Tanzania (Snow et al., 1994). Of those children under 10 
years of age admitted to a paediatric ward with malaria in Kilifi, 11% had 
cerebral malaria, and 13% had severe malarial anaemia. By comparison, 
only 2.8% of children in the Tanzanian hospital had cerebral malaria, but 
40% had severe anaemia (Snow et al., 1994). Another hospital based study, 
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including sites in Kenya and The Gambia, found cerebral malaria rates 
ranging from 0.7-10% of malarial admission and severe malarial anaemia in 
6.7-25% (Snow et al., 1997). Again, these percentages are likely to be 
overestimates given they are proportions of children already admitted to 
hospital, nevertheless, these figures illustrate the serious problem of severe 
malaria in young children.   
 
1.3.2 Management of severe malaria 
 
One of the especially challenging aspects of managing severe malaria, 
particularly in resource limited setting, is the lack of adjuvant treatments 
directed against severe forms of the disease (Maitland, 2015). The 
AQUAMAT study established intravenous Artesunate as the initial treatment 
of choice for African children with severe malaria (in preference to Quinine) 
(Dondorp et al., 2010), followed by a course of oral artemisinin-based 
combination therapy (WHO, 2012). However, despite treatment, around 10% 
of children with severe malaria still died (Dondorp et al., 2010) and a meta-
analysis assessing mortality from severe malaria over the past 30 years has 
shown minimal improvements in case fatality rates (Manning et al., WHO 
2014). In addition to these mortality figures, the morbidity suffered by 
survivors of severe malaria is significant and often not fully appreciated. 
Recent reports suggest that over half of children who survive cerebral 
malaria have some form of developmental, cognitive or behavioral 
impairment (Langfitt et al., 2019), greater than previously thought (Idro et al., 
2010). Adjuvant treatments which have been trialed for severe malaria 
include steroids (Warrell et al., 1982, Hoffman et al., 1988), anti-inflammatory 
drugs and aspirin (Hemmer et al., 1991, Di Perri et al., 1995, Looareesuwan 
et al., 1998, Das et al., 2003, Lell et al., 2010), heparin (Smitskamp and 
Wolthuis, 1971, WHO, 1986, Hemmer et al., 1991, Rampengan, 1991), 
monoclonal antibodies and intravenous immunoglobulins (Taylor et al., 1992, 
van Hensbroek et al., 1996, Looareesuwan et al., 1999), anti-convulsants 
(White et al., 1988, Crawley et al., 2000, Gwer et al., 2013), N-acetylcysteine 
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(Watt et al., 2002, Treeprasertsuk et al., 2003, Charunwatthana et al., 2009) 
and L-arginine (Yeo et al., 2013). None of these treatments have shown 
consistent benefit and many have even been harmful. Studies have also 
assessed the role of supportive therapies such as intravenous fluids (Day et 
al., 2000, Maitland et al., 2003, Maitland and Newton, 2005, Maitland et al., 
2005, Akech et al., 2006, Akech et al., 2010, Maitland et al., 2011), and have 
concluded that very cautious fluid resuscitation is required (Maitland et al., 
2011). Blood transfusion does appear to be beneficial (Bojang et al., 1997, 
Olupot-Olupot et al., WHO 2014) and the ongoing TRACT trial 
(ISRCTN8408586) may shed more light on the appropriate parameters for 
transfusion in severe malaria, however the availability of appropriate blood 
products can be a challenge in some settings.  
 
There is therefore a pressing need to develop a greater understanding of the 
pathological processes occurring in severe malaria, in order to better inform 
the development of therapies, specifically directed against this potentially 
devastating condition. 
 
1.4 The pathogenesis of severe malaria 
 
 
There are numerous factors, both known and unknown, which influence 
whether or not a person infected with P. falciparum will develop severe or 
uncomplicated disease. As with any infectious disease, both host and 
pathogen drivers play an important role, and as yet, our understanding of the 
pathogenesis of severe malaria is incomplete (Miller et al., 2002, Wassmer et 
al., 2015, Wassmer and Grau, 2017). For those living in malaria endemic 
regions, the risk of severe disease falls with increasing age (Figure 1-4) 
(White et al., WHO 2014) which suggests the development of some form of 
immunity or disease tolerance, though this does depend on transmission 
rates (Okiro et al., 2009). However, how this immunity/tolerance develops 
and what form it takes is unclear; data from Goncalves et al. (Gonçalves et 
al., WHO 2014) demonstrates that many cases of severe disease occur after 
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several uncomplicated infections; around 10% of those experiencing severe 




Figure 1-4 Severe malaria decrease with age. Taken directly from (White et al., WHO 2014). 
 
1.4.1 Cytoadhesion in malaria 
 
A key aspect of the pathogenicity of the P. falciparum parasites is the ability 
of infected erythrocytes to adhere to other human cells, such as endothelial 
cells (sequestration), other erythrocytes (rosetting), platelets (platelet-
mediated clumping), or the placenta (pregnancy associated malaria) (Miller 
et al., 2002, Rowe et al., 2009, Wassmer et al., 2015, Wassmer and Grau, 
2017).  
 
1.4.1.1 Sequestration and endothelial cell binding 
 
In P. falciparum, erythrocytes infected with mature trophozoite forms of the 
parasites adhere to endothelial cells in the microvasculature in a process 
known as sequestration. As a result, mature parasites are protected from 
removal by the spleen and only erythrocytes containing ring stage parasites 
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are seen in the periphery (Marchiafava and Bignami, 1894, David et al., 
1983, Silamut et al., 1999). Sequestered parasites have been seen at 
autopsy (Figure 1-5 ) (Marchiafava and Bignami, 1894, Silamut et al., 1999, 
Pongponratn et al., 2003, Ponsford et al., 2012, White et al., 2013, Barrera et 
al., 2018), in vivo in the retina (Beare et al., 2009, Barrera et al., 2018) and in 
the buccal and rectal mucosa (Dondorp et al., 2008a) (Figure 1-6). These 
sequestered parasites, possibly along with rosetting erythrocytes, cause 
obstruction of the microvasculature (Figure 1-5) (Silamut et al., 1999, 
Pongponratn et al., 2003, Dondorp et al., 2004, Dondorp et al., 2008a, Beare 
et al., 2009, Ponsford et al., 2012), with the level of congestion correlating 
with the disease severity (Dondorp et al., 2008a, Ponsford et al., 2012). In 
addition to obstruction, adhesion of the erythrocytes also leads to 
pathological endothelial cell activation with inflammation, dysregulation of 
coagulation and breakdown of the barrier function of the endothelium (Moxon 
et al., 2009, Wassmer et al., 2011, Moxon et al., 2013, Aird et al., WHO 
2014, Moxon et al., 2014, O'Sullivan et al., 2016, Wassmer and Grau, 2017) 
 
 
Figure 1-5 Sequestered parasites on postmortem samples. A An electron micrograph of an obstructed 
cerebral blood vessel full of infected erythrocytes from (Pongponratn et al., 2003). B Obstructed brain 
microvessels from (Ponsford et al., 2012) C Black stained parasites inside a cerebral vessel (Silamut et 







Figure 1-6 A retinal angiogram from (Beare et al., 2009) showing dark black patches of no perfusion 
and obstructed or “pruned” vessels, identified by black arrows. B Orthogonal polarization spectral 
image of rectal mucosa showing “cobblestone” congested capillaries containing dark grey erythrocytes 
from (Dondorp et al., 2008a) 
 
Much work has gone into trying to unpick the mechanisms of endothelial cell 
binding and identify the relevant parasite ligands and host receptors. In 
particular, binding to human brain endothelial cells is thought to be key to the 
pathogenesis of cerebral malaria (Marchiafava and Bignami, 1894, 
Pongponratn et al., 2003, Ponsford et al., 2012, Barrera et al., 2018, Storm et 
al., 2019). The important parasite-derived ligands are PfEMP1 (discussed in 
detail below), particularly the domain cassette (DC) 8 and 13 variants and 
those encoded by group A or B/A var genes (Kyriacou et al., 2006, Avril et 
al., 2012, Claessens et al., 2012, Lavstsen et al., 2012, Warimwe et al., 
2012, Bertin et al., 2013). The corresponding host receptors include CD36, 
intracellular adhesion molecule-1 (ICAM-1), E-selectin, P-selectin, 
Thrombospondin, neural cell adhesion molecule (NCAM), platelet endothelial 
cell adhesion molecule 1 (PECAM-1/CD31), heparan sulfate and endothelial 
protein C receptor (EPCR) (reviewed in (Rowe et al., 2009, Wassmer and 
Grau, 2017)). Binding to these host receptors is not necessarily associated 
with severe disease (Rowe et al., 2009, Turner et al., 2013), with the 
exception of EPCR which has generated much recent interest (Moxon et al., 
2013, Turner et al., 2013, Avril et al., 2016, Jespersen et al., 2016, Storm et 
al., 2019). In general, recombinant PfEMP1 variants associated with severe 
disease and clinical isolates from children with severe malaria bind in an 
A B
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EPCR dependent fashion (Turner et al., 2013, Storm et al., 2019), however 
results are not consistent throughout all studies (Azasi et al., 2018). In 
addition, children in Papua New Guinea who survived severe malaria were 
found to have increased antibodies directed against EPCR-binding PfEMP1 
variants in their convalescent serum compared to uncomplicated controls, 
suggesting that these EPCR-binding parasites contributed to their severe 




Rosetting is another important cytoadherence phenotype, specifically 
associated with severe disease in P. falciparum malaria (Rowe et al., 1995, 
Newbold et al., 1997, Kun et al., 1998, Rowe et al., 2002a, Doumbo et al., 
2009, Warimwe et al., 2012). It is usually defined as the adhesion of two or 
more uninfected erythrocytes to an erythrocyte infected with a mature, 
asexual parasite (Figure 1-7). Rosetting is thought to contribute to the 
sequestration of infected erythrocytes in the microvasculature which in turn 
causes obstruction, inflammation and tissue damage as illustrated above 
(Kaul et al., 1991, Miller et al., 2002, White et al., 2013). In Africa, rosetting 
has been linked with all types of severe malaria including cerebral malaria 
(Rowe et al., 1995, Kun et al., 1998, Doumbo et al., 2009), severe anemia 
(Newbold et al., 1997) and respiratory distress (Warimwe et al., 2012), and 
rosettes have been seen at autopsy in the brain (Dondorp et al., 2004). All 
the human-infecting malaria species rosette (Udomsanpetch et al., 1995, 
Angus et al., 1996, Chotivanich et al., 1998, Lowe et al., 1998), and while the 
link between severity of disease and rosetting seems to be confined to P. 
falciparum, there is some evidence that rosetting may contribute to severe 
anemia in P.vivax (Marín-Menéndez et al., 2013). The remainder of this 
introduction will focus on the role of rosetting in severe malaria and the 






Figure 1-7 A P. falciparum rosette (parasite line ITvar60 in static culture). Image shows an infected 
erythrocyte and four adherent uninfected cells. Images taken using a Yenway microscope camera on a 
Leica DM KB2 florescent microscope. 
 
1.5 Rosetting and severe malaria  
 
1.5.1 Evidence for the association between rosetting with severe 
malaria  
 
Much of the evidence that rosetting is associated with severe malaria comes 
from field studies in which P. falciparum clinical isolates from patients with 
varying degrees of malaria severity were cultured for 24 hours and the 
rosette frequency (usually defined as the percentage of 200 infected 
erythrocytes which are rosetting with 2 or more uninfected erythrocytes) 
counted and compared (Carlson et al., 1990, Treutiger et al., 1992, Ringwald 
et al., 1993, Rowe et al., 1995, Newbold et al., 1997, Kun et al., 1998, 
Heddini et al., 2001, Pain et al., 2001, Rowe et al., 2002c, Doumbo et al., 
2009) (Figure 1-8). For example, in Mali, Doumbo et al. (Doumbo et al., 
2009) found that 90% of isolates from children with severe malaria were 
capable of rosetting, with a median rosette frequency of 20%, compared to 
55% of isolates from uncomplicated cases and these parasites only had a 
median rosette frequency of 1%. These findings have been replicated in 
multiple different populations; in Kenya (Rowe et al., 1995, Newbold et al., 
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1997, Heddini et al., 2001, Pain et al., 2001, Rowe et al., 2002c), Mali 
(Doumbo et al., 2009), Uganda (Normark et al., 2007), Madagascar 
(Ringwald et al., 1993), the Gambia (Carlson et al., 1990, Treutiger et al., 
1992), Gabon (Kun et al., 1998) and a hyperendemic region of India (Rout et 
al., 2010) the rosetting frequency was higher in patients, usually children, 
with severe malaria. However, studies from Papua New Guinea (al-Yaman et 
al., 1995) and Malawi (Rogerson et al., 1999) found no significant 
differences. In Southeast Asia, the picture is less clear; adults in Thailand 
with severe malaria had similar rosetting rates to those with uncomplicated 
malaria (Angkasekwinai et al., 1998, Chotivanich et al., 2004). However, 
rates were higher in one cerebral malaria group (Chotivanich et al., 2004), 
and it is important to bear in mind the epidemiological differences between 
African and Asian malaria in terms of age, incidence, transmission intensity 
and mortality (Dondorp et al., 2008b, Rowe et al., 2009, WHO, 2018).    
 
 
Figure 1-8 Countries in which the association between rosetting and severe disease has been studied. 
Blue stars show countries in which an association with increased rosetting and severe disease has 
been demonstrated with multiple stars indicating the number of independent studies, red crosses show 
countries in which studies have found no significant difference between rosetting rates in severe and 
uncomplicated disease. Note, map is not to scale and some countries have been overlaid to 
emphasise the relevant malaria endemic countries.  
 
Other evidence supporting the role of rosetting in the pathology of severe 
malaria has been found by examining the sera of children at different ages or 
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with varying severities of malaria. Anti-rosetting antibodies are found more 
commonly in children with mild, rather than severe, malaria (Carlson et al., 
1990, Treutiger et al., 1992, Vigan-Womas et al., 2010) and the ability of sera 
from children living in malaria endemic areas to disrupt rosettes increases 
with age, in keeping with the age-related decline in both incidence and 
mortality (Barragan et al., 1998). Of note, erythrocytes from patients with 
conditions which provide natural protection against severe malaria, such as 
sickle cell trait, Thalassemia, and blood group O form smaller, weaker 
rosettes (Carlson et al., 1994, Barragan et al., 2000b, Opi et al., 2014).  
 
1.5.2 Why do parasites form rosettes?   
 
The benefit to the parasite of rosetting is not entirely clear, as causing severe 
disease or death of the host is certainly not in its best interests. Plausible 
suggestions include that the formation of rosettes may shield the infected cell 
from the host immune system, or that close contact with uninfected 
erythrocytes could enhance invasion (Wahlgren et al., 1989). Some adhesion 
phenotypes do provide shielding from the immune system, such as the 
PfEMP1 variant VAR2CSA, associated with placental binding in pregnancy 
associated malaria, which utilizes IgM to mask IgG binding sites (Barfod et 
al., 2011), however there is a lack of evidence for this in rosetting parasites. 
Erythrocytes infected with rosetting parasites do bind non-immune IgM 
(Scholander et al., 1996, Rowe et al., 2002c), however this does not appear 
to protect from IgG mediated phagocytosis (Stevenson et al., 2015a). In 
addition, merozoites released from rosetting infected erythrocytes do not 
appear to be protected and invasion rates are not enhanced (Deans and 
Rowe, 2006). There may be some specific scenarios where rosettes provide 
an element of antibody shielding (Moll et al., 2015) for example; parasites 
which show a rosetting preference for blood group A are able to form larger 
and stronger rosettes when cultured in this blood group (Rowe et al., 1995, 
Rowe et al., 2007). Two such parasite lines, FCR3S1.2 and PAvarO, showed 
significantly less rosette disruption by anti-PfEMP1 antibodies when grown in 
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blood group A compared to blood group O, though this was not seen in 
parasite strain R29, and invasion efficiency was not increased in the 
presence of larger rosettes (Moll et al., 2015).  
 
Invasion is also not increased in parasites selected for rosetting compared to  
non-rosetting parasite from the same clone in various laboratory-adapted 
strains (Clough et al., 1998b, Deans and Rowe, 2006, Ribacke et al., 2013) 
and, somewhat surprisingly, merozoites show no preference for invading 
adjacent uninfected cells contained within the rosette (Clough et al., 1998b). 
In field isolates, one study on African clinical samples found no correlation 
between rosette frequency and parasite multiplication rate in vitro (Deans et 
al., 2006), though another suggested there was increased multiplication in 
rosetting isolates (Ribacke et al., 2013). Similarly, the correlation between 
parasitaemia and rosetting is not straightforward, Carlson et al. (Carlson et 
al., 1990) found no relationship between rosetting and parasitaemia in the 
Gambia, while Rowe et al. (Rowe et al., 2002a) found that for Kenyan 
children with severe malaria (but not uncomplicated malaria), there was a 
positive correlation between rosetting frequency and parasitaemia. In vivo 
studies using splenectomized Saimiri sciureus monkeys demonstrated a 1.5 
times higher parasite multiplication with rosetting compared to non-rosetting 
parasites (Le Scanf et al., 2008) therefore more work is required to determine 
the contribution of rosetting in promoting invasion or reducing parasite 
clearance.   
 
Rosetting may have a role in aiding sequestration, thereby avoiding splenic 
clearance of the infected erythrocytes and contributing to microvascular 
obstruction (Kaul et al., 1991). Rosetting parasites of the line IT/R29 are also 
capable of binding human brain endothelial cells (Adams et al., 2014) and 
antibodies to the NTS-DBL1 or DBL2 domains of the IT4var09 PfEMP1 
variant were able to reverse this adhesion. Both these domains were also 
found to bind heparin, and heparin was also capable of disrupting adhesion 
to the endothelial cells (Adams et al., 2014). While heparin and NTS-DBL1 
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antibodies are also able to disrupt rosettes (Rowe et al., 1994, Ghumra et al., 
2011), antibodies to the DBL2 domain had no effect on rosette frequency 
(Ghumra et al., 2011) suggesting a different, but not mutually exclusive, host 
receptor-parasite ligand interaction for these two different cytoadhesion 
phenotypes (Adams et al., 2014).  
 
Therefore, while a role for rosetting in promoting invasion, immune evasion 
and sequestration is plausible, the evidence for each is incomplete and 
further studies are required to determine both the advantage which rosetting 
affords to the parasites, and the exact mechanism by which rosetting 
contributes to severe disease.  
 
1.6 Mechanisms of rosetting: Parasite derived rosetting 
ligands 
 
As alluded to above, there are two sides to consider when investigating the 
molecular mechanisms of rosetting in P. falciparum; the parasite derived 
ligands and the corresponding host receptors. While the work of this thesis 
concentrates mainly on the host receptors, a summary of the important 




Of the three variant surface antigen (VSA) families involved in rosetting, the 
most well established is Plasmodium falciparum Erythrocyte Membrane 
Protein One (PfEMP1). PfEMP1 variants are found on the cell surface of 
infected red blood cells, first appearing around 18-24 hours after invasion 
(Chen et al., 1998, Kraemer and Smith, 2006, Smith et al., 2013, Hviid and 
Jensen, 2015), and are encoded by var genes (Su et al., 1995, Hviid and 
Jensen, 2015). Usually only one var gene is transcribed at a time per cell, 
though exceptions to this have been described (Joergensen et al., 2010). 
There can be switching of transcription between around 60 var genes per 
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parasite isolate with minimal overlap between parasite strains (Roberts et al., 
1992, Su et al., 1995, Scherf et al., 1998, Kraemer and Smith, 2006). This 
switching can be fast, as often as every cycle (Bachmann et al., 2011), and is 
highly coordinated in vivo though this synchronization may be lost with 
prolonged in vitro culture (Bachmann et al., 2011). This high level of 
antigenic variation makes PfEMP1 a challenging vaccine target.  
 
1.6.1.1 Var genes 
 
Var genes consist of two exons; exon 1 encodes the multiple Duffy binding-
like (DBL) domains and cysteine-rich interdomain regions (CIDR) which 
make up the extracellular part of the protein, while exon 2 encodes the 
intracellular domain (Hviid and Jensen, 2015) (Figure 1-9).  In general, var 
genes can be grouped based on location and upstream promoter sequence 
as A/upsA, B/upsB or C/upsC, though intermediate groups (B/A and B/C) do 
exist (Gardner et al., 2002, Lavstsen et al., 2003, Kraemer and Smith, 2006). 
An additional gene, var2CSA, sometimes classified as UpsE, codes for the 
highly conserved chondroitin sulfate-binding PfEMP1 specific to pregnancy 
associated malaria (Salanti et al., 2003). Group A var genes, are 
subtelomeric and transcribed towards the telomere, group B are also 
subtelomeric but transcribed in the opposite direction, while Group C are 
internal (Gardner et al., 2002, Lavstsen et al., 2003). PfEMP1 encoded by 
Group A var genes are larger, consisting of five or more extracellular 
domains (as shown in Figure 1-9) and do not bind CD36 (Robinson et al., 
2003) while those from Group B and C var genes have only 4 domains and 
are able to bind CD36 (Lavstsen et al., 2003, Robinson et al., 2003). 
Importantly, particularly for vaccine design, PfEMP1 from Group A var gene 
are associated with severe disease, while Group C are not (Rottmann et al., 
2006, Kaestli et al., 2006, Kyriacou et al., 2006, Falk et al., 2009, Warimwe et 
al., 2009, Warimwe et al., 2012, Turner et al., 2013, Tembo et al., 2014). The 
association is less clear for Group B var genes, though the intermediate 
group B/A may be linked to severe disease (Kaestli et al., 2006, Kyriacou et 





Figure 1-9 PfEMP1 of ITvar9 adapted from (Ghumra et al., 2011). NTS= N-terminal sequence, DBL= 
Duffy binding-like domain, CIDR= cysteine-rich interdomain regions. 
 
1.6.1.2 PfEMP1 structure 
 
The PfEMP1 protein has a molecular weight of around 200-450kDa, made up 
of the highly variable extracellular domains and an intracellular acidic 
terminal segment (Su et al., 1995, Smith et al., 1995, Baruch et al., 1995). 
The cytoplasmic region of PfEMP1 interacts with knob-associated histidine-
rich protein (KAHRP) leading to clusters of PfEMP1 on tiny projections 
known as knobs (Figure 1-10) (Berendt et al., 1994, Waller et al., 1999, 
Kilejian, 1979, Aikawa, 1988). Some lines, such as ITvar60, are knobless, 
though the lack of knobs leads to a decrease in overall PfEMP1 expression 






Figure 1-10 Scanning (LEFT) and transmission (RIGHT) electron micrographs of infected erythrocytes 
displaying knob protrusion (labelled k). Both infected erythrocytes are adherent to a human umbilical 
endothelial cells (en). Taken from (Berendt et al., 1994). 
 
The extracellular part of the molecule is made up of various DBL and CIDR 
domains which can be classified as DBL PAM,and CIDR 
 and PAM respectively (Rask et al., 2010). The domains can be 
further subdivided numerically, for example DBL1.1 or CIDR1.4, based on 
sequence similarity (Rask et al., 2010). When certain combinations of 
PfEMP1 domains are frequency seen together, these are known as ‘domain 
cassettes’ (DC), for example DC8 is made up of DBL2, CIDR1.1, DBL12 
and DBL4/6, and DC13 is made up of DBL1.7 and CIDR1.4 (Rask et al., 
2010). Both these domain cassette variants are of particular interest as the 
they bind human brain endothelial cells and have been linked to severe 
malaria (Avril et al., 2012, Claessens et al., 2012, Lavstsen et al., 2012, 
Turner et al., 2013).  
 
Not all PfEMP1 variants are capable of rosetting, however the rosetting 
variants for a number of parasites lines have been identified, as shown in 
Figure 1-11(Vigan-Womas et al., 2011, Ghumra et al., 2012). In terms of 
rosetting, the DBL1α domain is thought to be most important (Rowe et al., 
1997, Russell et al., 2005, Vigan-Womas et al., 2008), though other domains 
can bind uninfected erythrocytes (Rowe and Donat personal communication 
and Chapter 3). Antibodies raised against various domains of PfEMP1 
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disrupt rosettes, however, perhaps unsurprisingly given the very variable 
PfEMP1 repertoire, these antibodies do not cross react across all strains 
(Ghumra et al., 2011, Ghumra et al., 2012), a key requirement for an 
effective anti-rosetting vaccine. 
 
 
Figure 1-11 Rosetting PfEMP1 variants. Data from (Ghumra et al., 2012) and (Vigan-Womas et al., 
2011) 
 
1.6.2 Other molecules: RIFINS and STEVOR 
 
Recent evidence has renewed interest in both the repetitive interspersed 
families of polypeptides (RIFIN) and proteins encoded by sub-telomeric 
variant open reading frame (STEVOR) genes (Yam et al., 2017). Both RIFIN 
(Kyes et al., 1999, Goel et al., 2015) and STEVOR (Bachmann et al., 2015) 
are variant surface antigens also found on the membrane of infected 
erythrocytes. RIFINs are relatively trypsin resistant and earlier work had 
shown that removal of PfEMP1 from ITvar60 infected erythrocytes with low 
concentrations of trypsin greatly reduced rosetting frequency but did not 
abolish it completely (Kyes et al., 1999), indicating that RIFINs could have an 
accessory function. More recently, it has been suggested that RIFINs have a 
particular role in rosetting in blood group A (Goel et al., 2015). Experiments 
showed higher rosetting rates in parasites cultured in blood group A 
compared to O after removal of PfEMP1 with trypsin, higher binding of group 
A erythrocytes to RIFIN transfected CHO cells and increased rosetting rates 
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in parasites transfected with a rif gene, again only in blood group A (Goel et 
al., 2015). STEVOR proteins have been shown to bind Glycophorin C on 
uninfected RBCs and anti-STEVOR antibodies disrupt rosettes in some 
strains (Niang et al., 2014). Recent data have suggested that STEVOR may 
have a role in strengthening rosettes, particularly in later stage trophozoites 
(Singh et al., 2016). 
 
1.7 Mechanisms of rosetting: Host rosetting receptors 
 
Given the huge antigenic variance of the parasite-derived rosetting 
molecules described above, it is vital to identify the corresponding host 
erythrocyte receptors in order to investigate potential alternative therapeutic 
options. A number of receptors have been proposed (Figure 1-12) which are 
discussed in detail below and in Table 1-2, however none offers a full 
explanation for all parasite strains, and it is likely that different receptors can 
be utilized by various parasites at different times. In addition, some receptors 
may be essential whereas others may be neither necessary nor sufficient but 




Figure 1-12 Parasite derived ligands and host receptors involved in rosetting UE= uninfected erythrocyte, IE= infected erythrocyte, GAGs= glycosaminoglycans, HS= 
heparan sulfate, CS= chondroitin sulfate, CR1= complement receptor 1, GYPC = glycophorin C, GYPA = glycophorin A. Dashed lines represent proposed host receptors 
for each parasite ligand. From (McQuaid & Rowe, 2019 submitted) 
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1.7.1 ABO blood group 
 
Arguably the most clinically important blood group antigens are those of the 
ABO system which result in 4 different blood groups; A, B, AB and O (Dean, 
2005). The A and B antigens differ based on the sugar at the antigen 
terminus; for blood group A this is N-acetyl-D-galactosamine and for B, D-
galactose (Dean, 2005). Those with blood group AB have both antigens, 
while blood group O erythrocytes express only the H antigen, a precursor to 
the A and B antigens (Dean, 2005). Blood group O is known to protect 
against severe malaria as demonstrated by multiple studies across Africa 
(Rowe et al., 2007, Tekeste and Petros, 2010, Malaria Network, 2014, 
Degarege et al., 2019) and India (Rout et al., 2012). A recent meta-analysis 
by Degarege et al. (Degarege et al., 2019) found that the odds of severe 
disease were significantly higher for blood groups A,B and AB compared to 
O. Overall they also concluded that blood group does not appear to have any 
effect on parasitaemia or haemoglobin level, though there was some 
heterogeneity between the individual studies included in the meta-analysis 
(Degarege et al., 2019). Interestingly, Theron et al. (Theron et al., 2018) 
tested multiple donors of different blood groups and found that parasites 
preferentially invade blood group O erythrocytes. This was a surprising 
finding, however due to the single cell flow cytometry gating strategy used, it 
is possible that the authors unintentionally excluded erythrocytes in rosettes 
from their analysis.  
  
The proposed mechanism for the protection against severe malaria seen for 
blood group O is through reduced rosetting with this blood type 
(Udomsangpetch et al., 1993, Cserti and Dzik, 2007, Rowe et al., 2007). 
Parasites cultured from patients of different blood groups show significant 
variation in rosetting ability; samples from patients with blood group O rosette 
significantly less than those from blood group A, B or AB (Rowe et al., 1995, 
Rowe et al., 2007, Rout et al., 2012). The differences in median rosette 
frequency are relatively low, (rosette frequency 2 vs 7% for O vs A in Kenya 
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(Rowe et al., 1995), approximately 5 vs 15% in Mali (Rowe et al., 1995, 
Rowe et al., 2007) and approximately 17 vs 27% in India (Rout et al., 2012)). 
These figures do not necessarily reflect the size of the rosettes, which are 
often bigger in non-O blood groups (Barragan et al., 2000b) and may 
therefore contribute more towards microvascular obstruction and the 
observed differences in rosette frequency do correlate with protection against 
severe malaria (Rowe et al., 2007, Rout et al., 2012).  Of note, blood group O 
only appears to protect against severe disease in the context of rosetting 
parasites (Rowe et al., 2007); group O patients infected with non-rosetting 
parasites were no more protected against severe disease than other blood 
groups, adding further evidence to the hypothesis that this protection is due 
to a reduction in rosetting.  
 
In vitro studies culturing the same parasite in different blood groups have 
also confirmed that many parasites show a rosetting preference for blood 
groups A or B rather than O (Carlson and Wahlgren, 1992, Udomsangpetch 
et al., 1993, Barragan et al., 2000b, Pipitaporn et al., 2000). When cultured in 
their preferred blood group, these parasites form stronger, larger rosettes 
which are more resistant to disruption (Carlson and Wahlgren, 1992, 
Barragan et al., 2000b, Ch'ng et al., 2016), although the absolute rosette 
frequency (percentage of infected erythrocytes forming rosettes) does not 
change. Other studies have also shown that removing the A or B antigens 
with α-N-acetyl-galactosaminidase decreases the rosette size (Barragan et 
al., 2000b).  
 
For the group A preferring parasite, Palo Alto 89F5 VarO, the group A 
antigen binding site has been mapped to specific residues in the NTS-DBL 
domain of PfEMP1-VarO and binding is enhanced by the addition of the 
CIDR1 domain (Vigan-Womas et al., 2012). The NTS-DBL domain bound 
more efficiently to blood group A erythrocytes, followed by B then O, and this 
binding was related to the amount of blood group A antigen expressed 
(Vigan-Womas et al., 2012). As discussed above, Goel et al. (Goel et al., 
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2015) have suggested that RIFINs also bind to the blood group A antigen, 
which could account for the larger, stronger rosettes seen in this blood group.  
 
Therefore, different blood groups do seem to have a significant and clinically 
relevant effect on rosetting and susceptibility to severe malaria. However, 
given rosettes can form in blood group O, it seems likely that ABO blood 
group variations may have more of a role in strengthening and enlarging 
rosettes rather than being essential for rosetting. 
 
1.7.2 Complement receptor 1 
 
Complement receptor 1 (CR1) is a membrane glycoprotein which helps 
prevent damage to self by regulating the complement system (Stoute, 2011, 
Schmidt et al., 2015). There are a number of CR1 polymorphisms coding for 
differences in copy number on the cell membrane, molecular weight and 
sequence, including the Knops blood group system (Stoute, 2011). In the 
context of malaria, CR1 is thought to be involved in rosetting, complement 
regulation and invasion (Schmidt et al., 2015), though the association with 
disease severity varies between different studies and populations (Rowe et 
al., 2000, Nagayasu et al., 2001, Sinha et al., 2009).   
 
In laboratory based studies, red cells which are deficient in CR1 (i.e. express 
fewer than 100 molecules per cell (Moulds et al., 1992)) show reduced 
rosetting and soluble CR1/CR1 antibodies inhibit rosetting (Rowe et al., 
1997, Lee et al., 2014). The region of CR1 essential for complement receptor 
related rosetting has been mapped to the C3b binding site on the long 
homologous repeat regions (LHR) B and C, and a monoclonal antibody 
which recognizes these sites, J3B11, reversed rosettes in vitro in the parasite 
clone R29 (Rowe et al., 2000). When other parasite strains and field samples 
were investigated, J3B11 reversed rosettes in 3 out of 4 laboratory strains, 
14 of 15 Kenyan and 5 of 10 Malawian clinical isolates, though the reduction 
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in rosette frequency was less in the Malawian samples compared to those 
from Kenya (Rowe et al., 2000). 
 
In keeping with the diversity between isolates from different countries in the 
laboratory studies, results from population field studies also vary. CR1 
deficiency is very common in malaria endemic areas such as Papua New 
Guinea (Cockburn et al., 2004) and some parts of India (Sinha et al., 2009). 
There is less information from Africa, where the commonly studied HindIII 
restriction fragment length polymorphism does not correlate with CR1 copy 
number (Rowe et al., 2002b), however CR1 deficiency seems to be rare in 
Mali and Kenya (Rowe et al., 2002b, Opi et al., 2016). In a case-control trial 
in Papua New Guinea, those who were heterozygous for the CR1 low 
expression allele were protected against severe malaria compared to those 
homozygous for high expression, but the results for those homozygous for 
the low expression alleles were not statistically significant (Cockburn et al., 
2004). In India, low CR1 levels protected against severe malaria in endemic 
regions (Sinha et al., 2009, Rout et al., 2011, Panda et al., 2012), but 
predisposed to severe disease in areas of low malaria incidence (Sinha et 
al., 2009). The transmission intensity of malaria seems to be particularly 
important in determining whether high or low CR1 is beneficial as studies 
from Thailand, where transmission is relatively low compared to Africa, have 
also shown that low CR1 may be detrimental (Nagayasu et al., 2001, 
Teeranaipong et al., 2008).  
 
In addition to the association with CR1 copy number, there is evidence to 
suggest that polymorphisms in the Knops blood group antigens carried on 
CR1 may also affect susceptibility to severe disease. The Knops blood group 
consists of antithetical antigen pairs Swain-Langley 1 and 2 (Sl1 and Sl2) 
and McCoy a and b (McCa and McCb) (Moulds, 2010). Rowe et al. showed 
that erythrocytes of the Swain Langley 2 (Sl2) genotype had less binding to 
COS cells expressing a rosetting PfEMP1-DBL protein (Rowe et al., 1997), 
though another study found no difference in the ability of CR1 protein 
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fragments of  various Swain-Langly and McCoy genotypes to disrupt rosettes 
(Tetteh-Quarcoo et al., 2012). More recently, a large case-control study of 
Kenyan children found that the Sl2 allele was associated with protection 
against all severe malaria, cerebral malaria and death, while McCb gave an 
increased risk of cerebral malaria (Opi et al., 2018). The same study also 
found that isolates from Malian children with the Sl2/Sl2 genotype had 
significantly lower rosetting ex-vivo than those from children with Sl1/Sl1 or 
Sl1/Sl2, though no differences were found between the McCoy genotypes 
(Opi et al., 2018). 
  
More work is therefore required to investigate the links between CR1, 
rosetting and malaria severity. The laboratory studies suggest it may have an 
important role to play in rosetting, which could explain the significance of 
CR1 level in areas of high malaria transmission where rosetting is most 
strongly associated with severe disease. However, the potential beneficial 
effects of CR1 as a complement regulator modifying the host response to 
malaria may be more relevant in the low transmission setting (Stoute, 2011) 





The glycosaminoglycans, heparan sulfate (HS) and chondroitin sulfate (CS) 
play a part in multiple stages of the malaria life-cycle, including hepatic 
invasion for HS (Frevert et al., 1993), cytoadhesion (Vogt et al., 2003, Adams 
et al., 2014) and, for CS, placental sequestration (Ataíde et al., 2014). 
Chapter 3 of this thesis deals extensively with the role of these HS and CS in 
rosetting and a detailed overview of these molecules is given in the 
introduction to this Chapter 3. Briefly, many studies have used heparin, a 
highly sulfated form of HS found only in mast cells, as an analogue for HS. 
These studies found that heparin is effective at disrupting rosettes in many P. 
falciparum strains (Udomsangpetch et al., 1989, Carlson et al., 1992, Rowe 
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et al., 1994, Barragan et al., 1999), however the mechanism of this disruption 
is not clear and may not be specific. Importantly, there is only one paper 
suggesting that HS is indeed present on the surface of mature erythrocytes 
(Vogt et al., 2004), and I have been unable to replicate these findings 
(Chapter 3: Results). A further exploration of the role of HS and CS in 




The scavenger receptor, CD36, is widely expressed and has been shown to 
bind PfEMP1 (Baruch et al., 1996, Chen et al., 2000, Robinson et al., 2003, 
Cabrera et al., 2014), however these CD36 binding PfEMP1 variants tend to 
be encoded by var genes of the UpsB and C group which are generally 
associated with mild disease (Robinson et al., 2003, Kraemer and Smith, 
2006, Kyriacou et al., 2006). Anti-CD36 antibodies are capable of disrupting 
rosettes in a single laboratory adapted strain, Malayan Camp (Handunnetti et 
al., 1992b), but not in any other tested laboratory-adapted or Kenyan clinical 
isolates (Udomsangpetch et al., 1989, Wahlgren et al., 1992, Rowe et al., 
2000, Niang et al., 2014). While CD36 deficiency is fairly common in African 
populations (Fry et al., 2009), large-scale genetic studies have failed to find 
any CD36 polymorphisms that are associated with protection against severe 
malaria (Fry et al., 2009). In fact, CD36 may have an important role to play in 
innate immunity and platelet associated parasite death (McGilvray et al., 
2000, McMorran et al., 2012, Cabrera et al., 2014). It is therefore remains 
unlikely that CD36 is a clinically significant rosetting receptor or a useful 
therapeutic target (Cabrera et al., 2014). 
 
 
1.7.5 Glycophorin A (GYPA, CD235a) 
 
Glycophorin A (GYPA) is highly abundant on erythrocytes and is one of the 
few molecules to be identified as important for protection against severe 
malaria by genome wide association studies (Band et al., 2015, Leffler et al., 
 32 
2017). GYPA is an invasion receptor for P. falciparum through an interaction 
with the parasite ligand Erythrocyte Binding Antigen 175 (EBA-175) (Sim et 
al., 1994) and individuals who express a rare hybrid form of Glycophorin A 
and B, the Dantu blood group, are protected from severe disease, potentially 
through reduced invasion (Band et al., 2015, Leffler et al., 2017, Ndila et al., 
2018, Field et al., 1994). There is some limited evidence to suggest that the 
GYPA molecule may be involved in rosetting (Goel et al., 2015). Goel et al. 
found that FCR3S1.2 parasites transfected with a RIFIN gene rosetted poorly 
with GYPA null erythrocytes of blood group O and B, but were still able to 
rosette normally with GYPA null blood group A erythrocytes, which they 
concluded was due to the superior effect of RIFIN-Blood group A binding 
(Goel et al., 2015). However, GYPA monoclonal antibody fragments did not 
disrupt rosettes in clinical isolates (Lee et al., 2014) or the lab strain 3D7 5A-
R+ (Niang et al., 2014) and Rowe et al. did not detect a reduction in rosetting 
in MkMk (GYPA and GYPB null) erythrocytes (Rowe et al., 1997). 
 
Another possibility is that the protective mechanism is not directly via the 
GYPA molecule itself, but through its association with Band 3 to form the 
Wrightb antigen (Bruce et al., 1995). This hypothesis will be further developed 
throughout Chapters 4 and 5 of this thesis.   
 
1.7.6 Glycophorin C (GYPC, CD236) 
 
Glycophorin C (GYPC), responsible for the Gerbich blood group, is a known 
P. falciparum invasion receptor which binds Erythrocyte Binding Antigen 140 
(EBA-140) expressed on merozoites (Maier et al., 2003, Mayer et al., 2006). 
Recently, two studies have suggested GYPC as a potential rosetting receptor 
for both P. falciparum and P. vivax (Lee et al., 2014, Niang et al., 2014). Lee 
et al. focussed mainly on P. vivax but also assessed the ability of BRIC 4 and 
BRIC 10 GYPC monoclonal antibody fragments to inhibit rosette formation in 
ten fresh P. falciparum clinical isolates from Thailand (Lee et al., 2014). They 
reported a significant decrease in rosetting with BRIC 4 but not BRIC 10 
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antibody fragments, though the reduction was only around 5-10% and counts 
were based on a single experiment with no replication (Lee et al., 2014). A 
GYPC knockdown was also produced using RNA interference methods in 
haematopoietic stem cells and the knockdown erythrocytes showed a more 
convincing reduction in rosetting, but only P. vivax isolates were assessed 
(Lee et al., 2014). Niang et al. used both soluble GYPC and a different GYPC 
antibody, Ret40f, to reduce rosetting in the laboratory line 5A-R+ (derived 
from 3D7) (Niang et al., 2014). They also produced GYPC knockdown 
erythrocytes and found minimal rosetting compared to wildtype cells, again 
with the single laboratory strain (Niang et al., 2014).  
 
There are a number of naturally occurring altered GYPC phenotypes, though 
the true GYPC null, known as the Leach phenotype, is rare (Telen et al., 
1991). It is due to the deletion of exons 3 and 4 of the GYPC gene resulting 
in hereditary elliptocytosis (Telen et al., 1991), and the rosetting ability of 
these cells has not been tested. More common, particularly in Melanesian 
populations (Patel et al., 2001), are the Yus and Gerbich phenotypes, arising 
from deletions in exons 2 and 3 respectively and resulting in a shortened 
GYPC molecule with altered glycosylation (Jaskiewicz et al., 2018). Gerbich 
negative variants (Ge-2,3, Ge2,-3, Ge-1, -2, -3) have been tested and 
reportedly rosette normally (Rowe et al., 1997, Goel et al., 2015). 
 
The importance of GYPC as a rosetting receptor remains unclear, however 
there appears to be sufficient evidence to support further investigation with a 
wider range of parasites lines.  
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1.7.7 IgM and 2- macroglobulin 
 
Rosetting parasites can be classified according to those which bind non-
immune IgM and those which do not (Rowe et al., 2002c, Ghumra et al., 
2012), with IgM positive binding being associated with malaria severity 
(Rowe et al., 2002c). The binding site on IgM has been identified as the Cµ4 
domain of the Fc portion (Ghumra et al., 2008), with the corresponding 
PfEMP1 binding site within the DBL and DBLdomains (Semblat et al., 
2006, Rasti et al., 2006, Ghumra et al., 2008, Stevenson et al., 2015a), i.e. 
some distance from the NTS-DBL domain thought to be key for binding with 
host erythrocyte receptors. The minimal binding site for the DBL4of the 
TM284var1 variant has been localized to subdomain 2 and parts of 
subdomains 1 and 3 (Semblat et al., 2015). While IgM itself is not sufficient, 
or always necessary, for rosetting to occur, it is hypothesized to strengthen 
rosettes and may act by cross-linking PfEMP1 molecules (Scholander et al., 
1996, Clough et al., 1998a, Stevenson et al., 2015a). 
 
More recently,  2-macroglobulin has been proposed as an important serum 
rosetting factor for some parasites, which might also promote PfEMP1 cross-
linking (Stevenson et al., 2015b). Stevenson et al. found that both 2-
macroglobulin and IgM bound the DBL2 domain from HB3var06 and the two 
molecules worked together synergistically in promoting rosette formation. Of 
note, 2-macroglobulin was also sufficient to allow rosetting in serum-free 
media (Stevenson et al., 2015b). Of the 12 Ghanaian clinical isolates also 
tested, less than half bound IgM or 2-macroglobulin (4 for 2-macroglobulin 
and 5 for IgM) and no statistically significant correlation with severe disease 
was found, though the authors note the study was not designed or powered 




1.7.8 Unidentified receptors 
 
None of the candidate receptors discussed above fully account for the 
rosetting interactions between infected and uninfected erythrocytes and 
many questions remain about the relative importance of each. Therefore it is 
likely that other, as yet unidentified, receptors are involved. There is evidence 
to suggest that these unknown receptor candidates are carbohydrates, as 
uninfected group O RBCs treated with trypsin, other proteases and 





Table 1-2 Summary of host erythrocyte rosetting receptors. From (McQuaid & Rowe, 2019 submitted). 
NAME CHARACTERISTICS STUDIES* COMMENTS 
ABO BLOOD GROUP 
ANTIGENS 
Differ based on sugar at antigen 
terminus:  




O predominant blood group in Africa 
(Cserti and Dzik, 2007) 
 
Blood group O protects against severe 
malaria (Rowe et al., 2007, Tekeste and 
Petros, 2010, Malaria Network, 2014) 
 
 
Parasites from patients with group O have 
reduced rosetting (Rowe et al., 1995, Rowe 
et al., 2007, Rout et al., 2012) 
 
Rosettes from group O patients are more 
easily disrupted by immune sera (Barragan 
et al., 2000b) 
 
In vitro rosetting rates higher for some 
parasites cultured in A, B, AB compared to 
O (Carlson and Wahlgren, 1992, 
Udomsangpetch et al., 1993, Barragan et 
al., 2000b) 
 
Removal of A/B antigen decreases rosette 
size (Barragan et al., 2000b) 
 
Blood group antigen binding site mapped to 
NTS-DBL domain of PfEMP1-VarO 
(Vigan-Womas et al., 2012) 
Rosetting does occur in group O 
 
Challenging to manipulate 
therapeutically  
 
Group A may be particularly relevant for 
RIFINs (Goel et al., 2015) 
COMPLEMENT RECEPTOR 1 
(CR1) 
Membrane glycoprotein responsible for 
regulating the complement system 
 
Polymorphisms affect copy number, 
molecular weight and sequence  
Rosetting reduced in CR1 deficient RBCs 
(Rowe et al., 1997) 
 
Soluble CR1 and CR1 antibodies disrupt 
rosettes (Rowe et al., 1997, Rowe et al., 
2000, Lee et al., 2014) 
 
Association with disease severity may 
depend on transmission intensity 
 
Soluble CR1 has been used 
therapeutically in humans in other fields 
(e.g. cardiac and renal disease (Lazar 
et al., 2004, Zhang et al., 2013))  
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Essential region mapped to C3b binding 
site on LHR B and C (Rowe et al., 2000) 
 
Protection afforded by CR1 deficiency 
depends on transmission intensity and may 
be detrimental in areas of low transmission 
(Nagayasu et al., 2001, Cockburn et al., 
2004, Teeranaipong et al., 2008, Sinha et 
al., 2009, Rout et al., 2011, Panda et al., 
2012). 
 
Sl2 polymorphism reduces the risk of 
cerebral malaria and death, particularly in 
the absence of -thalassaemia. 
Conversely, the McCb phenotype increased 
the odds of cerebral malaria. (Opi et al., 
2018) 




Differs from heparin which has higher 
levels of sulfation and is only found in 
mast cells 
 
Invasion receptor for hepatocytes 
(Frevert et al., 1993) and red cells (Boyle 
et al., 2010) 
 
Heparin disrupts rosettes in approximately 
half tested isolates (Udomsangpetch et al., 
1989, Carlson et al., 1992, Rowe et al., 
1994, Barragan et al., 1999) 
 
Heparinase treatment reduced rosetting in 
lab strains FCR3S1 and TM284(Barragan 
et al., 1999) 
 
Heparin binds to rosetting infected 
erythrocytes (Barragan et al., 2000a, 
Heddini et al., 2001) 
 
Limited evidence that HS is present on 
mature RBCs (Vogt et al., 2004) 
 
Clinical trials of low anticoagulant 
heparin ongoing (Charunwatthana et 
al., 2014) 
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Both heparin and HS bind the DBL-1 
domain of FCR3S1.2 PfEMP1 (Barragan et 
al., 2000a) 
CHONDROITIN SULFATE (CS) Glycosaminoglycan 
 
Binds specific PfEMP1 variant 
VAR2CSA in placental malaria (Desai et 
al., 2007) 
 
Soluble CS did not disrupt rosettes 
(Rogerson et al., 1994, Rowe et al., 1994, 
Barragan et al., 1999)  
 
CS did not bind to DBL-1 domain of 
FCR3S1.2(Barragan et al., 2000a) 
 
Chondroitinase treatment reduced rosetting 
in one strain only  (Barragan et al., 1999)   
Minimal evidence of role in rosetting 
CD36 Widely distributed membrane protein and 
scavenger receptor 
 
Deficiency fairly common in Africa (Fry et 
al., 2009) 
Binds PfEMP1variants associated with mild 
disease (Kraemer and Smith, 2006, 
Kyriacou et al., 2006)  
 
Antibodies disrupt rosettes in single strain 
only (Handunnetti et al., 1992b) 
Minimal evidence of role in rosetting 
 
Deficiency not associated with malaria 
severity (Fry et al., 2009) 
GLYCOPHORIN C (GYPC)  Red cell membrane protein responsible 
for Gerbich blood group 
 
Red cell invasion receptor (Maier et al., 
2003) 
GYPC antibodies disrupted rosettes in a lab 
strain and Thai isolates (Lee et al., 2014, 
Niang et al., 2014) 
 
Reduced rosetting in GYPC knockdown 
RBCs (Niang et al., 2014) (single lab 
adapted parasite strain tested)  
Possible role in Plasmodium vivax 
rosetting (Lee et al., 2014) 
 
Associated with STEVOR binding 
(Niang et al., 2014) 
GLYCOPHORIN A (GYPA) Sialoglycoprotein which, along with 
Glycophorin B, constitutes the MNS 
blood group 
Red cells deficient in GYPA showed 
reduced rosetting with RIFIN transfected 
parasites  (Goel et al., 2015) 
Suggested to bind RIFINs in the 




*Parasite strains used are not consistent between studies with a wide range of lab adapted and field isolates in use. Results are therefore not 
necessarily generalizable to all strains and within each study may apply to some tested parasites only.  
**Many studies included here use heparin instead of/in addition to heparan sulfate.
 
Red cell invasion receptor (Bei et al., 
2010) 
 
Soluble sialic acid and neuraminidase or 
trypsin treatment reduced rosetting with 
RIFIN transfected parasites cultured in 
blood group O only (Goel et al., 2015) 
 
Soluble GYPA did not disrupt rosettes in 
strain 5A-R+ (Niang et al., 2014) 
UNKNOWN RECEPTOR/S Possibly carbohydrate 
 
Protease treated RBCs still capable of 
forming rosettes (Udomsangpetch et al., 
1989, Rowe et al., 1994) 




1.8 Potential for anti-rosetting therapies 
 
1.8.1 Disruption of rosettes  
 
The diversity and complexity of potential rosetting mechanisms described 
above, from both the parasite and host perspective, presents a challenge for 
designing rosette disrupting therapies. However, this is an important avenue 
to explore as parasites can continue to exhibit cytoadherence after 
administration of anti-malarial drugs, potentially contributing to mortality and 
morbidity even after treatment (Hughes et al., 2010).  In vitro, current anti-
malarials including atovaquone, artesunate, chloroquine and quinine do not 
reduce rosetting, though screening has identified a Malaria Box compound, 
MMV006764, which showed some modest rosetting disrupting and anti-
plasmodial capability (Ch'ng et al., 2016). Anti-PfEMP1 antibodies have been 
used in vitro as targeting molecules attached to the anti-malarial lumefantrine 
forming a ‘drug-loaded immunoliposome’ (Moles et al., 2016), which had both 
anti-rosetting and growth inhibition actions. However, the effects were 
specific to the parasite strain from which the antibodies had been derived, 
and more complex pools of antibodies have yet to be tested (Moles et al., 
2016).  
 
Heparin and other sulfated glycoconjugates such as curdlan sulfate and 
fucoidan are effective at disrupting rosettes (Rowe et al., 1994, Kyriacou et 
al., 2007) but as mentioned above, their anti-coagulant activity limit their 
therapeutic potential and heparin is especially not recommended for the 
treatment of severe malaria (WHO, 1986, WHO, 2015a). Chemically 
generated low anticoagulant forms of heparin have more potential (Skidmore 
et al., 2008) and disrupted rosettes by over 15% in the majority (89%) of 
fresh African clinical isolates (Leitgeb et al., 2011) and samples from Thai 
patients (Saiwaew et al., 2017) tested in vitro. In vivo sequestration in rats 
and macaque monkeys was also reduced (Vogt et al., 2006). Human phase 
I/II clinical trials of one such low anti-coagulant heparin, Sevuparin, have 
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taken place and some evidence of desequestration was seen with no 
obvious safety concerns (Leitgeb et al., 2017). 
 
1.8.2 Anti-rosetting vaccines 
 
As discussed above, different parasites appear to utilize different host 
receptors at different times, therefore it is likely that only a certain proportion 
of rosetting parasites would be susceptible to rosette disruption by targeting 
a single receptor. Prevention of rosette formation, possibly through adding an 
anti-rosetting component to the multi-component malaria vaccines currently 
in development, is therefore an attractive prospect. Antibodies from rabbits 
immunized with various PfEMP1 domains (NTS-DBL1, DBL, DBL3, 
DBL3, CIDR2, NTS-DBL-CIDR1) derived from the R29 parasite have 
also been shown to inhibit and disrupt rosettes and promote phagocytosis in 
a strain specific manner (Ghumra et al., 2011). The anti-NTS DBL1 
antibodies was the most effective (Ghumra et al., 2011), and the DBL1 
domain from the Palo Alto VarO strain showed the same effect (Guillotte et 
al., 2015, Guillotte et al., 2016). Correct folding of the PfEMP1 domain 
appears to be key and various expression systems have been successful in 
producing antigenic proteins (Guillotte et al., 2015). Further studies have 
shown that monoclonal antibodies generated from mice immunized with a 
NTS-DBL1 domain varied in their ability to either disrupt rosettes and/or 
promote phagocycytosis and these abilities were not necessarily correlated 
(Quintana et al., 2016).  Promisingly, pools of polyclonal antibodies obtained 
through immunization of rabbits with the NTS-DBL domains from different 
IgM-binding, rosetting parasites have been successful in inhibiting rosette 
formation and promoting phagocytosis in a diverse range of heterologous 
parasites strains, including African clinical isolates (Ghumra et al., 2012). In 
this study, there was a clear distinction between parasites which were IgM 
binding or not; antibodies to IgM binding parasites (HB3R+, TM284R+ and 
IT/PAR+) were able to bind to infected erythrocytes and disrupt rosettes of 
heterologous strains which were also IgM binding, but the same effect was 
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not seen for non-IgM binding parasites (Muz12R+, TM180R+ and IT/R29) 
(Ghumra et al., 2012). This is encouraging in terms of developing a useful 
anti-rosetting vaccine. Antibody responses have been seen in several 
different species (Ghumra et al., 2012, Angeletti et al., 2013, Guillotte et al., 
2015) and further work is therefore required in determining which PfEMP1 
domains derived from which strains are capable of inducing cross-reactive 
antibodies, and which adjuvants and dose schedules are most effective with 
a view to translating this work into humans.  
 
1.9 Summary and remaining questions 
 
The most convincing evidence that a host receptor is important for rosetting, 
is demonstrating that erythrocytes lacking the receptor of interest show 
reduced rosetting with infected erythrocytes across a wide range of diverse 
clinical and laboratory adapted parasite lines. From a therapeutic point of 
view, it is useful to show that rosettes can be disrupted by blocking, or 
otherwise interfering, with the receptor, without causing harm to the host. 
Unfortunately, none of the receptors described above fully meet these 
criteria. The evidence that blood group antigens, particularly group A, have 
an important role in rosetting is perhaps the most convincing, however 
designing a therapy targeting these receptors is extremely challenging; IgM 
atnibodies to blood group antigens can cause potentially fatalhaemolysis and 
such a therapy would not benefit those with blood group O. . Though 
naturally occurring low CR1 cells and GYPC knockouts have been tested, 
reduced rosetting was only seen in a subset of parasites, and the GYPA data 
is conflicting. Heparin does appear to be effective at disrupting rosettes 
across a broad range of clinical and laboratory parasites, though the 
evidence for HS as a specific rosetting receptor is incomplete. As such, a 
thorough investigation into the GAGs, HS and CS, forms a substantial part of 
this work.   
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There is therefore a pressing need to develop new methods for investigating 
and screening for rosetting receptors. The generation of multiple, well-
characterized knockout erythrocytes would be an extremely useful tool for 
rosetting research. Such cells could be tested with multiple parasites lines 
and used for a large-scale screen such as that designed by Egan et al. (Egan 
et al., 2015). Until recently, the ability to generate usable quantities of 
genetically engineered knockout erythrocytes has been hampered by the 
lack of appropriate cell lines, but the advent of CRISPR-Cas9 technology 
(Doudna and Charpentier, 2014) and the development of immortalized 
erythroid lines (Kurita et al., 2013, Kanjee et al., 2017, Trakarnsanga et al., 
2017) may allow these obstacles to be overcome. The aim of this thesis is 
therefore to reflect back by re-evaluating the evidence for existing receptors, 
specifically HS, and look forward by developing new methods and identifying 
novel, strain-transcending rosetting receptors using erythrocyte knockouts.  
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1.10  Aims of this thesis 
 
The overall aim of this thesis is to identify the key receptors essential for 
rosetting in P. falciparum malaria, in order to inform the development of 
therapies specifically targeting severe forms of the disease. This will be 
achieved using three different lines of enquiry:  
 
1. The investigation and re-evaluation of the role of the 
glycosaminoglycans, heparan sulfate and chondroitin sulfate, as 
potential rosetting receptors: 
a. How does the specific removal of HS/CS affect rosetting? 
b. Are these molecules present on mature erythrocytes? 
 
2. The use of cultured haematopoietic stem cell derived erythroid 
cells (cRBC) to investigate potential rosetting receptors and identify 
novel targets: 
a. How does the cell surface receptor complement of cRBC from 
haematopoietic stem cells compare to mature peripheral 
erythrocytes? 
b. Do cRBC rosette? 
c. Can we use differences in rosetting between cRBC and 
peripheral erythrocytes to identify novel rosetting receptors? 
 
3. Creating knockout erythrocytes using CRISPR-Cas9 technology 
and a novel immortalized erythroid line: 
a. Are erythroid cells generated from immortalized lines suitable 
for use in rosetting research? 
b. Do knockout erythroid cells rosette? 
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2. CHAPTER II: MATERIALS AND METHODS 
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This chapter describes the procedures for in vitro culturing of P. falciparum 
parasites and the various other cell types used throughout this work, along 
with general protocols for frequently recurring techniques. Further details of 
the cell lines and specific methods are included at the beginning of each 
results chapter.  
 
All culturing was undertaken in a containment level 3 (with derogations) 
laboratory within a Class II microbiological safety cabinet under sterile 
conditions. 
 
2.1 Culturing Plasmodium falciparum  
 
2.1.1 Parasite lines 
 
A number of different culture-adapted P. falciparum lines have been used 
throughout this work in an, albeit limited, attempt to reflect the diversity of the 
parasite in the field. These have ranged from well-established and highly 
characterized lines such as ITvar60/Palo Alto, to those which have been 
more recently adapted to culture from the field such as 9605. The lines and 
their known characteristics are listed in Table 2-1. By necessity, these are all 
rosetting parasites, and it is important to acknowledge that they therefore 
represent a small proportion of an already select group. Field studies have 
shown that around 90% of parasites isolated from Malian children with 
severe malaria were able to form rosettes, compared to 55% from children 
with uncomplicated malaria, and the median rosette frequencies were 20% 







Table 2-1 Parasite lines used in this thesis.  
 
Parasite line (alternative 
names) 




(Palo Alto, PAR+, FCRS1)* 
South East Asia (Robson et 
al., 1992, Mu et al., 2005) 
First publication- 
(Udomsangpetch et al., 
1989) 
Blood group A preferring 
(Barragan et al., 2000b) 
R29/ITvar9* South East Asia (Mu et al., 
2005) 
First publication - (Roberts 
et al., 1992) 
Highly dependent on CR1 
for rosetting (Rowe et al., 
1997) 
9605 Kilifi, Kenya 
First publication - (Abdi et 
al., 2017) 
Isolated from a child with 
cerebral malaria in 2009 
(Abdi et al., 2017) 
11019 Kilifi, Kenya 
Not yet published 
Isolated from a child with 
cerebral malaria in 2009 
(Personal communication P. 
Bull) 
TM284R+ Thailand (Mu et al., 2005) 
First publication - 
(Scholander et al., 1996) 
Blood group B preferring, 
rosettes sensitive to 
disruption by soluble 
chondroitin sulfate 
(Barragan et al., 2000b) 
HB3R+ Honduras (Bhasin and 
Trager, 1984) 
First publication (of rosetting 
variant)-(Kyriacou et al., 
2007) 
The original HB3 did not 
rosette but has been 
selected for rosetting (see 
methods below and 
(Kyriacou et al., 2007)) 
*Of note, there is some uncertainty of the true origin of IT-derived parasite lines such as ITvar60 and 
ITvar9. Although the IT isolate originally came from Brazil, the culture-adapted parasite line is thought 
to have been cross-contaminated with another line some 30-40 years ago (Robson et al., 1992). PAR+ 
and R29 are clones derived from the strain IT which express different PfEMP1 variants (Rowe et al., 






2.1.2 P. falciparum culture methods 
 
Parasites were cultured in RPMI-1640 media (Lonza, BE12-167F) 
supplemented with 2mM L-glutamine (Invitrogen,. 25030-024), 25mM Hepes 
(Lonza, 17-737F), 16mM Glucose (Sigma, G8270), 25µg/ml Gentamicin 
(Lonza  17-518Z), and 1M sodium hydroxide (Fisher Scientific, S/4920/60) 
added to give pH 7.2-7.4. This ‘incomplete media’ was supplemented with 
0.25% AlbuMAXTM II Lipid-Rich BSA (Gibco, 11021-037) and 5% pooled 
human serum (Scottish National Blood Transfusion Service). Parasites were 
cultured in non-vented flasks (ranging from 25-150cm2 depending on volume 
of media required) which were gassed for 30-60 seconds (depending on flask 
size) with a mixture of 1% oxygen, 3% CO2 and 96% Nitrogen (BOC Limited, 
228446-L) and incubated at 37oC. 
 
The parasite media was changed daily, except over the weekend. A 250µl 
sample was taken from the culture flask each day and used to determine the 
parasitaemia (as detailed below). The entire culture was then centrifuged at 
900g for 4-5 minutes and the supernatant aspirated. Fresh media was added 
to give a final haematocrit of 2% (1% over the weekend) and the 
parasitaemia was adjusted to the required percentage (for maintenance 
cultures, approximately 2-5%; for rosetting experiments, 5-10%) by adding 
human erythrocytes prepared and stored as described in section 2.1.3. 
 
2.1.3 Processing donor blood for culturing 
 
In general, parasites were cultured in blood group O+, unless otherwise 
stated. Blood for parasite culturing was obtained from volunteer Scottish 
donors via the Scottish National Blood Transfusion Service based in 
Edinburgh, UK (ethical review reference number 15-37). White blood cells 
were removed by passing the contents of the blood pack through the 
leukodepletion filter provided with the pack with the aid of gravity, and the 
filtered red cells aliquoted into 15 or 50ml Falcon tubes. These tubes were 
then centrifuged at 2400g for 5 minutes and the plasma removed. 
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Erythrocytes were then washed twice with 10ml of incomplete RPMI by 
spinning at 2400g for 5 minutes, removing the supernatant then repeating. 
An equal volume of incomplete RPMI was then added to the remaining 
packed cells to give a 50% haematocrit and the blood was stored at 4oC. 
Blood was used for a maximum of two weeks after washing. 
 
2.1.4 Determination of parasitaemia using Giemsa staining 
 
A 250µl sample of the parasite culture was taken and the red cells pelleted 
by brief centrifugation. The majority of the supernatant was removed, leaving 
sufficient to resuspend the pellet at approximately 40% haematocrit. A thin 
smear was made onto a glass slide which was then dried, fixed with 
Methanol, dried again, then stained with filtered 10% Giemsa solution (TCS 
Biosciences, HS295-506 in Giemsa buffer, Merck, TP936968 805) for 25 
minutes. The stain was rinsed off with water and the smear visualized with a 
100x oil immersion objective using an Olympus BX45 light microscope. Five 
hundred cells from several different fields were counted and scored as 
uninfected, infected with ring stage parasite or infected with mature parasite 
(pigmented trophozoite or schizont) and the percentage parasitaemia 
calculated. 
 
2.1.5 Selection for rosetting 
 
Parasites were selected for rosetting using two different, alternating methods; 
Percoll (Aley et al., 1984, Handunetti et al., 1990) or flotation in 3% 
Gelatin/0.9% Saline (Gelofusine) (Handunnetti et al., 1992a). For both 
methods, selection was performed when the majority of the parasites were at 





2.1.5.1 Percoll selection 
 
A solution of 60-70% Percoll was made by first adding 10ml of 10x RPMI 
(Sigma, R1145) to 90ml of Percoll (GE Healthcare, 17-0891-01), to give 90% 
Percoll, then taking 33.3ml of the 90% solution and adding 16.7ml of 
incomplete RPMI to give 60% Percoll (volumes were adjusted to give 
different percentage solutions as required). The parasite culture was pelleted 
then resuspended in 5ml of complete RPMI and gently layered over 7ml of 
the Percoll solution in a 15ml tube using a serological pipette. The tube was 
then centrifuged at 2400g for 10 minutes. This resulted in an upper band of 
non-rosetting trophozoites at the Percoll/RPMI interface and a pellet of the 
remaining cells; uninfected and rosetting trophozoite/ring infected red cells. 
The supernatant and non-rosetting band were discarded and the remaining 
pellet washed twice with incomplete RPMI then placed back in culture. 
 
2.1.5.2 Gelofusine selection 
 
The parasite culture was centrifuged and resuspended at 50% haematocrit 
with incomplete RPMI in a 15ml Falcon tube. An equal volume of Gelofusine 
(Braun PL, 03551/0047) was added and the tube incubated, upright, at 37oC 
for 15 minutes. This resulted in the formation of two separate layers, the top 
contained the non-rosetting knob-positive trophozoites and the bottom the 
remaining cells. The top layer was removed and the bottom washed once in 
incomplete RPMI and once in complete RPMI before being placed back in 
culture.  
 
2.1.6 Synchronisation of parasites 
 
Parasites were kept synchronised at the same lifecycle stage using 5% D-
Sorbitol (5g of Sorbitol, [Sigma, S-3889] in 100ml of dH2O, sterilized by 
autoclave) which lyses mature parasites which are more permeable to 
Sorbitol (Lambros and Vanderberg, 1979). The culture was pelleted and 
resuspended in 10ml of 5% Sorbitol and incubated for 15 minutes at 37oC. 
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The solution, now containing only ring stage parasites, was then washed 
twice with incomplete RMPI and placed back in culture with complete RPMI.  
 
2.1.7 Freezing and thawing of parasites 
 
Parasites were thawed by placing a frozen vial in the water bath until the 
contents had just melted. The suspension was transferred to a 50ml Falcon 
tube and 200µl of 12% sodium chloride added (12g of NaCl [BDH, 10241AP] 
in 100ml dH2O, sterilized by autoclave) very slowly by droplet with continuous 
mixing. The suspension was left to stand for 5 minutes, then 10ml of 1.8% 
sodium chloride (1.8g of NaCl [BDH, 10241AP] in 100ml dH2O, sterilized by 
autoclave) was added in the same manner, followed by 10ml of 0.9% sodium 
chloride with 0.2% glucose (0.9g of NaCl, BDH, 10241AP, and 0.2g glucose, 
Sigma, G8270, in 100ml dH2O, sterilized by autoclave). The suspension was 
centrifuged for 4 minutes then washed with 20ml of incomplete RPMI before 
being placed into culture with a few drops of fresh blood.  
 
The parasites were frozen by pelleting the culture in a 50ml Falcon tube, 
removing the supernatant then adding filter-sterilized Glycerolyte (made of 
57g glycerol, 1.6g sodium lactate, 30mg potassium chloride, 1.38g sodium 
dihydrogen phosphate in 100ml of dH2O) in a 2 stage- process. For the first 
stage, a volume of Glycerolyte equal to one third the pellet volume was 
added slowly and dropwise with constant mixing. The tube was left for 5 
minutes then four times the original volume of Glycerolyte was added in the 
same way (giving a total of 5 volumes Glycerolyte to 3 volumes packed cell 
volume). One ml aliquots were placed in 1.8ml Nunc CryoTubes (Sigma, 
V7634) and transferred to a minus 70oC freezer or liquid nitrogen for long 
term storage. 
 
2.1.8 Magnetic activated cell sorting (MACS) 
 
Infected erythrocytes were purified using Magnetic Activated Cell Sorting  
(MACS). This method relies on the haemozoin within the mature stage 
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parasites adhering to a strong magnet, while allowing the uninfected cells 
and ring-stage parasite to pass through (Miltenyi et al., 1990, Staalsoe et al., 
1999). A VarioMACSTM Separator (Miltenyi Biotec, 130-090-282) was used 
with CS columns (Miltenyi Biotec, 120-000-490). The column was fitted with 
a three way tap and 20G needle then equilibrated by running through 10ml of 
PBS, 15ml of incomplete RPMI then 5ml of incomplete RPMI with 0.5% BSA 
(Sigma, A8577-1L) and 0.1-1mg/ml heparin (Sigma, H4784, concentration 
dependent on parasite heparin sensitivity). In parallel, the parasites were 
prepared by washing a culture aliquot contained 200µl of packed cell volume 
with incomplete RPMI then resuspending in 10ml of incomplete RPMI/0.5% 
BSA and heparin in order to disrupt the rosettes. The concentration of 
heparin required varied with the parasite strain but ranged from 0.1-1mg/ml. 
The heparin/erythrocyte mixture was incubated at room temperature for 5 
minutes then a 10µl sample checked by microscopy to ensure all rosettes 
had been disrupted.  Once the rosettes had been fully disrupted, the parasite 
solution was added to the top of the MACS column and allowed to run 
through with the flow rate controlled using the 3-way tap to approximately 1 
drop per second. The flow-through was collected and added back to the top 
of column and allowed to passed through the column a second time. Once 
the parasite solution has passed through a second time, a smear slide of the 
flow-through was made to confirm all infected erythrocytes had been 
removed, and the column was washed with 10-20ml of incomplete RPMI with 
heparin and 0.5% BSA. The column was then removed from the magnet and 
10ml of incomplete RPMI/0.5% BSA/heparin plunged into the column using a 
20ml syringe through the side port of the three way tap. The liquid was 
withdrawn then plunged back in and out of the column several times to obtain 
the infected erythrocytes which had adhered to the magnet, before being 
place in a 15ml tube. A 500µl aliquot of the parasite containing solution was 
taken and a thin smear made to check the percentage purity of the parasites. 
The remainder of the cells in the heparin solution were centrifuged for 4 
minutes at 900g and the supernatant aspirated. The pellet was resuspended 
in incomplete RPMI without heparin and centrifuged again to wash the cells 
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two further times. After washing, the purified parasites were resuspended in 
complete RPMI and used immediately for experiments. If multiple purified 
parasite lines were required on the same day, the smaller QuadroMACSTM 
cell separator was used along with the corresponding LS columns (Mitenyi 
Biotec,130-042-401). The columns and parasites were prepared in the same 
manner, however only 50µl of PCV was purified and the parasite solution 
allowed to flow through by gravity, not controlled by a 3-way tap.  
 
 
2.2 Culturing and maturation of haematopoietic stem cells 
(HSC) 
 
Frozen, human, adult bone marrow CD34+ cells were purchased from 
StemcellTM technologies (www.stemcell.com, 70002). All donors (with one 
exception, see Table 2-2) were of Caucasian origin to minimise the possibility 
of the cells containing malaria-protective polymorphisms that could influence 
rosetting, and all had tested negative for HIV, Hepatitis B and C. Additional 
frozen, human, adult bone marrow CD34+ cells were also purchased from 
Lonza (Lonza PoieticsTM, 2M-101). The characteristics of each of the donors 
provided by the companies are listed in Table 2-2. Two vials of human 
umbilical cord haematopoietic stem cells were a kind gift from Professor 






















SCT D001004313 40/F Caucasian 156/57 UNK 
SCT D001003739 37/F Caucasian 176/75 UNK 
SCT 1002328 55/M Caucasian 176/98 A+ 
SCT 1001448 46/M Caucasian 182/92 A+ 
SCT D001004150 30/M Caucasian 181/84 B+ 
SCT D001003739 37/F Caucasian 176/75 O+ 
SCT 1000779 49/M Caucasian 180/94 O+ 
Lonza 0000578848 29/F Caucasian UNK UNK 
Lonza 0000521847 28/F Caucasian UNK UNK** 
Lonza 0000573127* 26/M Asian UNK UNK 
*This donor was selected and shipped by Lonza in error. Cells were used in preliminary culturing 
experiments only and not in rosetting assays. **Did not express A antigen on flow cytometry.  SCT= 
Stem cell technology, F= female, M= male, UNK= information not available. 
 
2.2.1 Thawing of CD34+ HSC 
 
A frozen vial of HSC was placed in a water bath at 37oC until just thawed, 
then transferred to a 15ml Falcon tube to which 9ml of pre-warmed culture 
medium (see below) was added, dropwise with gentle mixing. The cells were 
then centrifuged at 300g for 10 minutes, the supernatant aspirated and the 
pellet resuspended at the appropriate density for the age of the cells as 
described below (i.e. 1x104 cells/ml for a fresh vial or 6x104 cells/ml for cells 
frozen on day 6 of culture) before being placed in 25cm2 vented flasks. 
 
2.2.2 CD34+ HSC cell culture methods 
 
The CD34+ haematopoietic stem cells, hereafter referred to as cRBC, were 
cultured using a three-stage technique adapted from (Giarratana et al., 
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2011). The protocol used here was kindly provided by Dr Jo Mountford 
(University of Glasgow). Cells were thawed as described above, and 
resuspended in base media consisting of Iscoves basal media with 4mM 
Glutamine (Biochrom AG, FG0465M), 5% Human AB serum, (“off the clot” 
and unfiltered, TCS Biosciences, CR300-500), 3U/ml heparin (Sigma, 
H4784), 10µg/ml Human Insulin solution (Sigma, I9278) and 200µg/ml Holo-
Transferrin (Sigma, T0665). The base media was supplemented with day 0-8 
additives (Table 2-3) and the cells placed in a 25cm2 vented flask which was 
kept in a 5% CO2/air incubator at 37oC. Table 2-3 illustrates the subsequent 
daily culturing process.  
 
Of note, until day 8 the culture media was not fully changed, fresh media was 
simply added to give the required cell density as shown in Table 2-3. 
However, the additives were fully re-supplemented, for example, if 4ml of 
media was added to an existing 10ml already in the flask on day 6 then 14ml 
worth of additives were also added. On and after day 8 (except on day 15) 
the entire culture was centrifuged at 300g, supernatant removed and fresh 
media added with additives to give the required cell density. Cells were 
generally used for experiments up to day 21, as significant deterioration and 
cell death was noted after this point. 
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Table 2-3 Culturing protocol for cRBC 
 Day 0 
 




1x104 2x104 4x104 6x104 1-3x105 5-10x105 1-10x106 1-10x106 1-10x106 



























































Additives D0-8 D8-11 D11-25 
SCF 60ng/ml (Peprotech, 300-07) 
IL3 5ng/ml (Peprotech, 200-03-2) 
EPO 3U/ml (Biolegend, 587102) 












2.2.3 Determination of cell count  
 
Cells were counted using an improved Neubauer haemocytometer (depth 
0.1mm, AC1000, Hawksley). Ten l of well-mixed cell suspension was 
placed under the haemocytometer coverslip and two separate counts from 
different large squares on the haemocytometer grid were made then 
averaged. This number gave the number of cells x104 per ml and could 
therefore be used to calculate the total number of cells. 
 
2.2.4 Filtration to remove nucleated cells 
 
In order to obtain a pure, enucleated culture, cells could be filtered to remove 
those which still contained a nucleus. The number of cells in the culture were 
counted, then the required volume was washed once in incomplete RPMI 
then resuspended in 5ml (to maximum 1x108 cells in 5ml) of warm 
incomplete RPMI. The plunger of a 10ml syringe was removed and a filter 
unit (Acrodisc Pall, 32mm syringe filter with 5µm Supor® membrane, 4650) 
attached. The syringe-filter set up was primed by running through 5ml of 
warm PBS with 2% BSA (PBS with 333µl of 30% BSA) after which the 5ml 
cell suspension was allowed to flow through into a 50ml Falcon tube using 
gravity. A further 5ml of incomplete RPMI was added to the top of the syringe 
and allowed to flow through. After this, a final 5ml of incomplete RPMI was 
added and the plunger reattached and slowly depressed. The resulting 
suspension was centrifuged for 15 minutes at 200g and the pellet washed 
once with incomplete RPMI before being resuspended as required.  
 
Of note, even with a highly enucleated culture, the filtration process reduced 
the number of cells by 80-90% therefore in general, unfiltered cells were 
used in experiments. These unfiltered cells generally contained 70-90% 
enucleated cells. 
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2.2.5 Freezing cRBC 
 
Cells were frozen up to and including day 7 of culture but not beyond. The 
cells were counted then centrifuged down at 300g for 5 minutes. The pellet 
was then resuspended in culture medium at 2x106 cells/ml before adding the 
same volume of freezing medium (60% KnockOutTM serum replacement 
[Thermo Fisher A3181501], 20% DMSO and 20% culture medium).  One ml 
aliquots were placed in 1.8ml Nunc CryoTubes (Sigma, V7634) and 
transferred to a minus 70oC freezer or liquid nitrogen for long term storage. 
 
2.3 Culturing and differentiation of an immortalized erythroid 
line (EJ cells) 
 
The immortalized erythroid line known as EJ cells was developed by Dr Erik 
J Scully, Dr Estela Shabani and others at Professor Manoj Duraisingh’s 
laboratory at the Harvard T.H. Chan School of Public Health in Boston, USA. 
The cells used in this thesis were a kind gift from Professor Duraisingh and 
the following protocols are adapted from those developed by Dr Erik J. Scully 
and Dr Estela Shabani. Further details about the EJ cells are contained in the 
introduction of Chapter 4. Of note, all the EJ cells used, including wildtype EJ 
cells, have been transduced with a LentiCas9-Blast as the first stage of the 
LentiGuide-Puro two vector CRISPR-Cas9 protocol (Sanjana et al., 2014). 
The EJ cells therefore have a Blasticidin inducible Cas9 integrated into the 
cell line.  
 
2.3.1 Thawing EJ cells 
 
EJ cells were thawed by placing the frozen vial in a water bath at 37oC for 3-
4 minutes then adding 10ml of pre-warmed pIMDM (see below), dropwise 
with gentle mixing in a 15ml Falcon tube. The cells were then centrifuged at 
200g for 7-8 minutes, washed once in pIMDM then seeded at 5x104 cells/ml 
in maintenance media. 
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2.3.2 EJ cell culture methods 
 
2.3.2.1 Maintenance  
 
 EJ cells were maintained in their replicating and relatively undifferentiated 
state in maintenance media (referred to hereafter as pIMDM, Table 2-4), with 
the addition of 5% human AB serum, Dexamethasone, Doxycycline, 
Erythropoietin and Stem Cell Factor (for details and concentrations, see 
Table 2-5). The pH of the media was adjusted to approximately 7.4. 
 
Table 2-4 Components of EJ base medium, pIMDM 
  Final concentration 
(after serum added) 
Iscove’s liquid medium with stable Glutamine  





Human Insulin solution 
(Sigma I9278) 
10µg/ml 
Heparin sodium salt  
(Sigma H4784) 
2IU/ml 
Penicillin/Streptomycin 10,000U/ml  
(Gibco 15140122 ) 
0.5% v/v 
 
Both Dexamethasone and Doxycycline prevent differentiation further along 
the erythroid line and maintain the immortalization of the cells. Blasticidin 
was used to select for expression of Cas9 enzyme, and Puromycin to select 
for the knockout cells (Table 2-5), as required, however these reagents were 
not routinely added for daily culturing. 
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Human AB Serum  
(TCS biosciences 
CR300-500) 
5% 5% 5% 
Dexamethasone  
(Sigma D4902) 
1µM Nil Nil 
Doxycycline hyclate  
(Sigma D9891) 
1µg/ml 0.5µg/ml Nil 
Erythropoietin 
(Biolegend 587102)  
3U/ml 3U/ml 3U/ml 
Stem cell factor 
(Peprotech 300-07) 
















*For cells integrated with Cas9 **For Knockout cells only 
 
Cells were seeded at 5x104 cells/ml in vented 75cm2 flasks and grown in 5% 
CO2 at 37oC. The medium was changed every 2-3 days by centrifuging the 
contents of the flask for 7-8 minutes at 200g, aspirating the supernatant and 




2.3.2.2 Differentiation  
 
The immature, undifferentiated EJ cells were driven down the pathway 
towards maturity by modifying the additives to the base pIMDM and 
supporting the cells with a murine stromal line, MS-5 (Itoh et al 1989) as 




Figure 2-1 Differentiation of EJ cells to maturity supported by MS-5 cells. Images show cell morphology at using a x40 objective on an Olympus BX45 light microscope 
on day 0, 4, 7 and 11











































Over the week prior to starting differentiation, the EJ cells were expanded to 
approximately 5-10x106 cells. According to Dr Shabani (personal 
communication), a further two- to four-fold expansion can be expected with a 
variable enucleation rate of 1-8%. However, I found that after an initial 
expansion, cell numbers reduced markedly after around 8 days due to cell 
death. On day zero, the EJ cells were centrifuged at 200g for 7-8 minutes 
then resuspended in pIMDM with early differentiation media additives (Table 
2-5). The day after the start of the differentiation process (D1), 2 x106 MS-5 
cells were thawed as described in section 2.5.2 and the media changed the 
following day. On day 3, the stroma cells were lifted and 3x105 cells per flask 
were seeded into 25cm2 vented flasks in preparation for plating of the EJ 
cells. On day 4 the EJ cells were centrifuged at 200g for ten minutes then 
counted and resuspended at 5x106 cell/ml in pIMDM with late differentiation 
media additives (Table 2-5). The cell-containing media was pipetted onto 
MS-5 stromal cells (after aspiration of stroma media) and the flasks 
incubated at 37oC in an incubator with 5% CO2 as before. Of note the 
minimum and maximum volumes of EJ cells per 25cm2 flask were 8 and 
12ml, therefore if the resulting volume of media was less than 8ml, the cells 
were diluted further and if greater than 12ml then more than one stromal 
flask was used. On day 7, the EJ cell media was changed as described for 
day 4 and the cells replated on fresh stroma. Mature EJ cells were harvested 
on day 8-11 by gently aspirating the EJ cell suspension off the adherent 
stroma, centrifuging at 200g for 10 minutes then resuspending in pIMDM with 
late differentiation media. Cells could be stored at 4oC for 1-2 days if 
required, though significant number of cells were lost during this brief period 
of storage. 
 
2.3.3 Determination of cell count  
 
Cells were counted as described in section 2.2.3. 
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2.3.4 Selection for undifferentiated cells using Percoll gradient  
 
If the undifferentiated EJ cell pellet was noted to be turning pink/red 
indicating the beginnings of maturation, the cells were separated into early 
and late stages using 40% Percoll (Kanjee et al., 2017). Briefly, the cells 
were pelleted then resuspended in 4ml of pIMDM with 0.1% BSA then gently 
layered onto 4ml of 40% Percoll (GE Healthcare, 17-0891-01, see section 
2.1.5.1) in a 15ml Falcon tube. The tube was then centrifuged at 1000g for 
ten minutes with low acceleration and deceleration. This resulted in the more 
mature cells pelleting at the bottom of the tube and the earlier, 
undifferentiated cells at the Percoll/medium interface (Figure 2-2). The 
separated cells were then washed three times in pIMDM and resuspended or 




Figure 2-2 Separating immature/maturing EJ cells using 40% Percoll. Cells were stained with May-
Grunwald/Giemsa as described in the text and visualized on an Olympus BX45 light microcope. 
Images were taken with an iPhone 5 camera phone.   
 
2.3.5 Freezing of cells 
 
The cells were counted then the required volume centrifuged for 7-8 minutes 
at 200g resuspended in 5ml of cold, sterile, heat-inactivated fetal bovine 
serum (FBS, Gibco, 10500-064) then centrifuged again at the same speed 
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for the same time. The cell pellet was then resuspended in sufficient FBS to 
given 2x106 cell/ml and an equal volume of cold freezing solution (80% FBS 
and 20% DMSO) was added, slowly and dropwise with gentle mixing. One ml 
aliquots were placed in 1.8ml Nunc CryoTubes (Sigma, V7634) and 
transferred to a minus 70oC freezer or liquid nitrogen for long term storage. 
 
2.4 Culturing of COS 7 cells 
 
2.4.1 Cell culture methods and passage 
 
COS 7 cells were obtained from ATCC (https://www.lgcstandards-atcc.org/, 
ATCC CRL-1651TM). COS 7 cells were cultured in Dulbecco Modified Eagle 
Medium (Sigma, D6421) with 100U/ml Penicillin/0.1mg/ml Streptomycin 
(Gibco 15140122), 2mM L-Glutamine (Gibco, 25030-024), 10mM Hepes 
(Lonza, 17-737F) and 10% heat inactivated fetal bovine serum (Gibco 
10500-064). Approximately 20-30ml of media was used per 75cm2 flask and 
cells were incubated at 37oC in an incubator with 5% CO2/air. 
 
When the cells reached 80-100% confluency (usually every 3-4 days), flasks 
were split at a ratio of 1:4 or 1:5.  The spent medium was removed by 
aspiration and the flasks washed twice with 10ml of sterile, warmed PBS. 
Three ml of Trypsin/EDTA (0.25%, Gibco, 25200056) was added and 
incubated for six minutes at 37oC. The flasks were inspected on an inverted 
microscope to ensure the cells had lifted, then 10ml of culture medium with 
FBS was added and the whole suspension centrifuged in a Falcon tube for 
10 minutes at 600g. The supernatant was removed, and the cell pellet 
resuspended in fresh medium and split as required. 
 
2.4.2 Freezing and thawing of cells 
 
A frozen vial of COS 7 cells was placed in a water bath at 37oC until the 
contents had thawed, then 10 ml of culture medium was added and 
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centrifuged at 600g for 4 minutes. The supernatant was removed, cells 
resuspended in 10ml of fresh medium then placed in a 25cm2 flask which 
was incubated 37oC in 5% CO2/air. 
 
For freezing, cells were lifted as described above, washed once in culture 
medium then counted and resuspend at 1x106 cells/ml in freezing solution 
(90% culture medium with 10% DMSO) before transfer to a minus 70oC 
freezer or liquid nitrogen. 
 
2.5 Culturing of MS-5 stromal cells 
 
2.5.1 Cell culture methods and passage 
 
MS-5 murine stromal cells were purchased from the Leibniz Institute DSMZ-
German Collection of Microorganisms and Cell Cultures (Drexler et al., 
2001). Cells were cultured in 75cm2 vented flasks in 5% CO2 at 37oC in 
Minimum Essential Medium  with nucleosides and GlutaMAXTM (Gibco, 
32571028), supplemented with 10% heat inactivated fetal bovine serum 
(Gibco 10500-064) and 0.5% v/v Penicillin/Streptomycin (Gibco 15140122). 
 
Confluent cultures were split 1:3 every 2-3 days using the same method 
described in 2.4.1, except that the centrifuge speed was adjusted to 200g. 
This process constituted one passage. As the ability of MS-5 cells to support 
EJ cell differentiation is related to the passage number of the MS-5 cells 
(Estela Shabani, personal communication), the stromal cells were not used 
beyond passage 14. 
 
2.5.2 Freezing and thawing of MS-5 cells 
 
The MS-5 cells were thawed by placing the frozen vial in a water bath at 
37oC for 2-4 minutes then adding 10ml of pre-warmed culture medium, 
slowing and dropwise with gentle mixing. The suspension was then 
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centrifuged for 5 minutes at 200g, the supernatant aspirated and the cells 
seeded at 1-2x106 cells per 75cm2 flask with 20ml of media per flask. 
 
Cells were frozen by lifting the cells as described above, counting, 
centrifuging at 200g for ten minutes, and resuspending at 2x106 cells/ml in 
freezing medium (70% culture medium, 20% FBS and 10% DMSO). One ml 
aliquots were placed in 1.8ml Nunc CryoTubes (Sigma, V7634) and 
transferred to a minus 70oC freezer or liquid nitrogen for long term storage.  
 
2.6 Rosetting assays 
 
2.6.1 General determination of rosette frequency 
 
The rosette frequency of parasites in culture was determined by taking a 
250-500µl aliquot of culture into a 500µl Eppendorf tube and staining with 
25µg/ml of ethidium bromide (1% stock, Sigma, 46067) for two minutes at 
37oC. A 10µl aliquot of the stained culture was then place on a microscope 
slide and covered with a 22x22mm coverslip. The cells were viewed under 
combined florescence and white light using a Leica DM LB2 florescent 
microscope. Trophozoite infected erythrocytes were identified by the bright 
orange dot of fluorescence and two hundred of these infected cells counted 
and scored as rosetting or non-rosetting, based on whether or not they were 
adherent to at least two uninfected erythrocytes. The rosetting frequency was 
expressed as the percentage of infected erythrocytes forming part of a 
rosette compared to all infected erythrocytes. An example image from a 




Figure 2-3 Rosetting parasite culture at x40 and x100 (inset) magnification. Rosettes are indicated with 
blue arrows. 
 
2.6.2 Rosette disruption 
 
A range of molecules, including heparin, antibodies, antibody fragments and 
soluble proteins were tested for their ability to disrupt rosettes. Further details 
are included in the relevant chapters, however the basic protocol for these 
rosette disruption experiments is described here. For rosette disruption 
assays, parasite infected cultures were washed and resuspended in 
complete RPMI binding medium which does not contain sodium bicarbonate, 
and therefore has a more stable pH than regular culture medium when 
carrying out experiments in which the parasites are not gassed. Binding 
medium consists of RPMI powder (Gibco 13018-015, contains Glutamine 
and HEPES) dissolved in distilled water with pH adjusted to 7.4, 16mM 
Glucose (Sigma, G8270), 25µg/ml Gentamicin (Lonza, 17-518Z), and 10% 
heat-inactivated human serum. Incomplete RPMI binding medium is 




As rosetting only occurs at the pigmented trophozoite and schizont stage, 
synchronized cultures containing predominantly these mature stages were 
used for experiments. Generally, 2ml of mature-stage culture suspension at 
2% haematocrit was pipetted into a 15ml Falcon tube and 2µl of ethidium 
bromide (i.e. 1:1000 of 1% ethidium bromide, Sigma 46067) added. This was 
incubated for 2 minutes at 37oC then centrifuged for 4 minutes at 900g and 
the supernatant removed for disposal through charcoal-filtering and 
incineration as per protocol for ethidium bromide containing waste. The pellet 
was resuspended in 2ml of pre-warmed complete RPMI binding medium and 
45µl aliquots placed into 1.5ml Eppendorf tubes. Five µl of the substances 
under investigation at the appropriate concentration were added, along with a 
positive control (usually Fucoidan, final concentration 100µg/ml, Molekula, 
9072-19-9) and negative control (PBS) and all the tubes were blinded by a 
colleague before being incubated at 37oC for 60 minutes with resuspension 
via gentle flicking every ten minutes. Once the incubation time was complete, 
1.8µl samples were pipetted onto a multispot slide (12 well, 6mm, Hendley-
Essex, PH001) and two hundred infected erythrocytes were counted and 
scored to give rosette frequency as a percentage. This was then repeated 
with a fresh sample on a second slide and the mean rosette frequency from 
the two counts (i.e. two technical replicates) was calculated for each sample. 
 
2.6.3 Rosetting with cRBC and EJ cells 
 
Rosetting assays with cRBC and EJ cells (Figure 2-4) were carried out by 
first MACS purifying the infected erythrocytes as detailed in section 2.1.8. 
The resulting pellet contained both infected erythrocytes, and a percentage 
of uninfected erythrocytes (usually around 20-30%, but potentially up to 50% 
of the cells were uninfected). In order to distinguish between these 
‘contaminating’ erythrocytes, and the enucleated cRBCs/EJ cells, either the 
cRBC/EJs or the MACS purification pellet was stained with CellTraceTM 
Oregon GreenTM 488. To stain the pellet, the cells were resuspended in 
200µl of incomplete RPMI with heparin/0.5%BSA (heparin concentration 0.1-
 71 
1mg/ml depending on parasite line) and 0.2µl of CellTraceTM Oregon 
GreenTM 488 (Carboxylic Acid Diacetate, Succinimidyl Ester, InvitrogenTM, 
C34555), then incubated at room temperature on a 37cm diameter rotating 
wheel for 20 minutes at 30rpm. CellTraceTM Oregon GreenTM 488 is cleaved 
by intracellular esterase and binds to amines with minimal reported cell 
toxicity (https://www.thermofisher.com/order/catalog/product/C34555). Pilot 
experiments showed that staining had no effect on rosetting ability. Once the 
20-minute CellTraceTM incubation was complete, one ml of complete RPMI 
binding medium and 1.2µl of ethidium bromide were added and the tube 
incubated for a further 10 minutes at 37oC. The cells were then washed twice 
with incomplete RPMI to remove all traces of heparin then resuspended in 
100µl of complete binding RPMI for every 10µl packed cell volume. The 
process for staining cRBC or EJ cells was the same as that described above 
except RPMI binding medium without heparin was used and no ethidium 
bromide was added. 
 
In parallel to the infected erythrocyte preparation, 2.5x105 cRBC or EJ cells 
were stained with CellTraceTM if required, then washed once in complete 
RPMI binding medium then resuspended in 10µl of complete binding 
medium. A control sample of donor erythrocytes was also prepared in the 
same way. Approximately 2µl of the purified infected erythrocytes (resulting 
in approximately 10% parasitaemia) were added to the cRBC/EJ and control 
tubes, which were then incubated at 37oC for one hour. Every 10-15 minutes 
the tubes were gently resuspended by flicking the Eppendorf tubes. Slides 




Figure 2-4 Schematic of rosetting assay with cRBC or EJ cells 
 
2.7 Statistical analyses and production of figures  
 
All statistical analyses were carried out using Graphpad Prism software 
(Version 7.0, La Jolla California, USA, www.Graphpad.com). Specific tests 
used are described in the methods of the relevant chapters. A p-value of 
<0.05 was considered to be statistically significant throughout.  
 
Figures were created using Adobe Illustrator CC (2017.1.0 Release) and 
Microsoft PowerPoint for Mac (Version 16.16, 180812). Some microscopy 
images were modified using ImageJ (version 2.0.0-rc-46/1.50g, 
http://imagej.net); details of the microscopes and cameras used along with 
any image manipulations have been included in the text or figure captions. 




























3 CHAPTER III: ARE THE GLYCOSAMINOGLYCANS 
HEPARAN SULFATE AND CHONDROITIN 




The Glycosaminoglycans are an incredibly diverse group of molecules with 
important roles in maintaining the extracellular matrix, cell signalling, 
proliferation and adhesion, both physiological and pathological. Of particular 
interest in the context of P. falciparum malaria are heparan sulfate (HS) and 
chondroitin sulfate (CS). In addition to their roles in hepatocyte invasion, 
sequestration and placental malaria, both HS and to a lesser extent CS have 
been proposed as rosetting receptors, though the evidence for both is 
somewhat limited. The results of a screening glycan microarray added weight 
to the hypothesis that both HS and CS might be important rosetting receptors 
and I set out to investigate this further using both a “block” (disrupting 
rosettes with heparin) and “chop” (enzymatic cleavage of HS or CS) 
approach with a panel of laboratory adapted parasites. While rosettes were 
disrupted by heparin in all parasite lines tested, I found that treatment of 
erythrocytes with carefully validated enzymes (Heparinase III and 
Chondroitinase ABC) had no effect on rosetting, suggesting that neither HS 
nor CS were specific host erythrocyte rosetting receptors. The binding of 
recombinant PfEMP1 domains from rosetting parasites was also unaffected 
by enzymatic treatment of uninfected erythrocytes. In addition, we found no 
evidence that mature erythrocytes actually express either HS or CS, though 
HS can be detected on early haematopoietic stem cell erythroid precursors. 
These data suggest that, contrary to current dogma in the rosetting field, HS 
is not a rosetting receptor on the uninfected erythrocyte surface and I also 





3.2.1 Glycosaminoglycans and proteoglycans 
 
The glycosaminoglycans (GAGs) are a diverse group of carbohydrate 
molecules composed of repeating disaccharide units which form large, linear, 
unbranched, polysaccharide chains (Gandhi and Mancera, 2008). There are 
four GAG subgroups (Gandhi and Mancera, 2008, Caterson, 2012, Kamhi et 
al., 2013, Alberts et al., 2014): 
1. Hyaluronan (hyaluronic acid or hyaluronate, HA)- MW 4-8000kDa, 
the simplest but largest GAG with 25,000 non-sulfated disaccharide 
units consisting of glucuronic acid and N-acetylglucosamine. Different 
to other GAGs as it is not attached to protein (i.e. not a proteoglycan) 
and is unsulfated.  
2. Chondroitin/dermatan sulfate ABCDE (CS)- MW 5-50kDa, a 
Galactosaminoglycan. The disaccharide units consist of N-acetyl 
galactosamine and glucuronic or iduronic acid. The types, A-E, differ 
in their disaccharide repeats and sulfation pattern (A= GlcA1-
3GalNAc4S, B=IdoA1-3GalNAc4S, C= GlcA1-3GalNAc6S, D= 
Glc2S1-3GalNAc6S and E=  GlcA1-3GalNAc4S, 6diS). Dermatan, 
previously considered a separate subgroup, is now known as 
Chondroitin B.  
3. Heparin and heparan sulfate (HS)- MW 10-70kDa, 
Glucosaminoglycans. The disaccharide units consist of N-acetyl-
glucosamine and glucuronic or iduronic acid with variable sulfation 
patterns. Heparin is a distinct form of heparan sulfate which is found 
exclusively within mast cells and is very highly sulfated. 
4. Keratan sulfate (KS)- MW 4-19kDa. The disaccharide units consist of 
galactose and N-acetylglucosamine. 
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A schematic of the structure of the GAG subgroups, taken from (Caterson, 





Figure 3-1 Schematic taken from (Caterson, 2012) showing the structure of the GAG subgroups. HA = 
Hyaluronan, KS = Keratan sulfate, CS = Chondroitin sulfate, DS = Dermatan sulfate (now considered 
to be a chondroitin sulfate B), Hep/HS = Heparin/heparan sulfate. 
 
The majority of GAGs, with the exception of hyaluronan, exist as 
proteoglycans, consisting of a ‘core’ protein with attached GAG chains 
(Figure 3-2). The core protein can have a molecular weight of 10 to >600kDa 
(Alberts et al., 2014), and a hugely variable number of attached GAG chains 
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ranging from one (decorin) to over a hundred (aggrecan) (Alberts et al., 
2014, Iozzo and Schaefer, 2015). The core protein can also support more 
than one type of GAG chain and, in the case of the Glypicans, may be linked 
to the cell membrane via a glycosylphosphatidylinositol anchor (Iozzo and 
Schaefer, 2015). For example, the syndecan family, which are amongst the 
best characterised proteoglycans, have a core protein of 31-45kDa and carry 
1-3 GAG chains which can be both HS and CS (Varki   et al., 2009). This, 
combined with the variation in sulphation of the GAG chains, makes for an 
extremely diverse range of molecules (Iozzo and Schaefer, 2015).  
 
 
Figure 3-2 Examples of cell surface proteoglycans. Adapted from (Iozzo and Schaefer, 2015). 
 
The GAGs are negatively charged and hydrophilic with a tendency to adopt a 
large volume in solution (Gandhi and Mancera, 2008). It is therefore 
unsurprising that they are found in the extracellular matrix of connective 
tissue, synovial fluid, cartilage, tendons, ligaments and the vitreous humour 
of the eye (Gandhi and Mancera, 2008). Chondroitin sulfate is also present in 














Mancera, 2008). However, the GAGs offer more than just cushioning for 
joints; they are also involved in cell signalling, proliferation (as co-receptors 
for fibroblast growth factors), inflammation and adhesion (Gandhi and 
Mancera, 2008, Iozzo and Schaefer, 2015). Mutations affecting GAG 
biosynthesis, particularly HS and CS, results in serious, multi-system 
pathology including Ehlers-Danlos syndrome, hereditary multiple exostoses, 
Simpson-Globai-Behmel syndrome and other chondrodysplasias (Mizumoto 
et al., 2013, Iozzo and Schaefer, 2015). 
 
In addition to their important physiological role, a wide range of pathogens 
are thought to utilise GAG binding either to invade, or as a co-receptor for 
invasion. These range from viruses such as Cytomegalovirus, Dengue, 
Herpes simplex and Ebola (Chen et al., 2008, Kamhi et al., 2013, Tamhankar 
et al., 2018), bacteria such as Bordetella pertussis, Chlamydia, Helicobacter 
pylori and Mycobacterium tuberculosis, and parasites including Toxoplasma 
gondii and P. falciparum (for a complete list of GAG-pathogen interactions 
see (Chen et al., 2008, Kamhi et al., 2013). These pathological adhesion 
phenotypes make the GAGs particularly interesting candidates to study in the 
context of rosetting. For reasons discussed below, including the results of a 
GAG screening microarray (section 3.2.5), I chose to specifically focus on 
heparin/heparan sulfate and chondroitin sulfate as potential rosetting 
receptors and the remainder of this chapter will refer to solely to these GAGs. 
 
3.2.2 Heparan sulfate, heparin and chondroitin sulfate: Biosynthesis 
and expression 
 
The initial biosynthesis of both HS and CS is similar, taking place in the 
endoplasmic reticulum and Golgi apparatus (Prydz and Dalen, 2000). A four 
sugar ‘linker tetrasaccharide’ is formed and covalently bound to the serine 
residue of a core protein (Figure 3-3), after which either a glucosamine or 
galactosamine is added to determine whether the chain will become HS or 
CS respectively (Prydz and Dalen, 2000, Mikami and Kitagawa, 2013). The 
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chain is then extended and further modified through sulfation and/or 
acetylation giving rise to a multitude of different structures. Chondroitin 
sulphotransferases can add a sulfate group at the 4- or 6- position of the N-
acetyl-galactosamine or position 2 of the glucuronic acid of CS (Caterson, 
2012, Mizumoto et al., 2013). HS can be sulfated at the 2-, 3- and 6- position 
and the glucosamine residue can be N-acetylated or N-sulfated (Caterson, 
2012). In total, 1008 possible pentasaccharide combinations have been 




Figure 3-3 HS and CS biosynthesis. Both the coding genes and enzymes required for each link are indicated.
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HS molecules can be classified according to their location as membrane-
bound (syndecans, glypicans, betaglycan, neuropilin and CD44), contained 
within secretary vesicles (serglycin) or part of the extracellular matrix (agrin, 
perlecan, collagen XVIII) (Sarrazin et al., 2011). The membrane-bound 
forms, of particular interest here as potential rosetting receptors, are found 
on endothelial cells, fibroblasts, and lymphocytes (Sarrazin et al., 2011). 
There is a single paper which suggests that HS can also be detected on 
mature erythrocytes (Vogt et al., 2004), however, as will be discussed at 
length throughout this chapter, there are a number of issues regarding these 
findings.  
 
Heparin is a unique form of HS which is of great therapeutic importance due 
to its anticoagulant properties (Gandhi and Mancera, 2008). Compared to 
HS, heparin is much more highly sulfated with 1.8-2.4 sulfate units per 
disaccharide compared to 0.8-1.8 for HS (Gandhi and Mancera, 2008). This 
gives heparin the highest negative charge of any biological molecule, and, 
along with other structural modifications such as a higher L-iduronic acid 
content, makes heparin a distinct molecule from other types of HS (Gandhi 
and Mancera, 2008). In addition to these biochemical differences, heparin is 
only found within mast cells, where it can exist as the proteoglycan serglycin 
(Iozzo and Schaefer, 2015). Given this very limited expression, it is unlikely 
that heparin itself has a role as a specific rosetting receptor, but despite this, 
heparin has been used as an analogue for HS in rosette disruption 
experiments (for example (Carlson et al., 1992)) which has led to the general 
assumption that HS molecules are important rosetting receptors (Mercereau-
Puijalon et al., 2008, Rowe et al., 2009).  
 
As discussed above, CS is widely expressed in various human tissues from 
cartilage to the aorta (Gandhi and Mancera, 2008). However, there appears 
to be no published evidence as to whether CS exists on mature human 
erythrocytes, though two papers do describe the presence of CS on rat 
erythrocytes (Srikanth et al., 2012, Gowd and Nandini, 2015) 
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3.2.3 Multiple roles for heparan sulfate and chondroitin sulfate in 
malaria pathogenesis 
 
Both HS and CS have a role in multiple aspects of malaria pathogenesis. 
From the very beginning, sporozoites injected by the mosquito utilize HS 
expressed on hepatocytes to invade the liver (Frevert et al., 1993, Coppi et 
al., 2007, Dundas et al., 2018). Boyle et al. (2010) and Kobayashi et al. 
(2010) have suggested that HS-like molecules are also involved in merozoite 
invasion into erythrocytes. (Boyle et al., 2010, Kobayashi et al., 2010). 
However, both these studies rely on using heparin, rather than HS, to inhibit 
invasion. They demonstrate binding of heparin to their parasite ligand of 
interest (MSP142 for Boyle et al. and BAEBL for Kobayashi et al.), but do not 
appear to acknowledge that it could be this which is inhibiting invasion, rather 
than heparin blocking HS on the uninfected erythrocyte surface. There is, 
however, better evidence to suggest that host cell HS can act as a receptor 
for PfEMP1 on various endothelial cells, including human brain endothelial 
cells (Vogt et al., 2003, Adams et al., 2014). Large scale genetic analysis 
have shown a link between HS3ST3B1, a gene involved in heparan sulfate 
biosynthesis, and malaria resistance (Mackinnon et al., 2016), and another 
study has demonstrated an association between polymorphisms in the same 
gene and asymptomatic parasitaemia, but no data were given on any link 
with symptomatic or severe disease (Atkinson et al., 2012). 
 
Chondroitin sulfate has a well-established role in the high levels of placental 
sequestration seen in pregnancy associated malaria (Ataíde et al., 2014) in 
which a specific variant of PfEMP1 known as VAR2CSA binds chondroitin 
sulfate A on the placenta leading to severe maternal anaemia, low birth 
weight babies, prematurity and significant perinatal mortality (Desai et al., 
2007). Other non-VAR2CSA PfEMP1 recombinant proteins have also been 
showed to bind CS but it is not clear that this binding is truly representative of 
parasite infected erythrocyte binding in vivo (Resende et al., 2009).  
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3.2.4 Heparan sulfate and Chondroitin sulfate as potential rosetting 
receptors 
 
Therefore, as the Plasmodium falciparum parasite has evolved to use both 
HS and CS at multiple points of the life cycle, it seems plausible that one or 
both may be involved in rosetting. A number of papers have showed that 
heparin and soluble HS can disrupt rosettes in about half of clinical strains in 
vitro (Udomsangpetch et al., 1989, Carlson et al., 1992, Rowe et al., 1994, 
Barragan et al., 1999) and inhibit binding of the rosette mediating NTS-
DBL1of Palo Alto 89F5 VarO to uninfected erythrocytes (Juillerat et al., 
2011). Barragan et al. (2000a) showed that the size and sulfation of heparin 
is key in determining the rosette disruption effect. Rosettes were only 
disrupted by heparin fragments of 12 or more sugar units and desulfated 
heparin fragments had a much reduced or even no ability to disrupt rosettes 
(Barragan et al., 2000a). Given the level of sulfation has a significant effect 
on the charge of the heparin molecule, these findings perhaps suggest that 
rather than interacting with HS molecules on the surface on uninfected 
erythrocytes, heparin may exert its rosette disrupting action through 
electrostatic mechanisms. Alternatively, heparin may bind to PfEMP1 and 
block rosetting by interacting with the parasite ligands. Heparin has been 
shown to bind to the surface of rosetting infected erythrocytes (Barragan et 
al., 2000a, Heddini et al., 2001), but less so to the same non-rosetting variant 
(Barragan et al., 2000a) and it appears that  the NTS region of the PfEMP1 is 
of particular importance for heparin binding (Juillerat et al., 2011).  
 
An alternative to this relatively non-specific “block” methodology of using 
heparin/soluble HS to disrupt rosettes, is the use of enzymes which 
selectively cleave (“chop”) HS chains. Treatment of erythrocytes with 
Heparinase III, which selectively cleaves HS chains, offers a more specific 
way of ascertaining which HS on uninfected erythrocytes has a role in 
rosetting, assuming the enzymes have been properly validated. This sort of 
assay has been used in only a very few parasites strains, namely FCR3S1 
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(analogous to ITvar60) and TM284, which showed a reduction in rosetting 
after Heparinase III treated of uninfected RBCs, to approximately 20 and 
30% of control respectively (Barragan et al., 1999).  
 
The studies outlined above have led to a general acceptance that HS is a 
rosetting receptor, however closer scrutiny of the evidence suggests a 
number of potential issues. Caution must be used in interpreting data from 
rosette disruption assays using heparin/soluble HS as the decreased rosette 
frequency could be due to non-specific electrostatic effects from these highly 
charged molecules. The enzyme data may be more specific; however this is 
limited to a small number of laboratory-adapted strains, and many of the 
binding studies have been conducted using recombinant proteins or 
COS/CHO cells rather than actual parasites. Importantly, there is only one 
paper suggesting that HS molecules are indeed present on the surface of 
mature erythrocytes (Vogt et al., 2004). Heparin has previously been used as 
an adjunctive therapy for severe malaria but is no longer recommended due 
to the high incidence of bleeding complications (1986, Smitskamp and 
Wolthuis, 1971), though clinical trials with low- molecular weight heparin 
variants have taken place (Leitgeb et al., 2011, Leitgeb et al., 2017). 
 
The evidence for CS as a rosetting receptor is much more limited. No effects 
were seen in studies which tested the rosette disrupting abilities of soluble 
CS (Rowe et al., 1994, Barragan et al., 1999), though treatment with 
Chondroitinase did reduce rosette frequency in one strain (TM284) (Barragan 
et al., 1999). Bastos et al. found that a fucosylated form of CS derived from 
sea cucumbers was able to disrupt rosettes and decrease adhesion to lung 
endothelial cells (Bastos et al., 2014), but the effects were lost when the 
highly charged, sulfated fucose branches were removed and no effect on 
rosetting was seen with soluble CSA. The effects of fucosylated CS on 
rosetting rates was similar to that of heparin, again suggesting this may be a 
charge related interaction, rather than specific blocking of host cell CS.  
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3.2.5 Oligosaccharide screening microarray results  
 
Immediately prior to my arrival in the laboratory, Professor Rowe had 
collaborated with the Imperial College Glycosciences laboratory in London to 
investigate recombinant PfEMP1 binding to a glycan microarray in an attempt 
to screen for potential rosetting receptors. Recombinant PfEMP1 proteins 
(NTS-DBL domains) from the parasite lines TM284 and ITvar60 were used 
and binding to the oligosaccharides was detected using monoclonal 
antibodies v2 14.1 (for ITvar60) and PH5 (for TM284). The report from Dr 
Yan Liu and Professor Ten Feizi (personal communication), which contained 
the images shown in Figure 3.4, stated that no binding was seen for the 
TM284 recombinant proteins. However, the ITvar60 NTS DBL domain 
bound strongly to certain CS probes (14mers of CSA, CSB and CSC), and 
weakly to HS (Figure 3.4 and Liu and Feizi, personal communication). 
Binding was also seen to blood group A oligosaccharides for the ITvar60 
proteins only. These findings suggested that CS could be a possible host 





TM284var1 NTS DBL 















Figure 3-4 Glycan array results for TM284 NTSDBL and ITvar60 NTS DBLPlots derived from 
Glycan array carried out by Imperial College Glycosciences laboratory showing no binding for the 
TM284 NTS DBL domain (UPPER) but binding to chondroitin sulfate A, B and C, and to a lesser 
extent, heparan sulfate by the ITvar60 NTS DBL domain (LOWER).
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To conclude, HS and CS are attractive as potential rosetting receptors; they 
are known invasion receptors for multiple pathogens, P. falciparum itself has 
adapted to use both HS and CS at different points of its life cycle and there is 
some evidence to suggest they may be involved in rosetting. However, this 
evidence is problematic; it is not clear that the rosette disrupting effect of 
heparin or soluble HS specifically relates to blocking of the host receptors on 
the uninfected erythrocytes and the data using Heparinase III are limited to 
two parasite lines and unvalidated enzymes. The evidence that HS is present 
on mature erythrocytes is poor and, to my knowledge, CS on human 
erythrocytes has not been investigated. However, the results from the glycan 
microarray were sufficient to reignite our interest in both HS and CS as a 
potential rosetting receptor and suggested further investigation was 
warranted. 
 
3.3 Hypothesis and aims 
 
Based on the previously published evidence presented above, and the 
preliminary results of the screening microarray, I hypothesised that the 
glycosaminoglycans heparan sulfate and chondroitin sulfate are potential 
host rosetting receptors on human erythrocytes. The aim of this chapter was 
to confirm this hypothesis by providing evidence that both heparan sulfate 
and chondroitin sulfate are present on mature erythrocytes and that removal 
or blocking of these molecules has a negative effect on rosetting across 
different P. falciparum strains.  
 
3.4 Methods  
 
3.4.1 Rosette disruption with heparin 
 
As described in the introduction, heparin is related, though not identical, to 
HS and has been used in multiple previous studies to provide evidence that 
HS is a rosetting receptor (Udomsangpetch et al., 1989, Carlson et al., 1992, 
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Rowe et al., 1994, Barragan et al., 1999). I therefore began by replicating 
and expanding on these experiments using both previously tested parasite 
lines and recently adapted P. falciparum strains to characterise their 
susceptibility, or otherwise, to rosette disruption using heparin. 
 
P. falciparum parasites were cultured in human blood of blood group O as 
described in section 2.1, and two of the lines, ITvar60 and R29, were also 
separately cultured using erythrocytes of blood group A. High rosetting 
frequencies were maintained by selection as described in section 2.1.5. For 
each heparin disruption experiment, 2 ml of 2% haematocrit culture 
containing parasites at the mature trophozoite stage was stained with 2µl of 
10 mg/ml ethidium bromide (final concentration 25µg/ml, Sigma46067) for 2 
minutes at 37oC. The culture was then centrifuged at 600g for 4 minutes and 
the supernatant removed. The pellet was resuspended, again at 2% 
haematocrit, with complete binding RPMI (culture medium with 
serum/Albumax but without bicarbonate) and 45µl aliquots were added to five 
500µl Eppendorf tubes. Five µl of heparin sodium salt derived from porcine 
mucosa (Sigma, H4784, diluted with PBS as required) was added to aliquots 
to give a final concentration of 1mg/ml, 100µg/ml or 10µg/ml. Fucoidan 
(100µg/ml, Molekula, 9072-19-9) was used as a positive control and the 
same volume of PBS only as the negative control. Samples were blinded by 
a colleague then incubated for 30 minutes with gentle flicking every 10 
minutes to ensure continued mixing. After this incubation, 1.8µl samples 
were pipetted onto a multispot slide (12 well, 6mm, Hendley-Essex, PH001) 
and 200 infected erythrocytes on two separate slides were counted and 
scored to give rosette frequency as a percentage. Three independent 
experiments were carried out for each parasite strain. Statistical analyses 
were carried out using one-way ANOVA with post-hoc Dunnet’s test for 




3.4.2 Summary of enzymatic cleavage approach 
 
As discussed in the introduction of this chapter, the use of heparin to disrupt 
rosettes cannot determine whether blocking of HS on the surface of the 
uninfected erythrocytes is the specific mechanism of action. In order to 
resolve this issue, the erythrocytes in culture can be enzymatically treated to 
remove the GAG chains of interest (HS or CS) and the effect on rosetting 
observed. However, the enzymes must first be tested to ensure that they are 
able to remove HS or CS, particularly if no effect is seen on rosetting. The 
enzymes used in this study were validated using COS cells (which 
constitutively express both HS an CS), treated with either the enzyme or a 
mock treatment. The cells were then labelled with either an antibody to the 
whole HS/CS molecule or one directed at the stub molecule which is 
revealed by enzymatic cleavage of the GAG chain. In this way we were able 
to determine whether the enzymes were functioning as expected under the 




Heparinase III (from Flavobacterium heparinum, Amsbio, AMS 50-012-001) 
which degrades heparan sulfate (HS), and Chondroitinase ABC (from 
Proteus vulgaris, Amsbio, AMS.E1028-02), which cleaves hyaluronic acid, 
chondroitin sulfate (CS) and dermatan sulfate, were purchased from Amsbio. 
Heparinase III was used at a concentration of 0.04IU/ml at pH 7.4 and 
Chondroitinase ABC at 0.5IU/ml at pH 8.0 throughout.  
Of note, Heparainase III (also known as heparin sulfate eliminase, heparan 
lyase III or heparintinase I) is one of a number of enzymes directed at HS-like 
molecules, the others being Heparinase I and Heparinase II. Heparinase I  
acts on the highly sulfated regions of heparin while Heparinase III is not 
active against heparin and instead cleaves the (1-4) glycosidic bond 
between glucosamine and glucuronic acid only in unsulfated regions of HS 
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(Desai et al., 1993, Dong et al., 2012). Heparinase II has a broader range of 
action and can cleave both heparin and HS (Desai et al., 1993). Treatment of 
HS chains with Heparinase III (as opposed to Heparinase I or II) also reveals 
the desaturated glucuronate epitope for the antibody 3G10 (see below) 
(David et al., 1992). 
3.4.4 Antibodies 
 
Two antibody related approaches have been used throughout this work. The 
first is the straightforward use of primary antibodies to whole HS or CS 
chains, followed by an appropriate secondary antibody. The second involved 
prior treatment of the cell of interest with either Heparinase III or 
Chondroitinase ABC, followed by incubation with a primary antibody targeted 
to the ‘stub’ molecule which remains, and is revealed by, enzymatic cleavage 
of the whole molecule Figure 3-5. The advantage of this second approach is 
that it allows validation of the enzymes used and improves the specificity of 
the detection of the molecule of interest. Non-specific binding can be a 
problem, despite the use of appropriate isotype controls, however the 
comparison of mock and enzyme treated cells using these ‘stub’ antibodies 
reduces this issue and has allowed me to validate each part of the 
experimental set-up.  
 
Figure 3-5 Treatment of HS and CS to reveal neoepitopes targeted by 3G10 (HS) and 1B5, 2B6 and 
3B3 (CS) 'stub' antibodies 
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The whole molecule antibodies and their corresponding isotype controls used 
were; anti-heparin sulfate mouse IgM (final concentration 20µg/ml, Clone 
F58-10E4 Amsbio 370255-S), anti-Chondroitin sulfate mouse IgM (final 
concentration 16µg/ml Clone CS-56 Sigma C8035) and a mouse IgM isotype 
control (Thermo Scientific 02-6800). The anti- HS stub antibody, 3G10 (final 
concentration 40µg/ml, mouse monoclonal IgG2b,k, Clone F69-3G10, 
Amsbio, 370260-1), which recognises the desaturated glucuronate exposed 
by Heparinase III treatment was used with an IgG2b control (final 
concentration 40µg/ml, Abcam, ab18457). Three monoclonal antibodies to 
the CS stub were used; 1B5 (30µg/ml, mouse monoclonal IgG, clone 1B5, 
mdbioproducts, 1042014), which recognises the zero sulfated CS stub 
neoepitope generated by Chondroitinase digestion, 2B6 (30µg/ml, mouse 
monoclonal IgG, clone 2B6, mdbioproducts, 1042009), which recognises the 
4-sulfated disaccharide stub and 3B3 (30µg/ml, mouse monoclonal IgM, 
clone 3B3, Cosmo Bio Co Ltd, PRPG-BC-M04), which recognises the 6-
sulfated unsaturated disaccharide stub. For the erythrocyte experiments, an 
additional positive control, Glycophorin A/B (2.5µg/ml, mouse monoclonal 
IgG, clone E3, Sigma, G7650) was used.  
 
Secondary antibodies used were goat anti-mouse IgG (H+L) highly cross-
adsorbed secondary antibody, Alexa 488 conjugated (Life technologies, 
A11029), and goat anti-mouse IgM (Heavy chain) cross-adsorbed secondary 
antibody, Alexa 488 conjugated (Life technologies, A21042). 
 
3.4.5 Validation of enzymes with COS cells 
 
Due to the uncertainties regarding the presence of HS and CS on mature 
erythrocytes, a COS 7 cell system was used to validate both Heparinase III 
and Chondroitinase ABC prior to use in rosetting assays. COS 7 cells 
constitutively express both HS and CS. COS 7 cells were cultured as 
described in section 2.4 and approximately 2x105 cells per well seeded onto 
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12mm round glass coverslips placed inside a 6 well plate the day before 
enzyme treatment. Once cells were 80-100% confluent, the coverslips were 
rinsed with incomplete RPMI for 5 minutes then removed with tweezers and 
placed, cell-side down, on a 50µl drop of enzyme solution (0.04IU/ml 
Heparinase III or 0.5IU/ml Chondroitinase ABC, diluted in incomplete RPMI 
at pH 7.4 or pH 8.0 respectively), or incomplete RPMI at the corresponding 
pH for mock treatment, on top of parafilm. The parafilm was then placed onto 
damp paper towels inside a petri dish to minimize evaporation during the 
incubation period. The COS 7 coverslips were incubated on top of the 
enzyme solutions for 3.5 hours at 37oC in the CO2 incubator (Figure 3-6).  
 
Figure 3-6 Incubation set-up for COS 7 cells on circular coverslips. The coverslips were place on top of 
a drop of enzyme/mock solution on parafilm on top of a damp paper towel contained within a petri dish. 
 
The coverslips were then placed, cell side up, into a 6 well plate and washed 
once in complete RPMI and twice with warm PBS by gently pipetting 2ml into 
each well then aspirating, taking care not to disturb the coverslips. Cells were 
then fixed using 1ml of 2% PFA per well for 15 minutes at room temperature, 
followed by two further washes and blocking with 10% goat serum (Sigma, 
S26-M) in the same manner for 30 minutes. The primary antibodies and 
isotype controls detailed in section 3.4.4 were diluted in PBS/10% goat 
serum and 50µl drops placed on labelled parafilm as above. The COS 7 cell 
coverslips were then placed on top of the antibody and incubated at 4oC 
overnight in a humidified chamber. The following day the coverslips were 
carefully placed on a staining rack in a trough full of PBS to wash for 5 
 93 
minutes then onto a 50µl drop of the appropriate secondary antibody, 
containing 1µg/ml DAPI (Sigma D9542), and incubated at room temperature 
and protected from light. The coverslips were then washed again in PBS and 
mounted onto glass slides using a small drop of FluoromountTM aqueous 
mounting medium (Sigma, F4680) or 5-10µl of Dabco/Glycerol (2.5mg 1, 4-
Diazabicyclo[2.2.2]octane, Sigma, D27802, and 0.5ml glycerol and 0.5ml 
PBS) followed by sealing around the coverslip edge with nail polish. 
Slides were visualized using a Leica DM LB2 fluorescent microscope or the 
Zeiss Imager Z1 fluorescent microscope.  
 
3.4.6 Enzymatic treatment of parasite cultures 
 
Two 50µl aliquots of parasite culture at 2% haematocrit was stained with 
ethidium bromide as detailed in section 2.6.1 then washed twice in 1ml of 
incomplete binding medium at either pH 7.4 (for Heparinase III/mock 
samples) or pH8.0 (for Chondroitinase/mock samples). After the second 
wash, erythrocytes were resuspended in 45µl of incomplete binding medium 
of the correct pH and either enzyme (to give final concentration of 0.04IU/ml 
of Heparinase III or 0.5IU/ml Chondroitinase ABC), or the equivalent volume 
of PBS (mock treatment), was added. The samples were then blinded by a 
colleague and incubated at 37oC for 3.5 hours with regular flicking to 
resuspend the erythrocytes. After the incubation period, samples were 
washed with complete binding medium then resuspended in 50µl of complete 
binding medium and incubated for a further 60 minutes to allow rosettes to 
reform. Rosette frequency was counted using multispot slides. Three 
independent experiments were carried out for each parasite strain and 
statistical analyses were carried out using paired t-tests in GraphPad Prism 




3.4.7 Rosette disruption after Heparinase treatment 
 
In order to determine whether removal of HS had any impact on the ability of 
heparin to disrupt rosettes, 150µl aliquots of parasite culture were first 
treated with either Heparinase III or mock treated with PBS as detailed in 
section 3.4.6. The aliquots were then washed twice in complete RPMI 
medium and placed in a sealed incubation chamber (Modular Incubation 
Chamber, Billups-Rothenberg, MIC-101, www.brincubator.com). Damp paper 
towels were placed in the bottom of the chamber to maintain humidity and 
the chamber was gassed by flowing through 1%O2/3%CO2/Nitrogen gas mix 
for 2 minutes with the exit port open, then sealing the exit port of the 
chamber and gassing the chamber for a further 15 seconds. Samples were 
incubated at 37oC for 1 hour to allow rosettes to reform. The treated aliquots 
were then stained with ethidium bromide and the heparin disruption 
experiment carried out as detailed in 3.4.1. These experiments were carried 
out using ITvar60 cultured in either blood group O or A, as these parasites 
had exhibited differing susceptibilities to heparin disruption depending on the 
blood group used to culture. Three independent experiments were carried 
out for each blood group.  
 
3.4.8 Recombinant PfEMP1 domain binding to enzyme treated 
uninfected erythrocytes 
 
The recombinant PfEMP1 domains and rabbit polyclonal antibodies used in 
these experiments had previously been generated by Dr Ashfaq Ghumra and 
others in the Rowe laboratory as described in (Ghumra et al., 2011, Ghumra 
et al., 2012). 
 
Uninfected O positive erythrocytes from Scottish blood donors were filtered 
and washed as described in section 2.1.3 then resuspended at 20% 
haematocrit in 50µl of incomplete binding RPMI. The uninfected erythrocytes 
were then treated with either Heparinase III, Chondroitinase ABC or PBS 
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mock treatment using the same protocol as the parasite cultures in section 
3.4.6. After enzyme or mock treatment, samples were washed with complete 
RPMI medium, then incomplete RPMI medium and resuspended with 500µl 
PBS to give a haematocrit of 2%. These diluted samples were washed twice 
in PBS and finally resuspended in PBS/0.1% IgG free BSA (Sigma, A0336) 
before being aliquoted into 1.5ml Eppendorf tubes, 45µl per tube. Five 
microlitres of protein as detailed in Table 3-1 were added to pairs of enzyme 
and mock treated samples giving an approximate final recombinant PfEMP1 
domain concentration of 100µg/ml. Tubes were incubated on ice for one hour 
with regular resuspension by gently flicking the tubes. Samples were then 
washed twice with 750µl of PBS and resuspended in 45µl PBS/0.1% IgG free 
BSA before adding 5µl of rabbit polyclonal antibody giving final antibody 
concentration of 100µg/ml. Samples were again incubated on ice for 45 
minutes, washed twice with PBS then incubated for another 45 minutes on 
ice with 50µl of goat anti-rabbit IgG Alexa Fluor 488 secondary antibody (1: 
1000, Invitrogen, A11034). After secondary incubation, samples were 
washed twice with PBS then resuspended in 500µl 0.5% paraformaldehyde 
(PFA)  diluted in PBS for 30 minutes on ice then gently centrifuged using the 
microcentrifuge. The PFA containing supernatant was removed and cells 
resuspended in 750µl of FACS buffer (PBS/0.5% BSA with 0.01% Sodium 
azide, Sigma, S2002) before being transferred to 5ml round-bottomed 
polystyrene FalconTM tubes (Fisher Scientific, 352052). Samples were run on 
a Becton-Dickinson LSR II flow cytometer (BD Biosciences), counting 
100,000 events per sample, and analysed using FlowJo software (version 10 
FlowJo LLC, Oregon). Between three and five independent experiments 
were carried out for both Heparinase III and Chondroitinase ABC, each with 
a different blood donor. 
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Table 3-1 List of recombinant PfEMP1 domains and antibodies used in uninfected erythrocyte binding 
experiments 























ITvar09 NTS DBL1 Anti-NTS DBL1 (ITvar09) 
(5776) 
ITvar09 didomain 
(NTS DBL1+ CIDR) 
Anti-NTS DBL1 (ITvar09) 
(5776) 
ITvar09 NTS DBL2 Anti- DBL2 (ITvar09) 
(4772) 
ITvar09 NTS DBL4 Anti- DBL4 (ITvar09) 
(6202) 
ITvar60 NTS DBL1 Anti-NTS DBL1 (ITvar60)  
(6217) 
ITvar60 didomain 
(NTS DBL1+ CIDR) 
Anti-NTS DBL1 (ITvar60)  
(6217) 
TM284 NTS DBL Anti-NTS DBL1 (TM284) 
(6219) 
None 
(no protein control) 




3.4.9 Immunofluorescence assay and flow cytometry for GAGS on 
uninfected erythrocytes and erythroid precursors 
 
Thus far, the enzyme experiments had found no evidence to support the 
theory that HS or CS are important rosetting receptors. I therefore decided to 
challenge the basic assumption that HS and/or CS are even present on 
mature erythrocytes as the evidence for this is limited to a single paper for 
HS only (Vogt et al., 2004). Both IFA and flow cytometry were used in an 
attempt to detect evidence of HS and CS on mature uninfected erythrocytes. 
In order to try to replicate the findings of Vogt et al. (Vogt et al., 2004), an 
identical protocol to that described in their paper was used with the same 
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suppliers for each reagents as far as possible. This protocol was then 
modified to improve the specific-binding of the primary antibody and 
Concanavalin A staining introduced to improve visualisation of the 
erythrocytes. Both the Vogt et al. protocol and subsequent modifications are 
detailed below. 
 
3.4.9.1 Immunofluorescence assay to detect HS/CS stubs on 
uninfected erythrocytes: Vogt et al. 2004 protocol and 
modifications 
 
Blood from Scottish blood donors (Scottish National Blood Transfusion 
Service) was washed with incomplete RPMI as described in section 2.1.3 
and diluted to a haematocrit of 2% with incomplete RPMI. Four samples of 
150µl each were aliquoted into four Eppendorf tubes and washed three times 
with PBS. After the final wash, two of the aliquots were resuspended with 
150µl of incomplete binding RPMI at pH 7.4 and the other two at pH 8.0, 
maintaining a haematocrit of 2%. Heparinase III was added to one of the pH 
7.4 samples to give a final concentration of 0.04IU/ml and Chondroitinase 
ABC to one of the pH 8.0 samples (final concentration 0.5IU/ml). The 
remaining samples of the corresponding pH had the same volume of PBS as 
enzyme added as a mock treatment. The tubes were incubated at 37oC for 
3.5 hours then washed three times with PBS, separated into three further 
aliquots of 50µl each and incubated with primary antibody for one hour at 
37oC as follows: 
 
Heparinase samples: 
1. Mock treated Negative isotype control- Mouse IgG2b, final 
concentration 40µg/ml (Abcam, ab18457).  
2. Heparinase treated Negative isotype control- Mouse IgG2b, final 
concentration 40µg/ml (Abcam, ab18457). 
3. Mock treated Positive IgG control- Mouse monoclonal IgG1 Anti-
Glycophorin A/B, final concentration 2.5µg/ml (Sigma, G7650). 
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4. Heparinase treated Positive IgG control- Mouse monoclonal IgG1 
Anti-Glycophorin A/B, final concentration 2.5µg/ml (Sigma, G7650). 
5. Mock treated HS stub antibody, 3G10- Mouse IgG2b, final 
concentration 40µg/ml (Amsbio, 370260-1). 
6. Heparinase treated HS stub antibody, 3G10- Mouse IgG2b, final 
concentration 40µg/ml (Amsbio, 370260-1). 
 
Chondroitinase samples: 
A. Mock treated Negative isotype controls mouse IgG (Abcam, 18443) 
and IgM control (Serotec MCA692)- final concentration 30µg/ml. 
B. Chondroitinase treated Negative isotype controls mouse IgG (Abcam, 
18443) and IgM control (Serotec MCA692)- final concentration 
30µg/ml. 
C. Mock treated positive IgG control Gly A/B as above 
D. Chondroitinase treated  positive IgG control Gly A/B as above 
E. Mock treated CS stub antibodies, 1B5 (Mdbioproducts, 1042014), 2B6  
(Mdbioproducts, 1042009) and 3B3 (Cosmo Bio Co Ltd, PRPG-BC-
M04)- each concentration 30µg/ml 
F. Chondroitinase treated stub antibodies- as above. 
 
All samples were then washed three times with PBS then resuspended with 
a FITC-tagged rabbit anti mouse- secondary antibody (1:25, Dako, F026102-
2) for one hour at 37oC. This secondary incubation was followed by a further 
three PBS washes then a tertiary incubation with an Alexa 488 conjugated, 
rabbit anti-FITC, antibody (1:25, Molecular probes, A11090). The samples 
were finally washed three more times with PBS, resuspended at 20-30% 
haematocrit in PBS/1% BSA and smeared onto a slide. The slides were dried 
then a coverslip mounted on top with FluromountTM. Images were taken 
using a photometric evolve camera on Zeiss Imager fluorescent microscope. 
 
Initial images showed a high level of background florescence and non-
specific staining of the isotype control samples, therefore the primary 
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incubation period was extended to overnight (approximately 16 hours) at 4oC. 
Concanavalin A conjugated to Alexa Fluor 594 (200µg/ml, Molecular probes, 
C11253) was also added to the tertiary incubation to allow for better 
visualisation of the red cells. Concanavalin A selectively binds to a-
mannopyranosyl and a-glucopyranosyl residues on erythrocytes and was 
helpful in finding the correct plane for microscopic imaging.  
 
3.4.9.2 Flow cytometry to detect HS/CS stubs on uninfected 
erythrocytes, cRBC and EJ cells 
 
In addition to uninfected mature erythrocytes, two other erythroid cell types 
were tested for HS expression on the cell surface. These additional cell types 
were CD34+ haematopoietic stem cells (referred to here as cRBC), cultured 
as described in section 2.2 and tested at various stages of maturation, and 
EJ cells, an immortalised erythroid lines developed by the Duraisingh 
laboratory at Harvard University. Further details of both these cell types are 
included in Chapters 2, 4 and 5. Briefly, both cells types represent immature 
erythrocyte precursors, which can be matured through various bone-marrow 
stages of erythrocyte development, resulting in mainly early reticulocytes 
(cRBC), or orthochromatic erythroblasts (EJ cells).  
 
Uninfected mature erythrocytes, cRBCs at various stages of culture, and EJ 
cells were Heparinase III treated as described in 3.4.6. Between 1-3x105 
cRBCs or EJ cells were used per antibody tested. The samples were 
resuspended in PBS/1% BSA and the primary antibodies added as described 
above followed by the appropriate secondary antibody tagged with Alexa 488 
(the tertiary antibody step was not used for flow cytometry experiments). All 
cell types were tested for 3G10 binding after Heparinase III treatment, but the 
Chondroitinase ABC assay was only carried out for mature RBCs. Untreated 
cRBCs were assessed for binding of antibodies to the whole CS molecule, 
but not EJ cells. 
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3.4.10 Western blotting of uninfected erythrocytes/COS cells for 3G10 
 
Having been unable to detect HS on mature erythrocytes by 
immunofluorescence assay or flow cytometry, additional attempts were made 
to identify HS using Western blotting. 
 
3.4.10.1 Enzyme treatment and preparation of cell lysate 
 
Uninfected erythrocytes were prepared by washing 240µl packed cell volume 
of mature donor erythrocytes with incomplete binding RPMI medium at pH 
7.4 then resuspending in 1.2ml of incomplete binding RPMI. The cells were 
aliquoted into three 400µl samples. Sixteen µl of 1IU/ml Heparinase III was 
added to one sample (giving a final concentration of 0.04IU/ml), and 16µl of 
PBS added to each of the others as a mock treatment. All samples were 
incubated at 37oC for 3.5 hours and regularly resuspended by gently flicking 
the tubes. Samples were then washed once with complete RPMI medium 
then twice with incomplete RPMI medium. The cells were thenwashed twice 
with PBS and lysed by resuspending in RIPA lysis buffer (Sigma, R0278, 1ml 
per 0.5-5x107 cells), with cOmplete Mini Protease inhibitor cocktail with 
EDTA (Sigma, 11836153001). The cells were incubated for 20 minutes on 
ice then centrifuged at 8000g for 10 minutes at 4oC to pellet cell debris. The 
supernatant was retained and frozen at -20oC until use. 
 
COS 7 cells were cultured as described in section 2.4.1 to 90-100% 
confluence in a T75 flask. The cells were then lifted by washing twice with 
PBS and adding 1ml of StemProTM Accutase cell dissociation reagent 
(Thermo Scientific A1110501). Accutase was used in preference to 
Trypsin/EDTA to allow for gentle lifting without stripping the HS 
proteoglycans from the cell surface. The flask containing Accutase was left at 
room temperature for 10 minutes until the cells began to lift then scraped with 
a cell scraper and washed with incomplete RPMI. The cells were 
resuspended in incomplete RPMI and split into two 400µl aliquots (each 
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containing 1.5x106 cells) to which was added either 16µl of Heparinase III 
(final concentration 0.04IU/ml) or PBS. The cells were incubated at 37oC for 
3.5 hours with constant shaking to discourage the cells from adhering. After 
enzyme treatment, the cells were lysed with RIPA buffer as described above, 
supernatant pelleted and frozen until use.  
 
3.4.10.2 Protein gel electrophoresis 
 
A 10% sodium dodecyl sulfate polyacrylamide gel was cast using 15mm thick 
plates and a 15-well comb. Solutions (sufficient to make two 15mm gels) for 
the lower/resolving and upper/stacking gel are listed in Table 3-2. 
 
Table 3-2 Upper and lower gel buffers for 10% SDS PAGE gel 
                                                            Lower gel Upper gel 
distilled H20 9.4ml 4.5ml 
30% Bis-Acrylamide (ratio 37.5:1, 
Severn Biotech 20-2100-05) 
7.5ml 1.9ml 




(TEMED, Sigma T9281) 
30µl 16µl 
Buffer* 5.6ml 1.1ml 
*Lower gel buffer consists of 1.5M TRIS base (National diagnostics, EC406) + 0.4% SDS 
(Sigma life science, L3771) with pH adjusted to 8.8 with concentrated hydrochloric acid. 
Upper gel buffer consists of 0.5M TRIS base + 0.4% SDS with pH adjusted to pH 6.8. 
 
Glass plates were fixed into the Mini-PROTEAN Tetra Cell casting module 
(Bio-Rad, 1658024) and the lower gel solution poured immediately after 
adding the TEMED. A small volume of 70% Ethanol was added to the top of 
the solution to prevent oxidation. The remaining solution in the 50ml Falcon 
tube was set at an angle and monitored to determine when the gel had set 
(approximately 15-20 minutes). Once the lower gel had set, the ethanol was 
poured off and TEMED added to the upper gel solution which was then 
immediately poured on top of the lower gel. A 15 well comb was quickly 
inserted and again left until the upper gel had set. The comb was then 
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removed and wells gently washed. If prepared ahead of time, the gels were 
stored flat at 4oC for up to one week, otherwise, the gel was inserted into the 
electrophoresis apparatus (Mini-PROTEAN Tetra vertical electrophoresis 
cell, Bio-Rad, 1658005) along with a dummy plate. The inner chamber was 
filled with SDS PAGE running buffer (100ml of 10x SDS buffer [0.25m TRIS-
Hcl, 1.92M Glycine, 1% SDS] + 900ml dH20) and the outer chamber half 
filled. 
 
Cell lysates were defrosted and reduced by adding 3µl of 6x loading buffer 
(New England Biotech Gel loading dye, Purple (6X), B7024S) with 30% 2-
mercaptoethanol (Sigma Aldrich, M3148) to 17µl of sample and heating at 
70oC for 10 minutes. Ten microlitres of Novex Sharp pre-stained Protein 
standard (Thermo Scientific, LC5800) was added to the first well followed by 
20µl of each cell lysate in the three subsequent wells. The gel was run at 
125V for one hour, or until the gel front was at the bottom of the membrane.  
 
3.4.10.3 Transfer, blocking and probing 
 
While the gel was running, a suitably sized polyvinylidene difluoride 
membrane (Immobilon-P PVDF membrane, Merck Millipore, IPVH00010) 
was cut and activated by spraying with 70% ethanol for one minute. The 
membrane was then washed in transfer buffer (100ml of 10x Tris Glycine, 
200ml Methanol and 700ml dH20) along with 4 sponges and 4 similar sizes 
pieces of WhatmanTM 3mm CHr Chromatography paper (GE Healthcare, 
3030-917). 
 
The gel was then removed from the glass plates and the transfer cassette 
loaded as follows: Sponge, 2x Whatman papers, gel, PVDF membrane, 2x 
Whatman papers and sponge. The additional sponges were placed in the 
dummy cassette and both cassettes were loading into the Mini Trans-Blot 
Cell (Bio-Rad, 1703930), along with an ice-pack. The cell was filled with 
transfer buffer and run at 80V for 1 hour. 
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After one hour the apparatus was disassembled and the membrane stained 
with Ponceau S stain (Sigma life sciences P7170) for 5 minutes to confirm 
protein transfer. The Ponceau stain was then washed off with PBS/0.1% 
Tween (PBS: Oxoid, 10209252, Tween 20, Sigma life sciences P9416) and 
the membrane blocked with 5% non-fat milk powder in PBS/0.1% Tween for 
one hour at room temperature. The membrane was then cut into strips; one 
mock-treated strip was incubated with anti-glycophorin A antibody as a 
positive control (1:1000 = 1µg/ml, anti CD236a BRIC 256, mouse IgG1, 
IBGRL, 9415) and the other two (mock and Heparinase III treated) incubated 
with 3G10 antibody directed against the HS stub (1:1000 = 1µg/ml, anti-D -
heparan sulfate [3G10 epitope], purified mouse IgG2b, Amsbio, 370260-S). 
The antibodies were made up with 5% milk blocking solution and incubated 
overnight on a rocker at 4oC. Membranes were washed three times for 5 
minutes each in PBS/0.1% Tween then incubated with secondary antibody 
(1:8000, IRDye 800CW Goat anti-Mouse IgG, LI-COR Biosciences, P/N 
925-32210, made up in Odyssey Blocking buffer, LI-COR Biosciences, P/N 
927-40000) for one hour at room temperature. After this incubation, the 
membranes were again washed three times in PBS/0.1% Tween then 
visualized on the LI-COR Odyssey scanner using the 700 and 800nm 
channels. Images were taken and analysed using Image Studio Lite version 
5.2.5 (https://www.licor.com/bio/products/software/image_studio_lite/). 
 
In order to confirm the presence of erythrocyte membrane proteins in lanes 
which were negative for 3G10, glycophorin A was used to reprobe the 
membranes as a loading control. The membranes were stripped using a mild 
stripping protocol (4g Glycine, 0.25g SDS, 2.5ml Tween in 250ml dH20, pH 
adjusted to 2.2 
https://www.abcam.com/ps/pdf/protocols/stripping%20for%20reprobing.pdf), 
washed in stripping buffer for ten minutes twice then washed with TBST 
twice for 5 minutes before being reblocked and incubated for 3-4 hours with 
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anti-glycophorin A antibody as above. Secondary antibody was then added 




3.5.1 Rosetting in all parasite strains is disrupted by heparin 
 
All the parasite lines tested were sensitive to rosette disruption by heparin to 
a greater or lesser extent as demonstrated in Figure 3-7, however, there 
were notable differences between parasite lines and, in the case of ITvar60, 




Figure 3-7 Rosette frequency after incubation with varying concentrations of heparin. Each graph 
shows the percentage rosetting frequency after treatment with different concentrations of heparin for 
the six parasite lines tested, with two graphs for ITvar60 and R29 showing the findings depending on 
the blood group of the erythrocytes used for culturing. Each individual symbol represents the results of 
one of three independent, blinded experiments and error bars show the mean with SD. p-values were 
calculated using one-way ANOVA with Dunnett’s post hoc test for multiple comparisons. 
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Rosettes of R29, regardless of culture blood group, and ITvar60, when cultured 
in blood group O, were most sensitive to heparin, even at the lowest 
concentration of 10µg/ml. The majority of the other lines showed a statistically 
significant reduction in rosette frequency at 100µg/ml, and rosetting was 
virtually abolished by 1mg/ml of heparin in all strains. Notable exceptions 
include ITvar60 when cultured in blood group A, which showed a less dramatic 
reduction in rosette frequency even at high heparin concentrations, and 11019 
which also stood out as the only line which was resistant to Fucoidan. Of note, 
ITvar60 has been described as having a ‘preference’ for blood group A, 
forming bigger, stronger rosettes which are more resistant to disruption, 
(Barragan et al., 2000b, Ch'ng et al., 2016) possibly due to the binding of the 
blood group A antigen to parasite-derived RIFINS (Goel et al., 2015). Such a 
preference is not seen for R29 in the published literature (Carlson and 
Wahlgren, 1992) (though some preference for Group A has been seen in our 
laboratory, Fennell and Rowe, personal communication), which may explain 
the variation in sensitivity for heparin seen for ITvar60 and not R29. 
 
3.5.2 Validation of enzymes and antibodies with COS 7 cells 
 
As discussed in the introduction to this chapter, the use of heparin, or indeed 
soluble HS or CS, to disrupt rosettes does not necessarily provide evidence 
that HS or CS are specific rosetting receptors. For this reason, the alternative 
approach of enzymatically removing HS or CS from the erythrocyte surface  
was used. Pilot experiments showed no obvious effect of enzymatic 
treatment on rosetting frequency, in contrast to the findings of Barragan et al. 
(Barragan et al., 1999), therefore before going any further, the decision was 
made to validate the enzymes using COS cells which constitutively express 
both HS and CS. Initially, the labelling of the whole HS or CS molecule was 
relatively poor on IFA, though a decrease in HS and CS expression could be 
seen after enzyme treatment (Figure 3-8 A). The effect was much more 
obvious when using the antibodies directed against the HS and CS ‘stubs’ 
(Figure 3-8 B). We therefore felt reassured that the enzymes were capable of 
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cleaving HS/CS under the same conditions (pH, temperature, duration of 




Figure 3-8 IFA showing validation of Heparinase and Chondroitinase enzymes with COS cells. A- COS 
cells treated with Heparinase (upper) or Chondroitinase (lower) were labelled with an antibody directed 
against the whole HS or CS molecule respectively. B- COS cells were again treated but labelled with 
antibodies directed against the stub molecules remaining after HS or CS cleavage. 
 
 
A  Whole antibody staining       
                                                     Mock treatment                 Enzyme treatment 
 
























3.5.3 Heparinase or Chondroitinase treatment does not reduce 
rosetting 
 
Having validated the enzymes as described above, cultures of rosetting 
parasites containing both infected and uninfected erythrocytes were treated 
with either Heparinase III or Chondroitinase ABC and the rosette frequency 
counted as detailed in section 3.4.6. Prior to treatment, the rosette frequency 
of the parasites ranged from 65-89%. After treatment there were no 
statistically significant differences (two-tailed, paired t-test, p>0.05 for all 
strains) between mock and enzyme treated cultures (Figure 3-9). Two 
strains, R29 and ITvar60, were also cultured in blood group A, but again, no 




Figure 3-9 Rosetting frequency after treatment with Heparinase III (UPPER) or Chondroitinase ABC 
(LOWER). Each data point indicates the rosetting frequency for a single, independent experiment with 
circular symbols representing mock treated cultures and squares, enzyme treated. The corresponding 
parasite lines are shown on the x-axis. Three independent experiments were carried out for each 
parasite strain and error bars show the mean and SD. Two-tailed paired t-test showed no significant 
differences between mock and enzyme treatment for any strain (p>0.05 for all comparisons).
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3.5.4 Ability of heparin to disrupt rosettes is not affected by 
Heparinase III treatment 
 
Having found no difference in the rosetting abilities of Heparinase III or mock 
treated erythrocytes, the effect of pre-treatment with Heparinase III on rosette 
disruption by heparin was investigated. The parasite ITvar60 was chosen for 
these experiments and was cultured separately in blood group A and O. 
ITvar60 was chosen as it is demonstrated marked sensitivity to heparin when 
cultured in blood group O, but less in its preferred blood group, A. If the 
rosette disruption by heparin was due to a specific interaction with HS on the 
surface of the uninfected erythrocyte, it might be expected that removal of 
HS would decrease the effectiveness of heparin, whereas if the mechanism 
was non-specific e.g. related to the negative charge of heparin, no difference 
would be seen.  
 
In fact, heparin was equally effective at disrupting rosettes in both the 
Heparinase III and mock treated erythrocytes, with rosetting significantly 
reduced at all concentrations of heparin in parasite cultured in both blood 
groups (Figure 3-10). Of note, in this experiment, the lower concentrations of 
heparin had more of an effect on rosetting on the parasites cultured in blood 
group A, than seen in the previous experiments shown in Figure 3-7. 
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Figure 3-10 The ability of heparin to disrupt rosettes is not affected by prior treatment of the culture 
with Heparinase III. ITvar60 parasite cultures grown in both blood group O (upper) and A (lower) were 
pre-treated with Heparinase III or mock treatment, followed by the same heparin disruption experiment 
described previously. Each individual symbol represents the result of one of three independent, blinded 
experiments and error bars show the mean with SD. p-values were calculated using one-way ANOVA 
with Dunnett’s post hoc test for multiple comparisons 
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3.5.5 PfEMP1 binding to uninfected erythrocytes is not reduced by 
Heparinase or Chondroitinase treatment 
 
While the removal of HS and CS did not appear to have any effect on the 
rosetting ability of infected and uninfected erythrocytes in culture, I was 
interested to discover whether the binding of recombinant PfEMP1 domains 
was changed by Heparinase/Chondroitinase treatment. As discussed in 
Chapter 1, the main parasite adhesion molecule involved in rosetting in P. 
falciparum is PfEMP1, which consists of multiple Duffy binding-like (DBL) 
domains and cysteine-rich interdomain regions (CIDR) with the end terminal 
DBL domain thought to be the most important for rosetting (Vigan-Womas 
et al., 2012). In order to explore which, if any, PfEMP1 domains might have a 
role in HS/CS binding, immunofluorescence and flow cytometry experiments 
were carried out assessing the binding of a panel of PfEMP1 recombinant 
proteins to Heparinase or Chondroitinase treated, uninfected erythrocytes. 
Recombinant proteins from variants ITvar09, derived from parasite strain 
R29, and ITvar60, were investigated. The NTS-DBL from TM284 acted as 
the positive control and the non-rosetting variant HB3var3 was included as a 
negative control in addition to no protein controls.  
IFA demonstrated binding to uninfected erythrocytes of the recombinant 
domains ITvar09 NTS-DBL, ITvar09 didomain, ITvar09 DBL2, ITvar60 
NTS-DBL, ITvar60 didomain and subtle binding for ITvar09 DBL4 (Figure 
3-11), suggesting that multiple PfEMP1 domains may contribute to rosetting. 
The remaining domains did not show any binding.  
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Figure 3-11 Multiple rPfEMP1 domains can bind uninfected erythrocytes. A- Schematic of PfEMP1 
domains from parasites R29 and ITvar60, adapted from (Rowe et al., 1997). (+) indicates that binding 
to uninfected erythrocytes was observed for the individual rPfEMP1 domain and (–) that no binding 
was seen. B- IFA of uninfected erythrocytes with green Alexa488 fluorescence indicating binding of the 
rPfEMP1 domain. 
 
Binding was not affected by either Heparinase III or Chondroitinase ABC 
treatment of the erythrocytes on flow cytometry (Figure 3-12) or IFA, with the 
exception of ITvar09 DBL2, which showed slightly decreased binding after 
Chondroitinase treatment in one donor, though this was not consistently seen 




Figure 3-12 Flow cytometry plots showing recombinant PfEMP1 domain binding to uninfected erythrocytes after mock or enzyme treatment. Three to five independent 
experiments were carried out with different donors (depending on availability of the recombinant protein domain) and a representative plot from these experiments for 
each domain is showed. A- Blue indicates Heparinase treated cells and red mock treated cells. B- Green indicated Chondroitinase treated cells and red mock treated. 
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3.5.6 Heparan sulfate or chondroitin sulfate not detected on mature 
uninfected erythrocytes 
 
Thus far, these results did not support the hypothesis that HS or CS are 
important, specific rosetting receptors. Therefore, it was decided to 
reinvestigate whether these molecules are even present on mature 
erythrocytes. Initial experiments using antibodies to whole HS or CS were 
unable to detect either GAG, therefore the alternative method using 
enzymatic pre-treatment and antibodies to the remaining stub molecule 
developed by Vogt et al. (2004) for detecting HS was used. No definitive 
staining for HS or CS stubs was demonstrated when compared to the isotype 
control, though the background staining was similar to that shown in Vogt et 
al. (Figure 3-13). 
 
To decrease the excessive background noise, the protocol was modified to 
include an overnight incubation and additional staining of erythrocytes with 
Concanavalin A. Cleaner images were obtained and again, there was no 
convincing evidence of HS or CS staining (Figure 3-14). 
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Figure 3-13 Fluorescent microscopy images showing Heparinase/mock treated cells (UPPER) and 
Chondroitinase/mock treated cells (LOWER) incubated with primary (3G10 for Heparinise and 1B5, 
2B6 and 3B3 for Chondroitinase), secondary (Rabbit anti-mouse FITC) and tertiary (Anti-FITC Alexa 
488) antibodies. Exposure time was 55msec with the exception of Anti-glycophorin AB positive control 
which was 1ms due to extremely bright staining and clumping of cells (hence darker background). 
Results are representative of three independent experiments. Images taken using photometric Evolve 









Figure 3-14 Representative images from revised protocol with overnight primary incubation (antibodies 
as above A- Heparinase treated cells, B- Chondroitinase treated) and additional staining of 
erythrocytes with Concanavalin A tagged with Alexa 594 during tertiary incubation. Identification of 
cells with ConA allowed for shorter exposure times (10ms for ConA images and 5ms for Alexa488) 
thereby reducing background noise. Again, no evidence of either HS or CS was observed. 
 
 
Uninfected erythrocytes enzyme-treated and incubated as above also failed 




Figure 3-15 Flow cytometry of enzyme treated cells. Erythrocytes were prepared as described and 
analysed on a Fortessa flow cytometer, 100,000 events were counted. Blue indicates Heparinase 
treated cells, green Chondroitinase treated cells and red represents mock treatment.  
 
3.5.6.1 Heparan sulfate is present on early erythroid precursors  
 
In contrast to the above finding on mature erythrocytes, HS could be 
detected using a similar protocol in the early stages of culture (Day 8 and 11) 
of both cRBCs derived from adult bone marrow (Figure 3-16) and 
undifferentiated EJ cells (Figure 3-17). Of note, though the concentration of 
Heparinase III was the same for mature erythrocytes and the precursors 





Figure 3-16 Progressive loss of HS expression with maturity of cRBC. Representative flow cytometry 
plots demonstrating the loss of HS expression from culture day 8 to maturity on day 18-29. Red- 
IgG2bk isotype control, Blue- mock treated cRBC incubated with the 3G10 antibody to the HS stub 
followed by Alexa488 tagged secondary antibody, Orange- Heparinase III treated cRBC labelled as per 
mock cells. Gating strategies are shown in Appendix 1. Of note, the apparently ‘positive’ signal in a 
minority of cells at D29 relates to disintegrating and dying cells, See figure Figure 5-10 for further 
details).  
  
HS was progressively lost as the cells matured and was undetectable in 
either cRBC or EJs cells in their matured stage (after approximately 18 or 8 




Figure 3-17 HS expression is lost as EJ cells differentiate. HS can be detected on undifferentiated EJ 
cells (approximately equivalent to D10 of cRBC culture) using both the 3G10 HS stub antibody on 
Heparinase III treated cells, and an antibody directed against the whole HS molecule (UPPER panel), 
however this is lost once the cells mature (LOWER panel). Red- isotype control, Blue- mock treated 
cells with 3G10 stub antibody or whole HS antibody, Orange- Heparinase treated cells with 3G10 stub 
antibody. 
 
Further details of the cRBC and EJ cells are discussed in depth in later 
chapters. Of note, even in their most mature state, cRBC and EJ are 
probably equivalent to erythrocytes which are still contained within the bone 
marrow and therefore these data support my previous findings that HS is not 
detectable in peripheral circulating erythrocytes though it is present on very 
early bone marrow erythroid precursors and is likely lost during maturation. 
 
Similar experiments were carried out with cRBC tested using the whole CS 





Figure 3-18 Flow cytometry plots showing no evidence of CS on cRBC. Red- IgM isotype control, Blue- 
antibody to whole CS.  
 
3.5.6.2 Western blotting detects heparan sulfate on COS 7 cells but not 
mature erythrocytes  
 
As no HS could be detected on the mature erythrocyte surface using the 
methods detailed above, it seemed prudent to use an alternative detection 
method, such as Western blotting. While any HS detected could not be 
localized to the cell surface, a negative result would further validate the 
findings of the IFA and flow cytometry experiments carried out thus far.  
Gel electrophoresis, protein transfer and probing for glycophorin A on mature 
erythrocytes was successful as demonstrated in Figure 3-19 by the Ponceau 
staining and positive glycophorin A bands. However, no evidence of the HS 
stub was seen when comparing the mock and Heparinase III treated mature 





Figure 3-19 Western blot of anti-GYPA and anti-HS stub (3G10) binding for mature erythrocyte lysate.  A- 
Ponceau staining of PVDF membrane after transfer from gel. B- Image of Western blot after stripping and 
reprobing with anti-GYPA antibody as a loading control to demonstrate presence of protein. C Image of original 
Western blot showing anti-GYPA binding in 2nd lane but no evidence of anti-HS stub binding in either mock or 
Heparinase III treated erythrocytes. 
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In order to confirm that the antibodies were capable of detecting HS on Western 
blotting, COS 7 cells were Heparinase III treated, lysed and blotted alongside the 
mature erythrocytes. Bands of the expected molecular weight (Bai et al., 1994) 
could be detected on the enzyme, but not mock treated COS 7 cells and no bands 
were seen in the mature erythrocyte lanes.  
 
 
Figure 3-20 Western blot showing detection of HS stub molecule with 3G10 antibody in enzyme treated COS 7 
cells only. On the LEFT, Ponceau staining of PVDF membrane after transfer from gel. On the RIGHT, western 
blot using GYPA antibody (loading control and reprobe on far right), or 3G10 HS stub antibody on mock or 
Heparinase III treated mature erythrocytes (RBC)/COS 7 cells.  
 
This experiment was also repeated using cRBC at day 8 of culture, which express 
HS detectable on flow cytometry as shown above, however cell numbers were 
limited (approximately 5x106 cells/lane). No evidence of HS could be seen however 
the loading control, glycophorin A (which is expressed by day 8, see figure 4.11), 
was also not detected suggesting the negative result was probably due to 





3.5.7 Evaluation of published proteomic and transcriptomic data 
 
These data described above, seem to suggest that neither HS nor CS are 
present in detectable quantities on mature erythrocytes, however very early 
erythrocyte precursors do express some HS.  I therefore returned to the 
literature to conduct an analysis of the published data on the erythrocyte 
transcriptome and proteome to discover further evidence to support this 
hypothesis. The studies, reviews and databases used are summarised in 
Table 3-3.  
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Table 3-3 Published papers used to investigate for evidence of HS and CS expression in erythrocytes and erythroid precursors. * see also  Figure 3-21
Reference Methodology Output Comments 
(D'Alessandro et al., 2010) 
 
 
Review and reanalysis of 
published red cell 
proteome studies to 2010 
Proteome: List of 1989 
individual proteins identified 
from mature erythrocytes 





RNA extraction from 
cultured erythroid 






expression levels at different 
stages of erythroblast 
development 
Database: Human Erythrocyte Maturation database 
http://cellline.molbiol.ox.ac.uk/eryth/index.html   
Erythroblasts were cultured from human peripheral blood 
mononuclear cells and sorted using flow cytometry into 4 
stages*: 
1. Colony-forming units (CFU-E)- 4 days in phase 2 culture 
2. Pro-erythroblasts (Pro-E)- 5-6 days 
3. Intermediate (Int-E)- 8-11 days 
4. Late erythroblasts (Late-E)- 13-15 days 
 
(Hegedűs et al., 2015) 
 
 
Mass spectrometry on 
erythrocyte membranes 
and comparison with 
other published 
databases 
Proteome: Database storing 
all experimentally identified 
mature erythrocyte proteins 
Database: http://rbcc.hegelab.org/ Data included in Table 3-4 
includes all proteins (not limited to membrane bound) 
(Wilson et al., 2016) 
 
 
Tandem Mass Tag mass 
spectrometry comparing 
proteome of matured cord 
or adult derived erythroid 
cells and autologous 
mature erythrocytes 
Proteome: Lists of proteins 
detected and comparison 
between cells types 
Data included in Table 3-4 are from either the membrane or 
cytosolic fractions of human RBCs (matured cRBC or 
autologous mature erythrocytes, supplemental table 2 from 
Wilson et al.) 
(Gautier et al., 2016) 
 
 
Mass spectrometry of 
cultured CD34+ cord 
blood stem cells at seven 
stages of maturation 
Proteome: Absolute 
expression of 6130 proteins 
at different stages of 
erythroblast development 
(including copy number/cell) 
Four cord donors. Cells analysed at stages: Prog1 (D8 after 
sorting for CD34 positivity), Prog2 (D9-11), ProE (D11-12), 
Baso1 (D12-13), Baso2 (D13-15), Poly (D15-17) and Ortho 




Figure 3-21 Flow cytometry and morphological criterea used to define the stages of erythroid 
development used by (Merryweather-Clarke et al., 2011) 
 
Table 3-4 lists all the genes coding for enzymes involved in HS and CS 
biosynthesis, along with haemoglobin beta, CD71and three other potential 
rosetting receptors (GYPA, GYPC and CR1) which are known to be highly 
expressed in mature erythrocytes for comparison. The stage and maximum 
expression levels of each gene, derived from Merryweather-Clarke et al.,  
(Merryweather-Clarke et al., 2011), are included, along with whether or not 
the protein product of each gene was detected from the mature erythrocytes 
in D’Alessandro et al., the database created by Hegedus et al. or Wilson et 
al. (D'Alessandro et al., 2010, Hegedűs et al., 2015, Wilson et al., 2016). Of 
note, the gene expression levels of all the enzymes involved in GAG 
biosynthesis were relatively low, even in early erythroblast stages, with the 
maximal expression mainly at the earliest, ‘Colony-forming unit’ stage, 
corresponding to the early stages of my cRBC cultures at which HS could be 
detected. None of the proteins, with the exception of heparan sulfate-




Table 3-4 Transcriptome of erythroblasts at different levels of maturity (‘Erythroid precursors’) and proteome of mature erythrocytes (‘Mature erythrocytes’). Data for the 
maximal level of gene expression at different erythroblast stages (see Table 3-3 for abbreviations and Chapter 4: Introduction for description of the stages) are taken 
from Merryweather-Clarke et al.*, while mass spectroscopy data for the resulting proteins on mature erythrocytes is compared across three different studies/databases 
as shown (‘Mature erythrocytes’). Black bordered cells- Molecules known to be highly expressed in mature erythrocytes/previously described rosetting receptors 
provided for comparison purposes. Orange border- Enzymes common to both HS and CS biosynthesis. Yellow border- HS biosynthesis. Blue border- CS synthesis. Cell 
shading indicates relative expression levels: Green= ‘high’, >1000, Orange= ‘medium’, 100-999, Red= ‘low’ 0-99. 

























dro et al., 
2010) 
N/A HBB, Haemoglobin Beta Mature RBCs Late-E 24,762.6 Yes Yes Yes 
N/A TFRC, Transferrin 
receptor/CD71 
Reticulocytes IntE 14378.9 Yes Yes No 
Other 
rosetting 






No Yes   Yes 
Other 
rosetting 
GYPA, Glycophorin A - Int-E 4012.87 Yes Yes Yes 
Other 
rosetting 
GYPC, Glycophorin C - Late-E 1064.15 Yes Yes Yes 
Common XYLT1, Xylosyltransferase I Catalyses transfer of Xylose to 
serine of core protein 
CFU-E 23.0 Yes No No 
Common XYLT2, Xylosyltransferase II Catalyses transfer of Xylose to 
serine of core protein 
CFU-E 73.63 No No No 
Common B4GALT7,  Xylosylprotein beta 
1,4-galactosyltransferase, 
polypeptide 7 
Attaches first Galactose in link 
tetrasaccharide 
CFU-E 131.76 No No No 
Common B3GALT6, Beta-1,3-
galactosyltransferase 6 
Attaches second Galactose in 
link tetrasaccharide 
CFU-E 520.61 No No No 
Common B3GAT3, beta-1,3-
glucuronyltransferase 3 
Attaches Glucaronic acid to link 
tetrasaccharide 
CFU-E 142.40 No No No 
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HS HSPG2, Heparan sulfate 
proteoglycan 2 
Encodes core protein of 
Perlecan 
Unavailable Unavailable No No No 
HS EXTL2; exostosin-like 
glycosyltransferase 2 
 
Alternating addition of 
Glycuronic acid and N-
acetylglucosamine to HS chains 
CFU-E 491.87 No No No 
HS EXTL3; exostosin-like 
glycosyltransferase 3 
 
Catalyses transfer of N-





No No No 




polymerises HS chain.  
Late-E 46.5 No No No 




polymerises HS chain. 
Pro-E 60.97 No No No 




polymerises HS chain. 





Catalyses both the N-
deacetylation and the N-
sulfation of glucosamine of 
heparan sulfate. Absolutely 

















Catalyses both the N-
deacetylation and the N-
sulfation of glucosamine of 
heparan sulfate. 





Catalyses both the N-
deacetylation and the N-








Catalyses both the N-
deacetylation and the N-
Similar 28.49 (Late-
E) 
No No No 
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 sulfation of glucosamine of 
heparan sulfate. 
HS GLCE; glucuronic acid 
epimerase 
 
Responsible for epimerization 
of D-glucuronic acid (GlcA) to L-
iduronic acid (IdoA) of HS, 
which endows the nascent 
polysaccharide chain with the 
ability to bind growth factors 
and cytokines 
 
Int-E 132.87 No No No 
HS HS2ST1; heparan sulfate 2-O-
sulfotransferase 1  
Transfers sulfate to the 2 
position of the iduronic acid 
residue of heparan sulfate 
 
Pro-E 374.17 No No No 
HS HS6ST1; heparan sulfate 6-O-
sulfotransferase 1  
 
Responsible for 6-O-sulfation of 
heparan sulfate 
 
CFU-E 230.27 No No No 
HS HS6ST2; heparan sulfate 6-O-
sulfotransferase 2  
 
6-O-sulfation of N-acetyl- 
Glucosamine 
Similar 8.10 (Late-E) No No No 
HS HS6ST3; heparan sulfate 6-O-
sulfotransferase 3  
 
Responsible for 6-O-sulfation of 
heparan sulfate 
 
Similar/Late-E 55.62 No No No 




Catalyses the transfer of a sulfo 
group to position 3 of 
glucosamine residues in 
heparan. Catalyses the rate 
limiting step in the biosynthesis 
of heparan sulfate (HSact). This 
modification is a crucial step in 
the biosynthesis of 
anticoagulant heparan sulfate 
as it completes the structure of 
the antithrombin 
pentasaccharide binding site. 
Late-E (/Pro-
E) 
59.73 No No No 
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Catalyses the transfer of a sulfo 
group to an N-unsubstituted 
glucosamine linked to a 2-O-
sulfo iduronic acid unit on 
heparan sulfate. Catalyses the 
O-sulfation of glucosamine in 
GlcA2S-GlcNS.  
 
Late-E 31.46 No Yes Yes 
HS HS3ST3B1; heparan sulfate-
glucosamine 3-sulfotransferase  
 
Catalyses the addition of sulfate 
groups at the 3-OH position of 
glucosamine in heparan sulfate 
Polymorphism linked with 
parasitaemia Atkinson et al. 
2012 
Late-E 38.73 No No No 
HS HS3ST3A1; heparan sulfate-
glucosamine 3-sulfotransferase  
 
Catalyses the addition of sulfate 
groups at the 3-OH position of 
glucosamine in heparan sulfate 
Polymorphism linked with 




10 No No No 
HS HS3ST5; heparan sulfate-
glucosamine 3-sulfotransferase 
5  
Catalyses the transfer of a sulfo 
group to position 3 of 







No No No 






to glucuronic acid (GlcUA). 
Required for addition of the first 
GalNAc to the core 
tetrasaccharide linker and for 
elongation of chondroitin chains 
 
IntE 145.87 No No No 
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to glucuronic acid (GlcUA). 
Required for addition of the first 
GalNAc to the core 
tetrasaccharide linker and for 
elongation of chondroitin chains 
IntE 236.36 No No No 
CS CHSY3; chondroitin sulfate 
synthase 3 
 
Transfers glucuronic acid 
(GlcUA) from UDP-GlcUA and 
N-acetylgalactosamine 
(GalNAc) from UDP-GalNAc to 
the non-reducing end of the 
elongating chondroitin polymer. 
Specific activity is much 
reduced compared to CHSY1. 
 
Similar 14.48 No No No 
CS CHSY1; chondroitin sulfate 
synthase 1 
 
Transfers glucuronic acid 
(GlcUA) from UDP-GlcUA and 
N-acetylgalactosamine 
(GalNAc) from UDP-GalNAc to 
the non-reducing end of the 
elongating chondroitin polymer. 
IntE 1015.18 No No No 
CS CHPF; chondroitin polymerizing 
factor 
 
Transfers glucuronic acid 
(GlcUA) from UDP-GlcUA and 
N-acetylgalactosamine 
(GalNAc) to the non-reducing 
end of the elongating 
chondroitin polymer. 
LateE 111.43 No No No 
CS CHPF2; chondroitin 
polymerizing factor 2 
 
Transfers glucuronic acid 
(GlcUA) to N-
acetylgalactosamine residues 
on the non-reducing end of the 
elongating chondroitin polymer. 
Has no N-





CS CHST11; carbohydrate 
(chondroitin 4) sulfotransferase 
11  
 
Catalyses the transfer of sulfate 
to position 4 of the N-
acetylgalactosamine (GalNAc) 
residue of chondroitin 
 
IntE 398.35 No No No 
CS CHST12; carbohydrate 
(chondroitin 4) sulfotransferase 
12  
 
Catalyses the transfer of sulfate 
to position 4 of the N-
acetylgalactosamine (GalNAc) 
residue of chondroitin and 
desulfated dermatan sulfate 
 
Late E 656.78 No No No 
CS CHST13; carbohydrate 
(chondroitin 4) sulfotransferase 
13  
 
Catalyses the transfer of sulfate 
to the C4 hydroxyl of beta-1,4-
linked N-acetylgalactosamine 
(GalNAc) flanked by glucuronic 
acid residue in chondroitin 
 
Late E 90.96 No No No 
CS CHST3; carbohydrate 
(chondroitin 6) sulfotransferase 
3  
 
Catalyses the transfer of sulfate 
to position 6 of the N-
acetylgalactosamine (GalNAc) 
residue of chondroitin 
 
Late E 44.61 No No No 




Catalyses the sulfation of 6-
hydroxyl group of GalNAc in 
chondroitin 
 
LateE 47.71 No No No 
CS CHST15; carbohydrate (N-
acetylgalactosamine 4-sulfate 
6-O) sulfotransferase 15 
 
Transfers sulfate from 3-
phosphoadenosine 5-
phosphosulfate (PAPS) to the 
C-6 hydroxyl group of the 
GalNAc 4-sulfate residue of 
chondroitin sulfate A and forms 
unavailable unavailable No No No 
 137 




CS UST; uronyl-2-sulfotransferase 
 
Sulfotransferase that catalyses 
the transfer of sulfate to the 
position 2 of uronyl residues. 
Has mainly activity toward 
iduronyl residues in dermatan 
sulfate, and weaker activity 
toward glucuronyl residues of 
chondroitin sulfate. Has no 
activity toward desulfated 
heparin 
 
Similar 18.05 No No Yes 
 
 
*The Human Erythroblast Maturation database can be accessed via http://cellline.molbiol.ox.ac.uk/eryth/index.html
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Of all the listed enzymes/proteins involved in HS and CS, only two, Heparan 
sulfate 2-O-sulfotransferase 1 (HS2ST1), and Basement membrane-specific 
Heparan sulfate proteoglycan core protein (HSPG2), were recorded in the 
supplemental tables of Gautier et al. Figure 3-22 shows a graphical 
representation of the copy number per cell at different stages of erythroblast 
maturation of these two molecules, along with glycophorin A and Band 3 for 
comparison (Data taken from the supplemental information of (Gautier et al., 
2016)). Further details on the stages of erythroid development and images 
are given in the introduction to Chapter 4. Consistent with all the data 
presented thus far, it appears that while HS (though not CS) is present on 
early erythroblasts during maturation in the bone marrow, HS expression is 
lost before the point of enucleation and release into the peripheral circulation, 
and therefore cannot be detected on mature erythrocytes.   
 
Figure 3-22 Molecular copy number per cell of Heparin sulfate proteoglycan core protein (HSPG2), 
Heparan sulfate 2-O-sulfotransferase 1 (HS2 ST1), glycophorin A (GYPA) and Band 3. Note differing 




Heparin sulfate has long been considered an important rosetting receptor 
despite much of the supporting evidence failing to convincingly demonstrate 
a specific interaction between the parasitized erythrocyte and HS native to 
the host erythrocyte cell membrane. The aim of my work was to further 
explore HS and CS as potential rosetting receptors using carefully validated 
methods designed to identify whether these molecules are actually 
expressed on circulating uninfected erythrocytes and if removing them had 
any effect on the rosetting ability of a range of parasites.  
 
3.6.1 Heparan sulfate and chondroitin sulfate are not specific rosetting 
receptors 
 
Initially, I used an enzymatic approach to remove both HS/CS from the 
mature erythrocytes in the hope that this would provide evidence of a specific 
interaction between the infected cells and HS/CS present on the uninfected 
erythrocyte membrane. However, no effect on rosetting was seen, and, 
interestingly, removal of HS also had no effect on the ability of heparin to 
disrupt rosettes, suggesting that different mechanisms were at play. When 
the removal of HS/CS also made no difference to binding of rPfEMP1 
domains, it seemed prudent to question the basic assumption that either of 
these molecules were present on mature erythrocytes. Consistent with my 
results thus far, I was unable to identify any evidence of HS or CS on mature 
erythrocytes. While this could have initially represented a problem with my 
detection technique, confidence in my methods was restored by the 
identification of HS on early erythrocyte precursors.  
 
To a certain extent, these findings contrast with the existing published 
literature. As a direct comparison, Barragan et al. (Barragan et al., 1999) 
tested two parasite lines, FCR3S1 (analogous to ITvar60) and TM284, using 
the same enzymatic technique and found substantial reduction in rosetting 
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frequency for both. However, there are some potential issues with this paper; 
the results are presented as percentage of control and no statistical analysis 
comparing the treated and control samples are given. This can be 
misleading, for example if the change in rosette frequency is from 10% to 
5%, this can be presented as a 50% reduction in rosette frequency but 
variation of level is commonly seen even within the same culture. The 
additional experiments in which only the uninfected cells are treated are also 
problematic; enzyme-treated, uninfected cells are labelled then mixed with 
untreated, parasite cultures (containing both infected and uninfected cells 
which have not been mock treated or labelled). The rosetting ability of the 
enzyme-treated uninfected cells and the uninfected cells already in the 
culture are then compared. No data are given to demonstrate that labelling 
does not affect rosetting, or that pre-existing rosettes were fully disrupted 
before mixing with treated cells (the ‘mechanical disruption’ of rosettes 
described in the paper is not effective in my experience). It is therefore 
arguably not an appropriate comparison and any decrease in rosetting of the 
enzyme treated cells could simply be due to the labelling or a non-specific 
effect of enzyme treatment. 
 
As discussed in the introduction, much of the evidence suggesting that HS is 
a rosetting receptor, relies on the use of heparin or soluble HS to disrupt 
rosettes. My data support the finding that heparin does disrupt rosettes 
across a range of parasite strains. However, the results of my enzyme 
experiments, and the lack of effect of enzyme treatment on PfEMP1 binding 
to uninfected erythrocytes, have led me to conclude that the mechanism of 
disruption is not blocking of host HS on uninfected erythrocytes. Rather, it 
seems likely that either the highly negatively charged heparin molecules are 
able to interrupt rosetting in a non-specific, charge related fashion, or that 
heparin is binding to PfEMP1 thus blocking rosetting from the parasite side, 
rather than host. There is some evidence to support both these hypotheses. 
Barragan et al. found that sulfation, and by extension charge, was important 
for rosette disruption ability with desulfated heparin having minimal effect on 
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rosetting (Barragan et al., 2000a). The binding of Duffy-like-binding domains 
from the VAR2CSA protein to Chondroitin sulfate can also be disrupted by 
relatively low concentrations of soluble HS, which Resende et al. concluded 
was evidence of the non-specific, charge related nature of this interaction 
(Resende et al., 2009). PfEMP1 has been showed to bind HS as seen in the 
glycan array, which reignited our interested in the GAGs as rosetting 
receptors, and multiple other studies (Barragan et al., 2000a, Heddini et al., 
2001, Juillerat et al., 2011, Adams et al., 2014). It seems quite plausible that 
the disruption of rosettes by heparin/soluble HS is in fact due to binding of 
PfEMP1, as suggested by Juillerat et al. (Juillerat et al., 2011), rather than 
blocking of host HS on the uninfected erythrocytes. Heparin binding to 
parasite derived molecules could also explain the results of several papers 
which propose heparan sulfate as a potential erythrocyte invasion receptor 
(Boyle et al., 2010, Kobayashi et al., 2010). 
 
3.6.2 Heparan sulfate and chondroitin sulfate are not present on 
mature erythrocytes: a comparison with the literature 
 
These data and hypotheses are all consistent with the second major 
conclusion from this work; that it is unlikely that either  HS or CS are present 
in detectable, and possibly by extension clinically relevant, quantities on 
mature erythrocytes. As alluded to previously, this is at odds with the single 
paper which suggests that HS can be found on mature erythrocytes (Vogt et 
al., 2004). When replicating the experiments described in Vogt et al., I 
identified a number of potential issues which could lead to a different 
interpretation of their results. In the first instance, the methods, namely 37oC 
incubation times and a double layer secondary and tertiary antibody 
technique, may not promote specific binding. However the appropriate 
comparison of the mock and enzyme treated cells should overcome this 
issue. When comparing mock and enzyme treated cells, I found a significant 
amount of background fluorescence, along with multiple dots, which could 
appear to be clusters of HS, except these areas were seen equally in both 
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control and treated samples (Figure 3-13). The single cell depicted in Vogt et 
al. shows similarly high levels of background fluorescence and bright dots, 
however the background of the control samples is significantly darker, 
perhaps suggesting different microscopy settings. Figure 3-23 compares the 
two image sets. Similarly, the flow cytometry plots depicted in Vogt et al. 
appear to show a large number of cells on the y-axis suggesting different 
voltage settings to those used for my analysis. 
 
 
Figure 3-23 Comparison of images from Vogt et al. (2004) and single cells taken from Figure 3-13 
showing mock and enzyme treated erythrocytes incubated with 3G10 primary antibody followed by 
secondary and tertiary antibodies. Colour has been added to the images from this thesis with Image J 
but no other image manipulation has taken place. 
 
It is important to note that Vogt et al. did conduct additional experiments 
involving purification of O-glycans which they conclude came from the 
mature erythrocytes and used a different method of blotting red cell 
membranes. However these methods involved lysing the cells therefore it is 
not possible to determine whether the O-glycans detected in these 
experiments was expressed on the cell surface or just intracellularly. They 
also separated fully mature erythrocytes from reticulocytes and report no 
differences in the expression of HS between these cell types. This differs 







stages but is lost with maturity, however the literature review presented in 
section 3.5.7 is more in support of my data. Though there are some 
variations between the studies, broadly speaking, there is some relatively 
low-level gene transcription of HS and CS biosynthesis genes at a very early 
stage of erythroid development, but very few of the corresponding proteins 
are expressed at later stages. Despite this, it is important to bear in mind that 
it is impossible to prove that something does not exist, and I cannot rule out 
the possibility that HS (or indeed CS) is expressed in very low levels on 
mature erythrocytes.  
 
3.6.3 Limitations of this work  
 
The other limitations of this work must also be acknowledged. All the 
experiments, and parasite culturing, have been carried out using blood from 
Scottish blood donors. Though the ethnicity of these donors is unknown, it is 
reasonable to assume, given the demographics of the Scottish population, 
that the majority of these would be of Caucasian origin, and all would be over 
the age of 17 years. Arguably, the erythrocytes of particular interest 
concerning severe malaria are those of the groups most affected by severe 
disease, namely African children. It is possible that children in Africa do 
express high levels of HS of their erythrocytes (either due to their ethnicity or 
age) and this is why they are more susceptible to severe disease. However, 
this seems unlikely; if high levels of HS do promote severe disease, one 
might expect this trait to be selected out of the African population and it 
would be unusual for a trait which predisposes to severe malaria to be 
present in the Africans but not Caucasians (in contrast, for example, with 
sickle cell trait). 
 
The use of enzymes and antibodies to stub molecules may seem a 
somewhat convoluted and indirect way to attempt to detect HS and CS. 
However, as discussed in the introduction, HS and CS are both inherently 
highly variable molecules and antibodies to the whole molecule of one 
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variant may not bind well to another. Using the common stub antibodies 
allows for the vast range of HS/CS types, and the superior detection 
compared to antibodies directed against the whole molecule can be seen in 
Figure 3-8. Nevertheless, while the stub antibodies can demonstrate that the 
enzymes are functional, they cannot determine to what degree the HS or CS 
is removed from the cell surface. I cannot rule out that a small quantity 
remains even after enzyme treatment and that HS/CS are potent enough 
rosetting receptors that only a few molecules are sufficient to bind to infected 
cells.  
 
There are also a number of technical and methodological issues which could 
be optimised. While the concentration of Heparinase III was consistent 
throughout in both the COS cell validation and erythrocyte experiments, the 
cell numbers were different (for example 8x108 erythrocytes versus 1.5x106 
COS cells in the Western blot assays). Ideally these cell numbers would be 
better matched, however one must also bear in mind differences in cell size. 
While the COS cell results demonstrate that the enzyme does function as 
expected under similar conditions to those used for the erythrocyte 
experiments, this does not absolutely prove that Heparianse III is capable of 
removing HS specifically from mature erythrocytes in large cell numbers. 
Additionally, glycophorin A was perhaps not the most appropriate positive 
control to use for Western blot experiments as it is one of the most 
abundantly expressed molecules on the erythrocyte surface. A protein with a 
lower copy number, for example CR1, may have been a better choice to 
confirm that the experimental methods were capable to detecting molecules 
with lower expression levels.  
 
3.6.4 Conclusions, clinical context and the way forward 
 
Nevertheless, the results of the experiments contained within this chapter 
have led me to believe that HS is expressed in the very early stages of 
erythroid cell development but is lost before the reticulocytes are released 
 145 
into the peripheral circulation. I am unable to discover any experiments that 
HS is an important, specific rosetting receptor on uninfected host 
erythrocytes. This also has important implications outside the rosetting field; 
HS has been proposed as an erythrocyte invasion receptor and my data 
suggest that further research into this receptor in an invasion context may not 
be particularly fruitful. The data on CS are new and, though negative, do 
present useful data to add to the literature. However, this is not to say that 
heparin, heparan sulfate and its derivatives are useless in the fight against 
severe malaria. The mechanism may not be specific, but heparin does 
disrupt rosettes very effectively. In itself, heparin is not a useful therapy due 
to its anticoagulant effects (Smitskamp and Wolthuis, 1971, WHO, 1986), but 
the low anticoagulant heparin derivative, Sevuparin, is already undergoing 
clinical trials as an adjuvant therapy for severe malaria (Leitgeb et al., 2017, 
Saiwaew et al., 2017). In vitro clinical isolates cultured from uncomplicated 
adult malaria cases in Thailand had a median rosette disruption effect of 40% 
at therapeutic concentrations of Sevuparin (estimated to be around 
100µg/ml) and adherence to human dermal endothelial cells was also 
reduced (Saiwaew et al., 2017). A small clinical trial of Sevuparin in Thai 
patients with uncomplicated malaria also showed apparent desequestration 
of mature parasites with no safety issues (Leitgeb et al., 2017). This is 
particularly interesting as it provides the first clinical data suggesting that 
rosette disruption may be a safe therapeutic target.  It appears that it’s not 
yet time to ignore the potential anti-rosetting effects of heparin and its 
analogues, however this makes elucidating the precise mechanism even 
more important. 
 
One of the important strengths of my work is the use of a range of actual 
parasites and erythrocytes which therefore present the molecules of interest, 
both host and parasite derived, in as natural a way as possible in vitro. The 
glycan screening array is an example of the perils of using recombinant 
proteins on artificial matrixes which may not represent the actual molecules 
present on mature erythrocytes. However, the “block” and “chop” techniques 
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used still leave much to desired in terms of specificity and screening 
potential. This highlights the need for new approaches to investigating host 
rosetting receptors. A more elegant solution could be the use of knockout 
erythrocytes which lack the receptor of interest. These cells could be tested 
on multiple laboratory and clinical strains and would have the benefit of being 
otherwise ‘normal’ erythrocytes in terms of shape and surface molecules. 
The remainder of my thesis is therefore dedicated to developing a new model 
for investigating host erythrocytes rosetting receptors using knockout 
erythrocytes to elucidate the true mechanisms of rosetting in severe malaria.  
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4. CHAPTER IV: USING CULTURED 
HAEMATOPOIETIC STEM CELLS TO 
INVESTIGATE POTENTIAL ROSETTING 
RECEPTORS AND IDENTIFY A NOVEL 
ROSETTING RECEPTOR 




The ability to generate ‘designer’ erythrocytes would be an extremely useful 
tool in determining the essential host-related mechanisms of rosetting. 
Experiments could be performed using well-characterised, knockdown/out 
erythrocytes, which express the remainder of the cell surface receptor 
complement as close to in vivo as possible. Such cells could be tested with 
multiple parasite lines to untangle which host receptors have an essential or 
accessory function for rosetting. Generating such cells is challenging as 
genetic manipulation must take place at the immature, erythroid precursor 
stage when the cell still contains a nucleus. This chapter deals with two 
sources of erythroid precursors; pilot experiments using induced pluripotent 
stem cell erythroid cultures (iPSC), and CD34+ haematopoietic stem cells 
derived from adult bone marrow (cRBC). Cells originating from iPSC were 
immature, heterogeneous and displayed an unusual adherence phenotype, 
however cRBC proved more promising. cRBC were characterised at multiple 
stages of maturation in terms of morphology, receptor expression and 
rosetting ability. Once matured, cRBC demonstrated excellent enucleation 
and showed a reticulocyte-like receptor profile indicating these cells were a 
good approximation of peripheral erythrocytes. The binding of recombinant 
rosetting PfEMP1 domains to cRBC was equal to that of mature cells, 
however rosetting experiments showed an unexpected result. Two parasite 
lines failed to rosette with cRBC, prompting a deeper investigation into the 
subtle differences in receptor expression. This led to the identification of 
Band 3 as a potentially important rosetting receptor, and further experiments 
showed that antibodies to the Wrightb antigen, carried on Band 3, had a 
remarkable ability to disrupt rosettes across all tested parasite strains. 
Attempts to generate knockdown cRBC had limited success and 
demonstrated the need for an immortalized erythroid line to fully realise the 




4.2.1 A new method for investigating rosetting receptors; the “knock” 
approach 
 
In Chapter 3, I discussed the importance of using ‘real’ infected and 
uninfected erythrocytes, as opposed to relying on recombinant proteins and 
other cell types. I also highlighted the challenge of dissecting whether a 
rosette disrupting molecule, such as heparin, is interfering with receptors on 
the parasitized or uninfected cells. In order to fully understand the 
mechanisms of rosetting, this is an importance distinction to make. I 
therefore decided to explore a different approach to the “block” and “chop” 
techniques used in the previous chapter, namely a “knock” methodology; the 
production of erythrocytes with reduced or absent expression of various 
receptors of interest. For the purposes of this thesis, I will refer to cells which 
have been manipulated using RNAi methods as knock-down cells, and cells 
which had had a permanent genome change (such as those generated using 
CRIPSR/Cas9 techniques) as knockouts. The advantage of using 
knockdown/out erythrocytes, is that, in theory (and depending on the function 
of the molecule), they will maintain the rest of the erythrocyte surface 
receptor complement, presented in a way as close to in vivo as possible. 
This allows the necessity of the knockdown/out receptor to be determined 
and the potential of the parasite to utilize accessory receptors to be explored. 
Knockdown cells have been used in such experiments to demonstrate that 
glycophorin A is an important invasion receptor for some P. falciparum 
strains (Bei et al., 2010) and in an exciting screening study which identified 
CD55 as a new, essential invasion molecule (Egan et al., 2015). The 
generation of knockdown erythrocytes has, in fact, already been used as a 
tool in the rosetting field (Lee et al., 2014, Niang et al., 2014). Lee et al. 
transduced CD34+ umbilical cord haemopoietic stem with short hairpin RNA 
targeted against glycophorin C (GYPC) to knockdown GYPC expression, 
sorted the cells based on GFP expression (indicating successful 
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transduction) and cultured the cells to maturity. The matured cells were then 
tested for rosetting ability with P. vivax isolates (Lee et al., 2014). They 
reported significantly reduced rosetting of the knockdown cells compared to 
control cells (the non-GFP expressing cells cultured to maturity in parallel) for 
the P. vivax isolates tested, but the experiments were not repeated for P. 
falciparum. Niang et al. (2014), transduced umbilical cord cells in a similar 
manner, and compared rosetting of the knockdown cells to controls using a 
single P. falciparum line, 5A, a clone of 3D7 (Niang et al., 2014). Again, they 
found a significant reduction in rosetting. 
 
Both these studies are limited in their sole focus on GYPC and that only one 
laboratory adapted P. falciparum strain was used; Niang et al. only assessed 
5A, and Lee et al. used P. vivax only. However, they demonstrate the proof 
of principle that knockdown erythrocytes can be used for rosetting assays.  
 
4.2.2 Generating knockdown cells 
 
4.2.2.1 Naturally occurring polymorphisms 
 
 Instead of generating artificial knockdown cells, a logical solution could be 
sourcing cells with naturally occurring polymorphisms leading to a decrease 
in receptor expression. In fact, Rowe et al. (1997) previously tested 23 
erythrocyte variants (see Table 4-1), though not all these polymorphisms 
lead to a decrease or null receptor expression.
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Table 4-1 Rare blood group variants tested by (Rowe et al., 1997) for rosetting phenotype 








Knops null CR1 null Yes, reduced <100 CR1 molecules/ erythrocytes 
Kell null Kell Ko No Express no Kell antigens 
Bombay H antigen Bombay No No H, A or B antigen 
Rh null Rhesus Null No No Rh antigens (including D, E etc.) 
LW ICAM4 a-b- No  
McLeod XK McLeod (lack 
of XK gene) 
No Absence of XK leads to weak Kell expression and neuromuscular 
problems 
Kidd null JK antigen Jk- No Rare in most populations, 0.9% of Polynesians 
Duffy Duffy a-b- No Duffy negativity is rare in Caucasians but present in 68% of Black 
populations (invasion receptor for P vivax) 
Gerbich GYPC and GYPD -1,-2,-3 No Leads to elliptocytosis, not a true null phenotype (cf Leach 
phenotype). Common in Papua New Guinea (Patel et al., 2001) 
Lutheran Lutheran  a-b- No  
Gregory Gregory a- No   
JMH null Semaphorin 7A null No  




-1,-2 No  
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P P antigens Tja-, now 
referred to as 
p 
No  
Colton Aquaporin 1 a-b- No  
Adult i I  Adult i No i antigen is present normally until 18 months of age when it converts 
to I (Yu et al., 2001) 
Chido 
negative 
Complement C4 null No Not an intrinsic erythrocyte protein, adsorbed from the plasma 
Lewis Lewis a-b- No Also adsorbed from plasma. The tested polymorphism is more 
common in Black, African and Indian populations. 
Xg negative Xg(a) and CD99 null No Gene located on X-chromosome 
Diego Band 3 b- No Diegoa is seem most commonly in South American (36%) and Asians 
of Mongoloid origin (5-15%) 
Lan negative Lan, carried on 
ABCB6 
null No Null is rare but commoner in black South Africans (1:1500) (Peyrard, 
2013) 
Vel negative Vel/small integral 
membrane protein 1 
null No Null is extremely rare but clinically significant for transfusion reactions 
Details on the antigens and information in the comments are taken from (Rowe et al., 1997), (Dean, 2005) and (Cooling, 2015) 
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While this approach led to the identification of CR1 as a rosetting receptor 
(Rowe et al., 1997), sourcing these very rare erythrocytes can be difficult and 
obtaining a continuous supply for multiple experiments is extremely 
challenging. The receptor expression can vary between individuals and for 
some receptors, for example Band 3, the null phenotype is not normally 
compatible with life (Ribeiro et al., 2000). 
 
I was therefore keen to develop techniques which would allow me to ‘design’ 
my own knockdown/out erythrocytes and, potentially in the future, to make 
multiple knockouts in a single cell. However, mature peripheral erythrocytes 
are not amenable to genetic manipulation given their enucleated state. Like 
those conducting the knockdown studies described above, I needed to find a 
source of nucleated, erythroid precursors which I could manipulate, then 
differentiate into cells as close to mature, enucleated, peripheral erythrocytes 
as possible. 
 
4.2.2.2 Sources of erythroid precursors 
 
On entering the world of laboratory generated erythrocytes, I had the 
advantage of many years of research undertaken by others in the field of 
blood transfusion. A great deal of work has gone on, and continues, into 
reaching the holy grail of culturing large quantities of enucleated erythrocytes 
which could be used for blood transfusion purposes (Anstee et al., 2012). 
The major sources of erythroid precursors used in these transfusion-related 
studies have been: 
 
1. Haematopoietic stem cells (HSC) derived from adults (either from 
bone marrow samples or obtained from the peripheral circulation with 
or without stimulation with Growth colony stimulating factor [G-CSF]). 
2. HSC derived from the umbilical cord of newborn infants. 
3. Human induced pluripotent stem cells (iPSC). 
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4. Human embryonic stem cells (ethical consideration may limit the use 
of such cells).  
 
In addition, in recent years exciting new developments have been published 
regarding immortalized human erythroid lines (Kurita et al., 2013, 
Trakarnsanga et al., 2017) and these will be dealt with in detail in Chapter 5.  
 
After initial pilot work with human iPSC, I decided to use commercially 
available HSC derived from adult bone marrow donors. However, I was also 
able to test one sample of umbilical cord derived HSC which were a kind gift 
from Professor Lesley Forrester. Further details on the characteristics of 
HSC and iPSC are described below. 
 
4.2.2.2.1 Haematopoietic stem cells 
 
CD34+ haematopoietic stem cells (HSC) are primary cells which have 
developed from pluripotent haematopoietic stem cells and, under the correct 
conditions, have the potential to expand and differentiate into mature, 
enucleated erythrocytes (Figure 4-1, adapted from (Attar, 2014), (Alberts et 





Figure 4-1 Development of haematopoietic stem cells in the bone marrow. Adapted from (Attar, 2014), 
the maturation stages of the other cells, including monocytes and neutrophils from the granulocyte 
progenitor cells, platelets from the megakaryocytes and B cells from the common lymphoid progenitors 
have been removed for clarity. The orthochromatic normoblast, pyrenocyte and reticulocyte images are 
from my own cRBC cultures.  
 
In one of the key final stages of development, the immature erythroid 
precursors lose their nuclei to form reticulocytes. Enucleation occurs 
between the orthochromatic erythroblast and reticulocyte states and the 
extruded nucleus is referred to as a pyrenocyte (Figure 4-1, (Nandakumar et 
al., 2016)). This enucleation step makes the erythrocyte significantly more 
flexible allowing it to pass through microvessels much smaller that the cells 
itself (Guzniczak et al., 2017). Reticulocytes still contain RNA, are more 







biconcave disc of mature erythrocytes (Piva et al., 2015).  They remain in the 
bone marrow for around three days before release into the peripheral 
circulation where they reach full maturity, probably through modification by 
the spleen, in around 24 hours (Anstee et al., 2012, Piva et al., 2015). The 
presence of numerous nucleated erythrocytes in the peripheral circulation is 
suggestive of pathology (Constantino and Cogionis, 2000). 
 
In postnatal mammals, in vivo, erythropoiesis occurs in the bone marrow 
(Nandakumar et al., 2016), however it is possible to culture HSC in vitro into 
relatively mature, reticulocyte-like cells (Anstee et al., 2012). These cultured 
erythrocytes (cRBC) have a moderately high level of enucleation (68% and 
above reported by (Giarratana et al., 2011)), but tend to be slightly larger, 
less deformable, and express a more immature repertoire of proteins on the 
cell surface (Giarratana et al., 2005, Giarratana et al., 2011, Anstee et al., 
2012, Hu et al., 2013, Wilson et al., 2016, Guzniczak et al., 2017). Figure 
Figure 4-2, taken from (Guzniczak et al., 2017), demonstrates how the 





Figure 4-2 (Guzniczak et al., 2017) cultured CD34+ HSC in a similar manner to that described in 
section 2.2 then assessed the deformability of cell using a Real Time Deformability Cytometer. A 
shows the change in cell area and deformation index at 4 time points. B shows the range of cell 
phenotypes present at D18 of culture, coloured coded based on nucleation status and C + D show the 
cell size/deformability of nucleated, enucleated and the extruded nuclei at different time points. Figure 
taken directly from (Guzniczak et al., 2017) 
 
 Giarratana et al. analysed the haemoglobin (Hb) content and oxygen binding 
of cRBC derived initially from leukapheresis of an adult stimulated with G-
CSF (Giarratana et al., 2011). They found around 10% of the Hb content was 
foetal Hb, which they attributed to a stress response to the various growth 
factors in the culture medium, and the remainder was normal adult HbA with 
an oxygen binding capacity similar to that of normal peripheral erythrocytes 
(Giarratana et al., 2011). In contrast, cRBC derived from umbilical cord stem 
cells contain predominantly fetal Hb, though the surface receptor profile is 
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similar to that of adult derived cells and they do have the advantage of a 
higher proliferative capacity (Wilson et al., 2016).  
 
In early systems, CD34+ HSC required co-culturing with murine MS-5 stroma 
cells, or other mesenchymal cells, for support and to promote differentiation 
(Giarratana et al., 2005), however the methods have since been simplified 
and cells can now be matured independently (Giarratana et al., 2011). 
Autologous HSC have even been matured ex-vivo then injected back into the 
original human donor where the survival of the cRBC at 26 days was 
between 41 and 63% (Giarratana et al., 2011). 
 
As discussed above, cRBC have been successfully genetically manipulated 
to produce knockdown cells using both RNA interference (for example, (Bei 
et al., 2010, Niang et al., 2014, Lee et al., 2014, Egan et al., 2015) and 
knockouts using CRISPR/cas9 methods (Mandal et al., 2014, Hu, 2016, Yu 
et al., 2016). However, cRBC do have a number of disadvantages which can 
impose limitations on their usefulness. The main problem is that cRBC are 
not immortalized cells and have limited proliferation capacity (Zeuner et al., 
2012, Hu et al., 2013). This can pose a particular technical challenge for 
experiments which require transduction and selection of modified cells. 
Culturing is also very expensive and somewhat time-consuming. I was 
therefore keen to also explore other potential sources of erythroid precursors, 
namely induced pluripotent stem cells. 
 
4.2.2.2.2 Induced pluripotent stem cells 
 
Induced pluripotent stem cells (iPSC) are an attractive potential source of 
erythroid cells due to their immortalized nature. Takahashi et al. first 
described the ‘reprogramming’ of human adult dermal fibroblasts into cells 
capable of differentiating into any cell type, by transducing the fibroblasts 
with the transcription factors Oct3/4, Sox2, Klf4 and c-Myc (Takahashi et al., 
2007). Erythroid cells have been generated from iPSC ((Lapillonne et al., 
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2010) and reviewed in (Easterbrook et al., 2016)), however culturing and 
differentiation is complex, the cells generated from this source have very 
poor enucleation  (4% in (Lapillonne et al., 2010)), and express mainly foetal 
haemoglobin (Lapillonne et al., 2010, Easterbrook et al., 2016, Olivier et al., 
2016, Yang et al., 2017, Ferreira et al., 2018). Nevertheless, I was fortunate 
enough to have access to samples of erythroid cells derived from iPSC from 
Professor Forrester’s laboratory based in the Scottish Centre for 
Regenerative Medicine. I therefore decided to use these cells in pilot 
rosetting experiments, with a view to investigating iPSC as a potential tool to 
develop null erythrocytes if these pilot experiments showed promise. 
 
4.2.2.3 Knockdown using RNA interference 
 
Once a suitable source of erythroid precursors has been identified, the next 
stage is to generate the knockout or knockdown cells. The genetic 
manipulation tool of the moment is CRIPSR/Cas9 (Jinek et al., 2012, 
Pyzocha et al., 2014), however, though this technology has been used 
successfully with HSC (Mandal et al., 2014, Hu, 2016, Yu et al., 2016), the 
efficiency in vitro was often poor (Yu et al., 2016). Given the limited life-span 
of the cRBCs, generating a useable knockout population is technically very 
difficult, therefore I decided initially to focus on the tried and tested short 
hairpin RNA (shRNA) interference methods used to generate knockdown 
cells in the studies described above. 
 
RNA interference, specifically the use of shRNA, is a gene expression 
silencing method in which messenger RNAs (mRNA) are targeted by 
small/short interfering RNA (siRNA) and cleaved by proteins in the RNA-
induced silencing complex (RISC) (Lord et al., 2009). A schematic of the 
process is showed in Figure 4-3. The shRNA DNA is introduced into the cell 
by transduction with lentiviral particles, where it is then transcribed into 
shRNA and exported from the nucleus (Lord et al., 2009, O'Keefe, 2013). 
The shRNA is converted into double stranded siRNA consisting of around 
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19-25 base pairs by the enzyme Dicer, and the siRNA are then incorporated 
into the RISC. The RISC then uses the siRNA to identify target mRNA 
through complementary base pairing, and cleaves it thus silencing protein 





Figure 4-3 Schematic of a cell undergoing mRNA silencing using shRNA lentiviral particles. The grey 
shaded area represents the cell nucleus. shRNA= short hairpin RNA, siRNA = small interfering RNA, 
RISC = RNA inducible silencing complex, mRNA= messenger RNA 
 
In this way, I hoped to generate a panel of different cRBCs, each with 
different receptor knockdowns to help distinguish which of the currently 





The aim of this chapter was to investigate the utility of iPSC and cRBC as 
tools for determining essential host rosetting receptors. Specifically, I wanted 
to characterize the matured cRBC in terms of morphology, receptor profile 
and rosetting phenotype, and explore the possibility of generating knockdown 




4.4.1 Induced pluripotent stem cells 
 
Induced pluripotent stem cells derived from adult skin fibroblasts were 
cultured in the laboratory of Professor Lesley Forrester by Dr Richard Axton, 
Helen Taylor and others at the Centre of Regenerative Medicine, University 
of Edinburgh. The development of these cells by Professor Forrester and her 
laboratory is described in Yang et al. (Yang et al., 2017). Essentially, adult 
skin fibroblasts from donors were transduced with the transcription factors 
OCT4, KLF2, SOX2 and cMYC (first described by (Takahashi and 
Yamanaka, 2006)) transforming the cells into pluripotent stem cells capable 
of differentiation into multiple cell types. The cells were then subject to 
specific culture conditions to promote differentiation into haematopoietic 
progenitors  
(Jackson et al., 2016, Olivier et al., 2016). Of note, I had no role in the 
generation or culturing of these cells. Aliquots containing 1x106 iPSC cells at 
D17 and 23/24 of culture were a kind gift from Professor Forrester and her 
laboratory and were transported from the Centre of Regenerative Medicine to 
the King’s buildings laboratories for pilot rosetting experiments. Cells were 
smeared and Giemsa stained, or mixed with MACS purified 9605 and 
ITvar60 parasites to assess rosetting capability and phenotype (see section 
2.1.4, section 2.1.8 and section 2.6.3 for detailed methods, of note, neither 
parasites nor iPSC were stained with CellTraceTM for these experiments). 
 162 
 
The remaining methods refer to cRBC and detailed culture methods are 
including in section 2.2. 
 
4.4.2 Morphology by cytospin and May Grunwald/Giemsa staining 
 
Samples for cytopsin were prepared by first counting the cells as described 
in section 2.2.3 then taking sufficient volume to give 1x105 cells per sample 
and centrifuging at 300g for 4 minutes. The culture supernatant was removed 
and the pellet washed twice in 100µl of 3% BSA/PBS then resuspended in 
100µl of 10% BSA/PBS. Cytospin slides were prepared using a Thermo 
ScientificTM CytospinTM 4 Cytocentrifuge (A78300003). A labelled slide was 
placed in the slide clip with a filter card on top, followed by the reusable 
cytospin funnel. Samples were loaded in to the cytospin funnels and 
centrifuged for 5 minutes at 120g. The slides were removed and allowed to 
dry for 5-10 minutes before fixing in Methanol for 5 minutes. Slides were 
stained with 10% Giemsa for 25 minutes, in the same manner as parasite 
smears, then rinsed and allow to dry before visualisation using brightfield 
microscopy. Alternatively, slides were first stained for 3 minutes with 10% 
May-Grünwald stain (VWR chemicals, 10047018, made up with dH2O), 
rinsed in water for one minute, then stained with 10% Giemsa (filtered and 
made up with Giemsa buffer) for 15 minutes. The two stage May-Grünwald-
Giemsa approach was demonstrated to me while visiting the Duraisingh 
laboratory and resulted in slides with better resolution for intracellular 
structures. 
 
4.4.3 Flow cytometry and IFA 
 
The receptor profiles of mature erythrocytes (from Scottish adult peripheral 
blood donors as before) and cRBC at various stages of culture were 
analysed using flow cytometry. CD34, CD71 and GYPA were chosen as 
markers of maturation through the erythroid lineage. CD34 positivity is 
 163 
expected to be lost around the proerythroblast stage, CD71 expression 
increases then falls as the cells develop into reticulocytes, while GYPA 
expression continues to increase as the cells mature (Table 4-2 and (Wood, 
2004). The other receptors, GYPC, CR1, HS, CS, Blood group A antigen, H 
antigen and CD36 are of interest as potential rosetting receptors. At this early 
point of my PhD, Band 3 was not considered to be of particular interest 
therefore was not included. The presence of HS was investigated using both 
IgM antibody to whole HS, and the enzyme-treatment approached followed 
by 3G10 antibody labelling discussed in Chapter 3 and detailed below. 
 
Table 4-2 Changes in receptor expression during maturation from CD34+ HSC to mature erythrocytes. 
Adapted from (Wood, 2004).  
 BLAST PRO BASO POLY RETIC MATURE 
CD34 ++ -/+ - - - - 
CD71 - +++ +++ +++ +/++ - 
CD36 - ++ +++ ++ -/+ - 
GYPA/ 
CD235a 
- +/++ +++ +++ +++ +++ 
Haemo- 
globin 
- - -/+ + ++ +++ 




4.4.3.1 Enzymatic pre-treatment with Heparinase III 
 
Three aliquots of culture containing 1-3x105 cells each were removed and 
treated with Heparinase III (two samples) or mock treatment (the same 
volumes of PBS, one sample) for 3.5 hours as described in Chapter 3. 
Samples were washed, then one of the Heparinase III treated samples and 
the mock treated cells, were incubated with 3G10 antibody. The remaining 
enzyme-treated cells were incubated with an isotype control (further details 
below in section 4.4.3.2). 
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4.4.3.2 Preparation of samples 
 
Sufficient cells to give 1-3x105 cells per antibody was washed with PBS then 
resuspended in 1ml PBS with 1µl of LIVE/DEADTM Near IR fluorescent 
reactive dye (Invitrogen L34975) and incubated at room temperature on a 
rotating wheel for 30 minutes. The cells were then washed twice with 
PBS/1% IgG free BSA (Sigma, A0336) and resuspended at approximately 2-
6x106 cells/ml. Fifty l aliquots containing 1-3x105 cells per tube were placed 
in Eppendorf tubes along with the primary antibody to the receptor under 
investigation (see Table 4-3) and incubated on ice for one hour. Cells were 
resuspended by gently flicking the tubes every ten minutes.
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Details Secondary antibody 
Unstained control NA - Nil 
No primary control  
(IgM secondary) 
NA - Goat anti-mouse IgM Alexa 488 
conjugated 
(Life technologies, A21042) 
1:1000 
IgM isotype control 10µg/ml IgM, Thermo Scientific, 02-6800 
No primary control  
(IgG secondary) 
NA - Goat anti-mouse IgG (H+L) 
secondary antibody, Alexa 488 
conjugated (Life technologies, 
A11029) 
1:500 
IgG1 isotype control 14µg/ml IgG1, Abcam, 18443 
IgG2b isotype control 40µg/ml IgG2b, clone MPC-11, Abcam, ab18457 
CD34 14µg/ml IgG1, BIRMA K3, IBGRL, 9437PA 
GYPA 14µg/ml IgG1, BRIC 256, IBGRL 9415PAg 
GYPC 14µg/ml IgG1, BRIC 4, IBGRL, 9417 
CR1 14µg/ml IgG1, J3D3, Genetex, 44217 
3G10 (HS stub) 40µg/ml IgG2b, clone F69-3G10, Amsbio, 370260 
CD36 20µg/ml IgG1, FA6-152, Beckman-Coulter, IM0766U 
HS (whole molecule) 10µg/ml IgM, Clone F58-10E4, Amsbio, 370255-S Goat anti-mouse IgM Alexa 488 
conjugated 
(Life technologies, A21042) 
1:1000 
CS (whole molecule) 16µg/ml IgM, Clone CS-56, Sigma, C8035 
IgG/FITC isotype control 20µg/ml IgG1/FITC conjugate, Dako, X0927 
H antigen 5µg/ml IgG1, conjugated to FITC, BRIC 198, IBGRL 9420 
A antigen 20µg/ml IgG1, conjugated to FITC, BRIC 145, IBGRL, 9434 
IgG/APC control 1:200 IgG1, ebioscience, 17471481 
CD71 1:200 IgG1, conjugated to APC, Clone OKT9, ebioscience, 17071942 
IBGRL = International Blood Group Reference Laboratory, Bristol, UK.
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After one hour the cells were washed once with 750µl of cold PBS then 
resuspended in 50µl of secondary antibody, made up in PBS/1% IgG free 
BSA (see Table 4-3) containing 1µg/ml of DAPI or Hoechst 0.5mg/ml (Life 
technologies, H3570). The secondary incubation lasted for 45 minutes on 
ice, after which the samples were again washed in 750µl of cold PBS. For 
antibodies which were already conjugated to a fluorophore, the secondary 
incubation was with 1µg/ml DAPI or Hoechst in PBS/1% IgG free BSA only, 
with no secondary antibody.  
 
After the final wash, the cells were fixed by resuspending the pellet in 500µl 
of 0.5% paraformaldehyde (made up in PBS with 16% Formaldehyde 
solution [w/v] Methanol free, Thermo Scientific, 28908) and incubating for 15 
minutes on ice. The tubes were gently centrifuged, the paraformaldehyde 
removed and the pellet resuspended in 500µl of FACS buffer (PBS/0.5% IgG 
free BSA/0.02% sodium azide) before being transferred to labelled FACS 
tubes. Samples were then analysed on a Becton-Dickinson LSR II flow 
cytometer (BD Biosciences). Depending on the receptor and time point, 
between three and five different cultures/donors were analysed (including 
cells derived from adult bone marrow and one umbilical cord). No major 
difference in results were seen at equivalent times points between donors, 
with the exception of blood group antigens, in keeping with the different blood 
groups of the donors. 
 
Once the data had been acquired on the flow cytometer, any remaining 
sample was centrifuged on to slides using the CytospinTM 4 Cytocentrifuge as 
described above, dried and covered with a coverslip mounted using 
Fluoromount. These slides were visualised using a Leica DM LB2 fluorescent 
microscope and photographs taken as described previously. 
 




4.4.4 Recombinant PfEMP1 domain binding to mature erythrocytes 
and cRBCs 
 
The binding of recombinant PfEMP1 domains (Ghumra et al., 2011, Ghumra 
et al., 2012) to mature peripheral erythrocytes and filtered, D18 cRBCs was 
assessed using flow cytometry and IFA. 
 
One million cells per PfEMP1 domain/ were used and day 18 cRBCs were 
filtered prior to the binding assay using the method described in section 
2.2.4. Cells were washed with PBS/1% IgG free BSA, resuspended in 22.5µl 
of the same and 2.5µl of recombinant PfEMP1 domain added giving the final 
concentrations listed in Table 4-4. 
 












480µg/ml Anti- 9197v5 
NTSDBL (25022) 











ITvar09 didomain 170µg/ml Anti-NTS DBL1 
(ITvar09) (5776) 
ITvar09 DBL2 350µg/ml Anti- DBL2 
(ITvar09)   (4772) 
ITvar60 NTS-
DBL1 
80µg/ml Anti-NTS DBL1 
(ITvar60)  (6217) 
TM284 NTS DBL 216µg/ml Anti NTS DBL-1 
TM284 (6219) 




125µg/ml Anti 9197v15 
(26888) 
None (No protein 
control) 
NA Anti-NTS DBL1 
(ITvar60)  (6217) 
 
 
The cells and proteins were incubated on ice for one hour then washed twice 
with cold PBS before being resuspended in 22.5µl of PBS/0.1% BSA and 
2.5µl of the corresponding primary antibody (Table 4-4). The cells were then 
incubated for 45 minutes, washed twice with PBS and incubated for a further 
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45 minutes with 50µl of the 1:1000 secondary antibody. The cells were again 
washed twice with cold PBS then fixed and prepared for flow cytometry as 
detailed in 4.4.3.2. Between 25,000 and 100,000 events per samples were 
counted and the remaining cells were used to prepare CytospinTM slides for 
IFA. 
 
4.4.5 Rosetting assays with cRBC 
 
Rosetting assays were carried out as described in 2.6.4. Four parasite lines 
were chosen, namely ITvar60, R29, 11019 and 9605, all cultured in blood 
group O. Rosetting to TM284 was also assessed for two donors at different 
time points. ITvar60 and R29 were chosen as they are well-characterised 
parasites lines with R29 being of particular interest due to its dependence on 
CR1 for rosetting, while ITvar60 relies less on CR1 (Rowe et al., 1997, Rowe 
et al., 2000). The other two lines, 11019 and 9605 probably provide a better 
representation of parasites causing severe malaria in Africa and were used 
for this reason.  
 
It is important to note that the ‘control’ blood (normal peripheral blood) was 
not matched to the cRBC donor and in some cases was a different blood 
group. Ideally, matched mature peripheral erythrocytes would have been 
purchased for each bone marrow donor, however this was not possible for 
practical reasons. All control blood was from blood group O Scottish blood 
donors and had been prepared and stored as detailed in section 2.1.3. 
 
Matured cRBCs (D18-25 of culture) from three separate adult bone marrow 
donors (table 2.2: donor numbers D001004150, B+; D001003739, O+ and 
D001004313, unknown) and one umbilical cord donor were tested for their 
ability to form rosettes. In addition, cRBC from donor D001004150 were also 
tested at day 7/8, 11, and 13/14 or 15, with each time point roughly 
corresponding to the different stages of culture (see Table 2-3). 
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4.4.6 Generation of Fabs and rosette disruption assays 
 
In order to further investigate the role of GYPA, GYPC and Band 3 in 
rosetting, antigen-binding fragments (Fab) of the relevant antibodies were 
generated and tested in rosette disruption assays. It was necessary to use 
Fab fragments rather than the whole antibody as pilot experiments showed 
that whole antibody caused massive agglutination of erythrocytes. Of the 
Band 3 antibodies available (see Table 5-3 for further details), BRIC 6 and 
BRIC 14 were chosen for the rosette disruption experiments. This is because 
BRIC 6 antibodies fail to react with erythrocytes with the South Asian 
Ovalocytosis mutation, which is known to protect against severe malaria and 
therefore seemed an interesting candidate to study further. The BRIC 14 
antibody is directed against the Wrightb antigen and pilot experiments by an 
undergraduate Honours student, Eden Taylor, whom I helped supervise, had 
shown it appeared to cause rosette disruption in ITvar60, while the other 
Band 3 antibodies had no effect.  
 
4.4.6.1 Generation of Fab, buffer exchange and concentration of Fabs 
 
The Fab fragments were generated using a PierceTM Fab Micro Preparation 
kit from Thermo Scientific (44685), which uses immobilized Papain to digest 
the whole IgG antibody into Fab and Fc, then purifies the Fabs by binding the 
undigested antibody and Fc to immobilized Protein A (Figure 4-4). The 
manufacturers guidelines were followed with the modification that Protein A 
binding buffer (Thermo scientific, 1861620) was used to wash the digested 
sample and equilibrate the Protein A immobilization columns. This was 
recommended by the manufacturer to improve the purification process for 




Figure 4-4 Generation of Fabs. The whole IgG antibody is first digested by Papain into Fab and Fc 
portions. The digested antibody is then passed through a protein A binding column which binds 
undigested antibody and the Fc portion, allowing the Fab to pass through. 
 
As the resulting Fab were contained in Protein A binding buffer, it was 
necessary to buffer exchange the sample into PBS before further use. This 
was done using ZebaTM spin desalting columns (Thermo scientific, 44685) 
which were first equilibrated with PBS by adding 300µl of PBS to the column, 
then centrifuging at 1500g for one minute, and repeating this process 3 
times. The sample containing Fab in Protein A binding buffer was then added 
to the top of the column and centrifuged for 2 minutes at 1500g. 
 
The resulting Fab solution in PBS was then concentrated using an Amicon® 
Ultra 0.5 centrifugal filter device. The device was first equilibrated with 150µl 
distilled water by centrifuging at 14,000g, then up to 500µl of sample was 
added and centrifuged for 8 minutes at 14,000g. The device was then turned 
upside down in a fresh centrifuge tube and centrifuged for 2 minutes at 
1200g to collect the concentrated Fabs. The concentration of Fab was 
measured using the NanoDrop 1000 spectrophotometer (Thermo Scientific).  
 
4.4.6.2 Confirmation of Fab generation by SDS PAGE 
 
Reduced Fab samples were run on SDS PAGE to confirm that fragments 
were of the expected size (around 25kDa for reduced samples). 
Approximately 0.4µg (2µl) of Fab was added to 2.5µl of NuPAGE® LDS 
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sample buffer (4x, Invitrogen, NP0008), 2.5µl DTT (0.1M, Invitrogen, 
Y00122) and 3µl dH20, and heated at 70oC for ten minutes to reduce the 
sample. A NuPAGE® Bis Tris Mini gel (4-12%, 1mm, 12-well, Novex, IM-
8042) was rinsed with dH2O then placed in an electrophoresis chamber 
(Novex Mini cell xCellsure lockTM, Invitrogen, EI0001) filled with MES running 
buffer (Novex, NP0002). Five l of Precision Plus ProteinTM All Blue 
Prestained Protein Standard (Biorad, 161-0373) was pipetted into the first 
well, followed by a reduced sample of the whole IgG antibody as a reference, 
then the Fab samples. Any empty wells were filled with 3-4µl of samples 
buffer and 500µl of NuPAGE® antioxidant (Invitrogen, NP0005) was added 
to the inner chamber. The gel was run at 200V for approximately 35 minutes 
after which it was removed from the plastic casing and rinsed three times by 
leaving in a container of fresh dH2O for 5 minutes each time on a table top 
rocker. The final wash was discarded and the gel covered with InstantBlue 
Coomassie stain (Expedeon, ISB1L) and left on the rocker for one hour 
before a final wash with dH2O. Images of the gel were taken using an iPhone 
5 camera.  
 
4.4.6.3 Rosette disruption with Fabs 
 
Rosette disruption assays were carried out as described in section 2.6.2. The 
test samples are listed below: 
 
1. GYPC BRIC 4 Fab (IBGRL, 9417) final concentration 100µg/ml  
2. GYPA BRIC 256 Fab (IBGRL 9415PA) final concentration 100µg/ml 
3. Band 3 BRIC 6 Fab (IBGRL 2618L) final concentration 100µg/ml 
4. Anti Wrightb BRIC 14 Fab (IBGRL, 9413PA) final concentration 
100µg/ml 
5. Positive control: Fucoidan (Molekula, 9072-19-9) final concentration 
100µg/ml OR 1mg/ml heparin (Sigma, H4784, diluted with PBS) for 
11019 and 9605. 
6. Treatment free tube, PBS only- as negative control 
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7. Isotype control: Fab of IgG mouse isotype control, (Abcam, 18443) 
final concentration 100µg/ml 
 
Due to limited volume of concentrated Fab, the final total volume of parasite 
culture and Fab was 10µl (approximately 3µl of Fab with 7µl of parasite 
culture). Three independent experiments were carried out for each parasite 
strain and every experiment was blinded. Rosette frequency was calculated 
from the mean of two separate slides on which 200 infected cells per slide 
were counted. Statistical analyses were carried out using GraphPad Prism 
software (Version 7.0, La Jolla California, USA, www. Graphpad.com). 
Comparisons were made using an Ordinary one-way ANOVA with Dunnett’s 
multiple comparisons test with p value of <0.05 considered to be significant. 
 
4.4.7 Lentiviral knockdown of cRBC 
 
Attempts were made to knockdown GYPA, GYPC and CR1 in cRBC using 
transduction via spinoculation with short hairpin RNA lentiviral particles, in a 
similar fashion to that described in (Lee et al., 2014, Niang et al., 2014). 
Ready-made lentiviral particles, all of which permit the use of Puromycin for 
selection, were purchased from Santa Cruz biotechnology as listed below: 
 
1. Control shRNA Lentiviral Particles-A (Santa Cruz Biotechnology, sc-
108080). A scrambled shRNA negative control, which should not 
affect receptor expression but confers Puromycin resistance.  
2. cop GFP Control Lentiviral Particles (Santa Cruz Biotechnology, sc-
108084). A control which should not affect receptor expression but 
introduces the green fluorescent protein gene, causing the cells to 
fluoresce, which was used to check the spinoculation method. 
3. Glycophorin C shRNA (h) Lentiviral Particles (Santa Cruz 
Biotechnology, sc-42884-V) 
4. CD35 (CR1) shRNA (h) Lentiviral Particles (Santa Cruz 
Biotechnology, sc-29994-V) 
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5. Glycophorin A shRNA (h) Lentiviral Particles (Santa Cruz 
Biotechnology, sc-42882-V) 
 
According to the datasheets provided by Santa Cruz Biotechnology, the 
shRNA lentiviral particles contain a pool of transduction-ready lentiviral 
particles and 3 constructs targeted to the gene of interest which contain 19-
25 nucleotides, though exact details of the target sequences are not 
provided. 
 
cRBC were cultured until day 6 or 7 then pelleted and resuspended in 
incomplete RPMI at a concentration of 1x106 cells/ml. In parallel, the lentiviral 
particles were thawed and a 96-well plate blocked with a 100µl per well of 
PBS/1%BSA for 20 minutes. The block was removed and 100µl of cell 
suspension (1x105 cells) was pipetted into the well. To this was added: 10µl 
of lentiviral particles, 90µl of incomplete media, and 0.8µl of Polybrene 
(Santa Cruz Biotechnology, sc-134220, diluted to 1mg/ml with PBS). This 
resulted in a multiplicity of infection (MOI, the number of transducing lentiviral 
particles per cell) of 0.5. My earlier experiments comparing an MOI of 0.5, 1 
and 5 (appendix 1) had shown no benefit to a higher MOI and discussions 
with the Duraisingh laboratory who have experience of this method 
suggested than an MOI of 0.5 was appropriate.  
 
The cell/lentiviral particle mix was then centrifuged for 2 hours at 1000g at 
room temperature; this ‘spinoculation’ method has been shown to enhance 
the in vitro infectivity of various viruses (O'Doherty et al., 2000, Guo et al., 
2011, Yan et al., 2015). The plate was then allowed to rest at 37oC for one 
hour before being washed with incomplete then complete media, and placed 
back into culture at a cell density of 2x105 cells/ml. After 24 hours, 2µg/ml of 
Puromycin (Calbiochem 540411) was added to the culture medium to select 
for transduced cells. Puromycin was added at every media change up to and 
including day 11. 
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At day 14-17 of culture, cells were checked for receptor or GFP expression 
using flow cytometry as described in section 4.4.3, except the secondary 
antibody used was an anti-mouse IgG tagged with Alexa 594 (1:1000, 
Invitrogen, A11032), to avoid confusion with the GFP expression in controls, 
and cells were analysed on the BD LSRFortessaTM flow cytometer (BD 
Biosciences). 
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4.5 Results I: Induced pluripotent stem cells 
 
Induced pluripotent stem cells derived from skin fibroblasts and cultured for 
17-24 days in culture medium and cytokines designed to promote maturation 
towards the erythroid pathway were stained with Giemsa. Staining revealed a 
morphologically diverse cell population as shown in Figure 4-5. All cells had 




Figure 4-5 iPSC after 17 days of culture stained with Giemsa 
 
When used in rosetting assays the iPSC derived cells did exhibit a form of 
cytoadherence, which is some cases resembled rosetting (Figure 4-6A). 
However, some of the larger cells demonstrated a very different phenotype, 
with the iPSC derived cells becoming coated with multiple infected 
erythrocytes (Figure 4-6 B and C). While this does not look like true rosetting, 
the images are very similar to that of an activated white blood cell covered 
with infected erythrocytes shown in (Wahlgren et al., 1995). Of note, the 
identify of these larger cells was not investigated further and cells were not 





Figure 4-6 iPSC with purified ITvar60 parasites. A shows a rosette-like formation consisting of an iPSC 
derived cell (black arrow-head), three infected erythrocytes (white arrows) and an uninfected 
erythrocyte (white arrowhead). B shows a cluster of large iPSC derived cells coated with infected 
erythrocytes. C a comparison of a similar, large iPSC derived cell (LEFT) to an image of an activated B 
cell coated with infected erythrocytes published in (Wahlgren et al., 1995) 
 
Taken together, these small, pilot experiments suggest that the population of 
cells generated from this form of iPSC culture are very heterologous and may 
not be suitable for the type of experiments investigating erythrocyte receptors 
which I intended to conduct. 
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4.6 Results II: cRBC derived from adult bone marrow HSC 
 
4.6.1 Expansion and maturation of HSC into enucleated erythrocytes 
 
CD34+ haematopoietic stem cells derived from adult bone marrow were 
successfully cultured into immature reticulocyte-like cells with enucleation 
rates up to 92%. Figure 4-7A shows the typical growth curves for the cells in 
terms of the fold change in cell numbers between each time point. Figure 
4-7B shows the fold change from day zero and absolute cell numbers; note 
that the data showed in this figure are projected numbers based on the fold 
increased measured in Figure 4-7A as cells were constantly being used for 
experiments. Growth was maximal between days 4 and 8, and cell number 
increased until day 15-18, after which there was a significant drop off due to 
cell death.  
 
 
Figure 4-7 cRBC growth. A Fold increase in cRBC cell numbers compared to the previous time point 
(usually about 48 hours). B Projected total cRBC cell numbers (x104) over time if no cells are used for 
experiments (solid blue line) and fold increase from day 0 of culture (red dashed line). Both graphs 
show data from donor 1001448 
 
The morphology of the cells matured over the 18 or more days of culture 
from large, nucleated cells, to haemoglobin producing, mostly enucleated 
cells (Figure 4-8). The enucleation rate at maturity (day 18) ranged from 76-
92% of unfiltered cells. Filtering produced a homogenous population of 
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enucleated cells (Figure 4-8), however despite the high number of 
enucleated cells prior to filtering, around 80-90% of the cells were lost during 
the filtration process, presumably due to lysis. 
 
 
Figure 4-8 Morphology of maturing cRBC over an 18-day culture period. Cells were stained with May 
Grunwald/Giemsa as described in the methods. The filtered cells from Day 18 were passed through a 
filter disc to remove nucleated cells as described in section 2.2.4. Note that unfiltered cultured from 
D14 and D18 contain the extruded pyrenocytes and debris from dead/dying cells. 
 
The cell pellet was noted to turn red, indicating the production of 




Figure 4-9 Pelleted cRBC at day 6 and 11 of culture. the red colour of the pellet on D11 indicating the 
production of haemoglobin 
 
The evolving size and nuclear staining profile can be seen in the flow 
cytometry plots of Figure 4-10, which also shows the gating strategy used for 




Figure 4-10 Flow cytometry plots evolve with increasing cRBC maturity. The FSC/SSC (UPPER) and nuclear staining (LOWER, stained with DAPI) patterns evolved over 
time from large, heterogenous, nucleated cells, to smaller, homo, mainly enucleated cells.  
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4.6.2 Cell surface receptor expression over time 
 
As the cRBCs matured, the cell surface receptor expression changed as 
expected (Figure 4-11). CD34+ expression was lost very quickly and could 
only be detected on day 4 (Figure 4-12), while GYPA and CD71 expression 
increased greatly. CD71 decreased between D18 and D29, but was still 
expressed to a fairly large degree, indicating that cRBC can, at best, 
represent relatively immature reticulocytes. CR1 expression remained 
noticeably low across all the donors tested. CR1 expression can vary 
significantly between individuals (Moulds et al., 1992), therefore these results 
could simply due to naturally low levels of CR1 expression from the donors 
tested. However, lower CR1 level have been previously documented on 
cRBC compared to peripheral erythrocyte samples (Dankwa et al., 2017). 
The progressive loss of heparan sulfate with cRBC maturity has been 
previously described in Figure 3-16.
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BLUE: Receptor  






Figure 4-12 CD34 expression on cRBC on day 4 of culture. A flow cytometry plots of D4 cRBC, RED- 
IgG isotype control, BLUE- CD34+. B IFA of CD34+ CRBC on D4, Green Alexa 488 tagged secondary 
antibody binding to anti-CD34 primary, and blue DAPI stained nuclei. Composite image generated 
using Image J without further image manipulation.  
 
 
4.6.3 Recombinant PfEMP1 domain binding to mature erythrocytes 
and cRBC 
 
Recombinant PfEMP1 domains from rosetting variants bound equally well to 
mature donor erythrocytes and filtered cRBC at D18 of culture (Figure 4-13 A 
and B respectively). Of note, the ITvar09 didomain (derived from parasite 
strain R29) and ITvar60NTS DBL (from ITvar60) showed particularly bright 
fluorescence on the cRBCs, a finding of particular interest when taken in 






Figure 4-11 cRBC receptor profile over time. The larger graph on the right shows the axes. RED= isotype control 
primary antibody and BLUE = receptor of interest. The bottom panel shows the receptor profile of mature peripheral 





Figure 4-13 Binding of rPfEMP1 to mature erythrocytes (A) and filtered D18 cRBC (B). Flow cytometry 
plots- RED = 9197var5 NTS-DBL (negative control), BLUE = rPfEMP1 binding, all normalized to 
mode. IFA- Green Alexa 488 showing binding of the rPfEMP1 to uninfected mature erythrocytes or 
D18 cRBC, visualised using the x100 objective. 
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4.6.4 Variation in ability of cRBC to rosette with P. falciparum infected 
erythrocytes 
 
The rosetting ability of cRBC after 18-25 days of culture from 4 independent 
donors (including one cord donor) were tested with parasite lines ITvar60, 
R29, 11019 and 9605, two donors were also tested used TM284. For 
reference, the cRBC from experiment 3 in Figure 4-14 are the same as those 
tested for rPfEMP1 binding in Figure 4-13B (Donor no. D001004313). 
Interestingly, given the excellent binding of the ITvar60 and R29 rPfEMP1 
domains, matured cRBCs showed very poor rosetting with purified parasites 
of ITvar60 and R29 (Figure 4-14). Rosetting frequency with 11019, 9605 and 
the single donor tested at day 18 with TM284 was close to that seen with 
unmatched peripheral donor erythrocytes (Figure 4-14, no significant 
differences based on an unpaired t-test, and Figure 4-16). Of note, the 
‘control’ peripheral donor erythrocytes were not matched to the bone marrow 
donor from whom the cRBC were derived. All the peripheral erythrocytes 
were of blood group O, while the cRBCs varied and were not known in all 




Figure 4-14 Rosetting of unfiltered D18-25 cRBC with various parasite lines. cRBC derived from either adult bone marrow (BM) or a single umbilical cord donor were 
cultured and tested between day 18 and 25 of culture. The origin and blood group of the cRBC (if known) is indicated above the data points. Of note the mature 
erythrocytes were unmatched and all of blood group O+. Each data point represents the mean of two technical replicates counted from two different slides. BM= bone 
marrow, ? = blood group unknown.
 187 
For one cRBC donor (D001004150, blood group B+), rosetting was tested at 
multiple stages of maturity. As shown in Figure 4-15, rosetting was poor at all 
stages of maturation for ITvar60 and R29. 11019 rosetted well even with 
early stage (basophilic and polychromatic erythroblast)  cRBC, while 9605 
did not rosette with earlier stages, but this improved as the cells matured. 
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Figure 4-15 cRBC rosetting at different stages of maturity. cRBC from a single adult bone marrow donor (blood group B+) were tested for rosetting a various different 
time points, broadly representing the different culture stages. Each data point represents the mean of two technical replicates counted from two different slides. Again, 
the mature erythrocytes were not matched
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TM284 was only tested at two time points, day 11 and day 18 using two 
different donors (Figure 4-16). Further experiments were not carried out with 
TM284 due to time constraints.  
 
 
Figure 4-16 Rosetting of cRBC at day 11 and 18 (two separate donors) with TM284. Each data point 
represents the mean of two technical replicates counted from two different slides.    
 
 
 A further observation made during these experiments was that even for 
parasites that had a high rosetting frequency with cRBC, there was a 
qualitative difference in the rosettes themselves. Rosettes with cRBC 
appeared smaller and looser that those with mature erythrocytes, even 
though the proportion of rosetting infected cells were equal (Figure 4-17). It is 
important to note that the cRBC shown in Figure 4-17 are of blood group B, 
while the mature peripheral erythrocytes are blood group O. However, in 
general, for parasites which have a preferring blood group for rosetting, 
rosettes in blood group O are smaller (Barragan et al., 2000b), therefore the 
discrepancy in size seen between the mature erythrocytes and the cRBC 




Figure 4-17 Smaller rosettes with cRBC. Parasites from line 11019 were purified and mixed with either 
A mature peripheral donor erythrocytes (blood group O+) or B cRBC (blood group B+). Infected 
erythrocytes were stained with ethidium bromide and can be seen as bright yellow/orange. Cells were 
imaged under combined fluorescence and white light using a x40 objective on a Leica DM LB2 
fluorescent microscope and photographed using a Yenway CMOS 5mpx camera. The brightness of the 
images has been increased equally for both images using Image J software. 
 
4.6.5 Analysis of Dankwa et al. comparing cRBC to mature 
erythrocytes 
 
The variability in rosetting phenotype by strain displayed by the cRBC was 
unexpected given the excellent rPfEMP1 binding and the similar receptor 
profile between cRBC and mature erythrocytes. In fact, one might even 
expect better rosetting given that cRBC express higher levels of some 
previously proposed rosetting receptors, namely heparan sulfate, in the early 
stages of cRBC culture, and CD36.  
 
I considered two possible explanations for this; firstly, that the cRBCs are 
lacking a key receptor(s) that is essential for rosetting for some strains, and 
has an accessory role in others, or that the cRBC express a receptor that is 
in some way blocking or interfering with rosetting. To investigate this further, I 
required more data on the wider receptor profile of cRBC compared to 
mature peripheral erythrocytes. These data were obtained from a paper 
published by Dankwa et al., in which the expression of 78 cell surface 
receptors was quantified on both cRBC and mature peripheral erythrocytes 
using Tandem Mass Tag mass spectroscopy  (Dankwa et al., 2017). In this 
paper, the receptors were clustered into three groups; those which were 
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upregulated on cRBC compared to mature erythrocytes, those which were 
similar and those which were downregulated on cRBC (Figure 4-18).  
 
 
Figure 4-18 Comparison of receptor expression on cRBC and mature erythrocytes. Adapted from 
(Dankwa et al., 2017). Receptor expression from two, presumably separate, day 17-20 cRBC cultures 
(referred to in the paper as pLKO cRBC) and two mature erythrocyte donors (pRBC) was quantified 
using mass spectroscopy. The blue arrows indicate whether receptor expression in cRBC was greater 
(cluster 1), the same (cluster 2) or less (cluster 3) than peripheral RBC. Receptors of interest have 
been underlined in red and listed on the far right.  
 
The lack of a certain receptor seemed more plausible than a blocking one, 
therefore I focused my attention on the receptors which were downregulated 
in cRBC compared to mature erythrocytes. Of interest in this group were the 
previously described rosetting receptors CR1, GYPA and GYPC. The lack of 
CR1 in particular, could explain the poor rosetting for R29 which is highly 
dependent on CR1 (Rowe et al., 1997), however ITvar60 which is much less 
reliant this molecule (Rowe et al., 1997, Rowe et al., 2000). Of the other 
under-expressed molecules, SLC4A1, otherwise known as Band 3, caught 
my attention as a receptor potentially worthy of further investigation. 
Autosomal dominant mutations of the Band 3 gene lead to the condition 
South Asian Ovalocytosis, which is known to protect against severe P. vivax 
malaria (Rosanas-Urgell et al., 2012) and cerebral malaria in P. falciparum 
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(Genton et al., 1995, Allen et al., 1999). I therefore decided to explore the 
importance of Band 3, GYPA and GYPC for rosetting across a range of 
parasites strains using rosette disruption with antibody fragments.  
 
4.6.6 Antibodies to Wrightb disrupt rosettes across all tested strains 
 
4.6.6.1 SDS PAGE showing successful generation of Fab 
 
Fab generation was successful and bands of the expected molecular weight 
of around 25kDa were detected on SDS PAGE as shown in Figure 4-19. 
 
 
Figure 4-19 Reduced SDS PAGE gel showing Fab at expected molecular weight of around 25kDa. A 
whole IgG isotype control antibody included in lane 2 shows the reduced heavy chain at around 50kDa 
and light chain at 25kDa. 
 
4.6.6.2 Wrightb Fabs disrupt rosettes across all parasite strains 
 
The antigen binding fragments of antibodies to GYPA, GYPC, Band 3 (BRIC 
6) and the Wrightb antigen (an antigen carried on Band 3 which is closely 
associated with GYPA, further details below and in Chapter 5) were tested in 
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rosette disruption assays for six different parasites lines, all cultured in blood 
group O. The ability of the Fab to disrupt rosettes varied across the different 
strains, except for the Wrightb Fab which significantly reduced the rosetting 
frequency across all lines tested to levels similar to that of the positive control 
(Figure 4-20). Neither GYPA, GYPC nor Band 3 (BRIC 6) Fabs showed any 
effect on rosetting for most of the lines tested, though the range of results 
was wide for 9605 suggesting that additional repeats may have revealed 
some effect. For R29 and ITvar60, both GYPA and Band 3 (BRIC6) Fab did 




Figure 4-20 Rosette disruption with GYPA, GYPC, Band 3 and Wrightb Fabs across six parasites lines. 
Each data point represents the results of one independent, blinded experiment (the mean of two 
technical replicates as described in the text). p-value <0.05 was considered significant. Error bars show 
the mean and standard deviation of the three results. For strain 11019, heparin 1mg/ml was used as 
the positive control as rosetting in 11019 is not sensitive to Fucoidan. 
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Images from the rosettes disruption assays for ITvar60 are shown in Figure 
4-21 and demonstrate the marked rosette disruption of the Wrightb Fabs, 
comparable to the Fucoidan positive control, and the more subtle effects of 




Figure 4-21 Rosette disruption of ITvar60 by Fab fragments. Infected erythrocytes are stained bright 
orange with ethidium bromide. Cells were imaged under combined florescence and white light using a 
x40 objective on a Leica DM LB2 florescent microscope and photographed using a Yenway CMOS 
5mpx camera. Wrb= Wrightb 
 
4.6.7 Lentiviral knockdown cRBC 
 
In order to investigate the role of specific rosetting receptors using an 
alternative approach, I attempted to generate knockdown cRBC in which the 
expression of receptors of interest was reduced. This proved technically 
challenging for a number of reasons, mainly due to the fact that cRBC are 
not immortalised cells. Each attempt required a fresh CD34+ culture which, 
once begun, had a limited lifespan of around 3 weeks. This gave minimal 
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time for growth and selection of the knockdown cells. In addition, the 
expense of the CD34+ haematopoietic stem cells was a limiting factor in both 
the number of cells I could start with at the beginning of each spinoculation, 
and the number of attempts. The spinoculation process, occurring during the 
peak expansion period of the cRBC culture, also appeared to have a 
detrimental effect on the cell growth and Puromycin selection decreased cell 
numbers further (Figure 4-22). Control cells (both GFP and scrambled 
shRNA controls) regained some growth after selection (Figure 4-22), 
however CR1, GYPA and GYPC knockdown cells did not, and the resulting 
cell numbers by day 14-18 were too low for meaningful rosetting experiments 
to take place. These limitations could potentially be overcome by starting with 
higher cell numbers. 
 
 
Figure 4-22 cRBC growth and lentiviral transduction on day 7. cRBC from the same culture were 
transduced with lentiviral particles using the spinoculation method on day 7 (red arrow). 2x105 cells 
were transduced with the GFP control and GYPC shRNA lentiviral particles, while 4x105 cells were 
transduced with the others. Cells were cultured as per the usual method and Puromycin was added on 
day 8, 10 and 11 (black arrows). On day 14, all remaining cells were used for flow cytometry 
experiments. 
 
Nevertheless, the spinoculation lentiviral transduction did appear to work to a 
certain extent. Green fluorescent protein (GFP) was incorporated into the 
control cells demonstrating successful delivery of the shRNA into the cells 
(Figure 4-23 A). However, knockdown results were disappointing with 
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minimal reduction in receptor expression seen for GYPC, GYPA and CR1 
shRNA transduced cells (Figure 4-23).  
 
 
Figure 4-23 Flow cytometry plots showing GFP or receptor expression after shRNA lentiviral 
transduction of cRBC. cRBC were transduced on day 6/7 and results shown are from day 14. A shows 
GFP expression (left) or GYPC expression (right) on GFP control (RED) and GYPC shRNA transduced 
cells (BLUE). B shows expression of GYPA (left) or CR1 (right) on control cells (RED) and those 
transduced with the relevant shRNA (BLUE). Three attempts at transduction were made with similar 
results each time, these plots are from the third experiment 
 
The estimated percentage efficiency of each knockdown was calculated 
using the formula developed by Egan et al. (Egan et al., 2015) which is 
based on median fluorescence intensity (MFI) after correction for background 
using the isotype control; 100-[MFIKDcRBC /MFIcontrol cRBC] x100. Results are 
shown in Table 4-5. Of note, while the percentage knockdown for CR1 
appears impressive, this is merely due to the very low expression levels in 
both knockdown and control (in keeping with the low CR1 expression seen 
on cRBC shown above), and the flow plots give a better representation of the 
level of knockdown. Three attempts at generating knockdown cells were 
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made, including the pilot experiments with different MOI (Appendix 1), with 
cRBC from different donors and the results were similar throughout. 
 
Table 4-5 Numbers used to calculate the percentage knockdown, according to the formula described in 
(Egan et al., 2015) 
MFI= median fluorescence intensity of PE-Texas Red (Alexa 594) taken from FlowJo, after 
subtracting the MFI of the isotype control labelled cell (267). Gates are as shown in 
Appendix 1.  
 
  
Receptor MFIKD cRBC  
 










GYPC 20232 19965 26828 26561 24.8% 
GYPA 58179 57912 91636 91369 36.6% 





4.7.1 Comparison of cRBC with mature peripheral erythrocytes 
 
The aim of this section of my thesis was to explore the potential of generating 
genetically modified erythrocytes and the use of these cells in rosetting 
assays to help disentangle the complex mechanisms of rosetting. While iPSC 
initially seemed to have many of the features desirable for this type of 
approach, in reality the heterogenous and immature nature of the cultured 
iPSC suggested more work needs to be done to create an end product which 
is a good approximation of mature peripheral erythrocytes. The cRBCs, 
however, matured and enucleated to produce cells which, morphologically 
and on flow cytometry, resembled reticulocytes and bound just as well, if not 
better, to rosetting rPfEMP1 proteins. But once again, the perils of using 
recombinant, laboratory generated proteins only as a surrogate for infected 
erythrocytes was revealed, when the rosetting phenotype of cRBC, was 
found to be markedly reduced for parasite strains R29 and ITvar60. As 
discussed in Chapter 3, it is important to bear in mind that the binding of 
individual rPfEMP1 domains may not accurately represent the adhesion of 
infected erythrocytes in vivo, possibly due to the structure of the full-length 
PfEMP1 leading to masking of the binding epitopes (Resende et al., 2009). 
 
4.7.2 A new rosetting receptor? 
 
Initially it was somewhat disappointing to discover that the cells which 
seemed to be such a good proxy for mature erythrocytes did not rosette 
normally. However, after some consideration, I realised this represented an 
excellent opportunity to search for potential new rosetting receptors. My 
analysis using the data published by Dankwa et al. is certainly not a 
systematic screen and a more structured bioinformatic approach may well 
throw up more potential candidates. Nevertheless, Band 3 seemed like a 
good start. Band 3 is known by a number of different names; CD233, AE1, 
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SLC4A1 (solute carrier 4 family of bicarbonate transporters) (Kalli and 
Reithmeier, 2018), and consists of 911 amino acids arranged across 14 
transmembrane regions as shown in Figure 4-24 and Figure 4-25 (Arakawa 
et al., 2015, Kalli and Reithmeier, 2018). Arakawa et al. (Arakawa et al., 
2015) have described the crystal structure of Band 3, and Figure 4-25 taken 
from their paper illustrates the complex topology of Band 3 in which 
transmembrane segments are separated into ‘core’ or ‘gate’ domains, and 
sequential transmembrane segments may not be directly adjacent to each 
other. Band 3 is found exclusively on erythrocytes and within the renal 
tubules. In erythrocytes  it functions as a chloride/bicarbonate exchanger 
enhancing the ability of blood to carry carbon dioxide in the form of 
bicarbonate (Kalli and Reithmeier, 2018). Each erythrocyte carries around 
one million Band 3 molecules which are arranged as dimers or tetramers in 
complex with Ankyrin, protein 4.2 and the Rhesus complex (Kalli and 
Reithmeier, 2018). A unique interaction with GYPA forms the Wrightb antigen 
which is located on the extracellular loop between two of the transmembrane 
regions (Figure 4-24). Of interest, around 50% of the total ABO blood group 





Figure 4-24 the structure of Band 3 on the erythrocyte membrane. The data used to produce this figure 
are from (Arakawa et al., 2015, Kalli and Reithmeier, 2018). The gate domain is the functional anion 
exchange part of the molecule. Red and blue coloured blocks represent the transmembrane segments 
of the molecule with are linked by the grey lines. SAO = south Asian ovalocytosis.  
 
 
Figure 4-25 Overall structure of Band 3, viewed in the plane of the membrane. Taken directly from 
(Arakawa et al., 2015) 
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Polymorphisms in Band 3 form the antigens of the Diego blood group and a 
specific autosomal dominant mutation, causing the deletion of amino acids 
400-408, leads to the condition South Asian Ovalocytosis (Cooling, 2015, 
Schofield et al., 1992). This condition, which is nearly always heterozygous, 
results in stiffer, oval shaped erythrocytes and has been shown to protect 
against both P. vivax and cerebral malaria in P. falciparum, though the exact 
mechanism of protection is unclear  (Genton et al., 1995, Allen et al., 1999, 
Cooling, 2015). 
Interestingly, however, my experiments with BRIC 6 Fab, (which do not react 
with SAO erythrocytes), failed to disrupt rosettes in most strains, while Fab of 
antibodies against the Wrightb antigen (BRIC 14) had a profound effect. 
These data suggest to me that SAO may not protect through the mechanism 
of reduced rosetting, and most significantly, it is possible that Wrightb is an 
important host rosetting receptor which will be discussed in more detail in 
Chapter 5. This hypothesis fits with some of the presumed features of the 
unknown rosetting receptors as discussed in Chapter 1, for example, Wrightb 
is resistant to Ficin/papain, trypsin, chymotrypsin, pronase and sialidase 
(Figueroa, 2013). However, once again, the antibody “block” method used 
here it unable to determine whether the rosette disruption is the result of the 
Fab blocking host Wrightb antigen, or an interaction with the infected cell. 
Hence the need to produce knockdown/out cells. 
 
My attempts to do this using cRBC and lentiviral transduction of shRNA leave 
much to be desired. My knockdown efficiency was poor and the cell numbers 
remaining at day 18 were so low as to be impractical for use. Lee et al. 
(2014) and Niang et al. (2014) report knockdown efficiencies of 81.5% and 
89-97% (for GYPC) respectively, however additional information in the 
supplemental data of Lee et al. suggests that this figures may have been the 
best results of multiple attempts (supplemental figure 3 from (Lee et al., 
2014)). Details between my methods and those described in these papers do 
vary and, perhaps importantly, the shRNA lentiviral particles were different 
 203 
(for example Lee et al. purchased Lentivector MISSION shRNA Target Set 
NM_002101 from Sigma Aldrich). Therefore, there is potentially much room 
for further optimization of my techniques. However, the challenges of using 
primary cells for this type of assays remain; without an immortalized cell line, 
the genetic manipulation must be repeated for each culture and carrying out 
rosetting assays within a strict timescale is a technical challenge when using 
multiple parasites lines. The BEL-A cells, “an immortalized adult human 
erythroid line” (Trakarnsanga et al., 2017), could represent a solution to this 
problem, however, as yet, we have been unable to obtain access to these 
cells. This led us to contact the Professor Duraisingh at the Harvard 
University T.H. Chan School of Public Health, whose laboratory has 
extensive experience of lentiviral shRNA transduction (Bei et al., 2010, Egan 
et al., 2015). While our original plan had been for me to visit their laboratory 
to learn how to improve my cRBC knockdowns, it transpired that Professor 
Duraisingh and his team had developed their own version of the BEL-A cells, 
the “EJ” cells, and my work with this fantastic new resource forms the next 
chapter of my thesis.  
 
4.7.3 Strengths and limitations 
 
Aside from my limited success in generating usable cRBC knockdowns, 
there are other important caveats to the data presented, which have already 
been described in the methods. The comparison of rosetting ability between 
the mature peripheral erythrocytes and the cRBC (Figure 4-14, Figure 4-15 
and Figure 4-16) should have been made with matched peripheral 
erythrocytes to the bone marrow donor, however this is challenging and (if 
possible) very expensive when using commercial donors. In particular, the 
different blood groups could have an impact on rosetting, as some parasites, 
for example ITvar60, appears to have preference for rosetting in certain 
blood groups (Barragan et al., 2000b). However, for this reason, the mature 
peripheral cells of blood group O would be arguably be at a disadvantage as 
no parasites appear to prefer blood group O (Rowe et al., 1995, Rowe et al., 
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2007, Rout et al., 2012). The very similar findings across four independent 
Caucasian donors suggests it is unlikely that specific polymorphisms present 
in the bone marrow, but not peripheral donors can explain the differences in 
rosetting ability for ITvar60 and R29, however this is not a possibility I can 
completely rule out.   
 
As mentioned above, my analysis of the data provided by Dankwa et al. may 
be overly simplistic. A fuller analysis using data from (Wilson et al., 2016) is 
showed in Table 4-6. This table combines the results from Rowe et al. (1997) 
testing of rare red cell variants, and the ratio of blood group antigen protein 
levels in mature erythrocytes versus cRBC cultured from both adult and cord 
CD34+ cells given in Wilson et al. Of the blood group antigens 
downregulated in the cultured cells (both cord and adult), the Kell, Scianna, 
MNS, JMH, Colton, Dombrock and Diego stand out as the most different 
(highlighted in bold in Table 4-6). Of these, Rowe et al. tested null 
phenotypes of Kell, MNS, JMH and Colton and found no evidence of reduced 
rosetting. The Scianna and Diego polymorphisms are not completely null 
cells and Dombrock null cells were not testedtherefore in addition to my 
investigation into Band 3/Diego, perhaps the Scianna and Dombrock blood 
groups are worthy of further study.
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Table 4-6 Comparison of data from Rowe et al. 1997 and Wilson et al. 2016, who compared blood group antigen protein levels in peripheral and cultured erythrocytes. 
Wilson et al. performed mass spectroscopy on pooled samples of matched peripheral erythrocytes and reticulocytes cultured from CD34+ cells derived from either adult 
peripheral blood or umbilical cords. In bold are the figures for which the ratio of expression in peripheral vs cRBC was notably reduced in both cord and adult cRBC 
      





(Wilson et al., 2016) 
Cord RBC/cRBC 
(Wilson et al., 2016) 
Knops  CR1 null Yes, reduced 1.885 1.083 
Kell  Kell Ko, null  No 3.245 2.189 
ABO A, B, H antigen Bombay, i.e. null No   




XK Xk glycoprotein and Kell McLeod, lacks XK 
gene 
No 2.411 2.520 
Landsteiner-Wiener ICAM4 a-b- No 2.414 4.418 
Kidd  JK antigen Jk-, No SCL14A1- 2.675 
Urea transporter 1- 2.844 
SCL14A1- 1.397 
Urea transporter 1- 2.518 
Duffy Duffy a-b-,  No ND ND 
Gerbich GYPC and GYPD -1,-2,-3,  No 2.685 2.892 
Lutheran Lutheran, basal cell 
adhesion molecule  
a-b- No 2.373 1.155 
Gregory Gregory a- No  ND ND 
JMH Semaphorin 7A null No 5.814 3.986 
MNS GYPA and GYPB MkMk No 12.251 11.878 
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Scianna ERMAP -1,-2 No 3.127 2.423 
P P antigens Tja-, now referred 
to as p 
No ND ND 
Colton Aquaporin 1 a-b- No 5.165 3.412 
Indian I  Adult i No 1.946 1.188 
Chido  Complement C4 null No 6.252 1.575 
Lewis Lewis a-b- No   
Xg  Xg(a) and CD99 null No 2.014 0.741 
Diego Band 3 b- No 3.826 3.604 
Lan  Lan, carried on ABCB6 null No 0.816 1.166 
Vel  Vel/small integral 
membrane protein 1 
null No ND ND 
Yt Acetylcholinesterase ND ND 2.742 1.406 
Junior ABCG2 ND ND 2.204 2.023 
Ok Basigin ND ND 0.954 1.260 
CD59 MAC inhibitory protein ND ND 2.014 0.741 
Cromer CD55 glycoprotein ND ND 2.113 2.026 
Dombrock GPI fixed glycoprotein ND ND 3.086 3.262 
RHAg Rh- associated 
glycoprotein 
ND ND 1.431 5.235 
ABC= human ATP-binding cassette, ERMAP= Erythrocyte membrane associated protein
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The data generated by my Fab experiments is exciting, but not completely 
conclusive. While it appears that the Wrightb antigen is key, it is possible that 
the whole Band 3 molecule is also involved. The BRIC 6 Band 3 antibody 
was chosen in relation to SAO, but it is possible that its limited binding, 
particularly in Fab form, does not block access of the parasitized cells to the 
vital part of the Band 3 structure, thus rosetting is not affected. Using a panel 
of Band 3 antibodies directed against different epitopes could help untangle 
this further.  
 
4.7.4 The way forward 
 
More work is required to optimize the shRNA protocols to produce usable 
knockdown cRBC, however, since beginning this project, new cells lines 
have emerged, namely the BEL-A and (as yet unpublished) EJ immortalized 
erythroid precursors which could offer significant advantages over the cRBC 
system. These cells are immortalized and amenable to genetic manipulation 
with CRISPR/Cas9 technology, thus presenting a much more useable tool. 
cRBC do retain some advantages over these immortalized lines, in particular 
excellent enucleation, and my work using cRBC has led to a potentially very 
exciting discovery. However, I will now focus my final chapter on the use of 
EJ cells to create knockdown erythrocytes in order to further investigate the 
essential host rosetting receptors across different P. falciparum strains.  
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5 CHAPTER V: USING AN IMMORTALISED 
ERYTHROID LINE TO GENERATE CRISPR/CAS9 
KNOCKOUT ERYTHROID PRECURSORS TO 





Data from rosette disruption experiments using antibody fragments suggest 
that the Wrightb antigen may represent an important novel, strain-
transcending, host rosetting receptor. However, confirmation of these results 
is required using a different technique; the use of knockout erythrocytes. Until 
recently, the ability to generate useful erythrocyte knockouts has been 
hampered by the lack of an immortalised erythroid line. However, over the 
past few years, a number of different immortalised lines have been published 
including the HiDEP, HUDEP and BEL-A cells. Another, as yet unpublished, 
line has been developed by the Duraisingh laboratory at Harvard University; 
the EJ cells. These cells differentiate into orthochromatic erythroblasts  and 
are amenable to genetic manipulation using CRISPR/Cas 9 technology.  
 
In this chapter, I characterise these EJ cells in terms of morphology, receptor 
expression and rosetting ability and discover that, unlike the cRBC, EJ cells 
can form rosettes with all tested parasite lines. CR1, GYPC, Band 3 and 
GYPA knockout EJ cells were characterised and the rosetting of CR1, Band 
3 and GYPA knockouts compared to that of wildtype EJ cells. Cells which 
lack the Wrightb antigen (Band 3 and GYPA knockouts) showed significantly 
reduced rosetting across all parasite lines, adding weight to the hypothesis 
that the Wrightb antigen is an important host rosetting receptor and potential 





The exciting data from the Fab experiments shown in Chapter 4 suggest that 
the Wrightb antigen may represent an important, novel, strain-transcending, 
host rosetting receptor. However, this hypothesis would be greatly 
strengthened if the results could be reproduced using alternative methods, 
for example using knockdown or knockout erythrocytes. My attempts to 
generate such erythrocytes using shRNA interference with cRBC revealed 
the limitations of these cells, and I was keen to identify a new source of 
immortalized erythroid cells which would be more amenable to newer 
genome editing techniques such as CRISPR/Cas9. 
 
5.2.1 Immortalized erythrocyte lines: HiDEP, HUDEP and BEL-A cells 
 
In recent years, a number of different immortalized erythroid lines have been 
published (Table 5-1) including the iPSC/HiDEP and HUDEP lines (Kurita et 
al., 2013) and the BEL-A cells (Trakarnsanga et al., 2017). The key limitation 
with all of these lines appears to be poor enucleation, a vital stage of the 
process when generating erythrocytes suitable for blood transfusion (Anstee 
et al., 2012, Kurita et al., 2013, Trakarnsanga et al., 2017). However, if the 
cell surface receptor complement is similar to that of enucleated cells, the 
presence of a nucleus does not necessarily preclude the use of such cells in 
rosetting assays. An important potential caveat is that the shape and reduced 
deformability of these nucleated cells (Guzniczak et al., 2017) may impeded 
rosetting, however we felt this was worth investigating further. 
 
In 2013, Kurita and colleagues published data on two immortalized erythroid 
lines, one from iPSC; HiDEP, and the other from CD34+ umbilical cord cells; 
HUDEP (Kurita et al., 2013). The HiDEP (human iPSC cell-derived erythroid 
progenitor) cells were produced by first transducing human iPSC with the 
TAL1 erythroid differentiation gene; this stage proved essential in order to 
produce cells which could be differentiated into haematopoietic cells (Kurita 
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et al., 2013). Cells were induced to differentiate into haematopoietic stem 
cells using erythropoietin (Grover et al., 2014), then lentivirally transduced 
with a tetracycline-inducible human papilloma virus 16 (HPV)-E6/E7 
expression system, and cultured for around 100 days on OP9 feeder cells 
with stem cell factor, erythropoietin, dexamethasone and doxycycline. The 
E6 and E7 proteins have an oncogenic function by inhibiting p53 and 
retinoblastoma tumour suppressors thus promoting immortalization (Münger 
and Howley, 2002).  To produce the HUDEP (human umbilical cord blood -
derived erythroid progenitor) line, human umbilical cord CD34+ blood cells 
were transduced with the same tetracycline-inducible HPV-E6/E7 expression 
system (Kurita et al., 2013). After maturing the immortalized erythroid 
precursors in a similar way to that described for the EJ cells in section 2.3, 
both HiDEP and HUDEP cells produced functional haemoglobin, with the 
HUDEP-2 line producing both  and  globin compared to the  globin of the 
HiDEP cells. However, enucleation levels were very low (Kurita et al., 2013). 
Of note, the HUDEP cells have been karyotyped and have a highly abnormal 
chromosomal complement with trisomy 6, 8, 19 and 21 (Vinjamur and Bauer, 
2018). One of the HUDEP lines, HUDEP-2, has been genetically 
manipulated using CRISPR/cas9 techniques in a number of studies, mainly 
focusing on upregulating  globin as a possible therapy for 
haemoglobinopathies such as Thalassemia (Antoniani et al., 2018, Vinjamur 
and Bauer, 2018, Chung et al., 2019). 
 
The Bristol Erythroid Line-Adult (BEL-A) cells were created from adult bone 
marrow CD34+ cells using a tetracycline-inducible HPV-E6/E7 expression 
system similar to that of the HUDEP cells (Trakarnsanga et al., 2017). Unlike 
the HUDEP cells, however the enucleation of BEL-A cells is reportedly up to 
30% (Trakarnsanga et al., 2017). Cell surface receptor patterns are similar to 
those of cRBC and the haemoglobin produced was predominantly adult HbA. 
The deformability of enucleated BEL-A cells was comparable to that of 
normal erythrocytes and had similar survival rates in vivo when injected into 
immunodeficient mice (Trakarnsanga et al., 2017). Trakarnsanga and 
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colleagues showed significant knockdown of RhAG using shRNA methods, 
and a subsequent study has used CRISPR technology to produce a cell line 
with multiple receptor knockouts including ABO, Rhesus, Kell, Duffy and 
Glycophorin B (Hawksworth et al., 2018). 
 
5.2.2 The Harvard EJ cells 
 
As the BEL-A cells are not yet available outside the developing institution, 
other groups have generated their own, unpublished, immortalized erythroid 
lines, including the Duraisingh laboratory at Harvard University, USA. In May 
2018, I travelled to Boston to learn more about these cells, named the ‘EJ’ 
cells, after the postgraduate student who developed them, Dr Erik James 
Scully. The following information regarding the EJ cells is from personal 
communication with Professor Duraisingh, Dr Erik Scully, Dr Estela Shabani, 
Dr Becca Lee and others in the Duraisingh laboratory. The EJ cells were 
created by harvesting peripheral blood mononuclear cells from the blood 
samples of an anonymised patient with haemochromatosis. All cells were 
then transduced with the same HPV16 E6/E7 expression system used to 
generate the BEL-A and HUDEP lines, and cultured for around 60 days using 
erythropoietin to select for erythroid cells (Grover et al., 2014). Cells were 
selected by limiting dilution and cloned to form the EJ line. EJ cells are of 
blood group O and produce normal adult haemoglobin. In terms of 
morphology and receptor expression, EJ cells are approximately equivalent 
to day 10 of cRBC culture. Enucleation levels are not as high as reported for 
the BEL-A cells, ranging from 1-15%. The Duraisingh laboratory has 
successfully generated multiple different knockout lines using CRISPR/Cas 9 
genome editing and the wildtype EJ cells used in this thesis have all been 
edited to express Cas9 when selected with Blasticidin (further details in the 
methods below). A comparison of the different immortalized erythroid lines is 
showed in Table 5-1.  Of note, I have not considered here the immortalized 
erythroid lines generated from human embryonic stem cells (Ma et al., 2008) 
or leukaemic cells (Okuno et al., 1990). 
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Table 5-1 Comparison of immortalised erythroid lines. Data taken from (Kurita et al., 2013, 
















Human iPSC  Transduced with 
TAL1 gene then 
Tet-inducible 
HPV 16 E6/E7 
expression 
system 











HPV 16 E6/E7 
expression 
system 








HPV 16 E6/E7 
expression 
system 













HPV 16 E6/E7 
expression 
system 
and  1-15% 
PBMC= peripheral blood mononuclear cells, Tet= Tetracycline 
 
 
5.2.3 CRISPR/Cas9 genome editing 
 
The Duraisingh laboratory had already made a number of knockout EJ cells 
using CRISPR/Cas9 genome editing, including knockouts for CR1, Band 3 
and Glycophorin A. The CRISPR/Cas 9 method differs from RNA 
interference described in section 4.2.2.3 in that it creates a knockout at the 
DNA level, rather than a knockdown by affecting mRNA (Jinek et al., 2012, 
Wiedenheft et al., 2012, Ran et al., 2013).  Clustered regularly interspaced 
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short palindromic repeats (CRISPR) and CRISPR associated genes (Cas) 
are part of the bacterial adaptive defence system against viruses and other 
foreign invaders (Jinek et al., 2012). The bacterium integrates foreign DNA 
into its genome in between the repeats which can then be transcribed as 
CRISPR-derived RNA (crRNA). The crRNA complexes with Cas 
endonucleases, which are capable of cutting double stranded DNA, and 
patrols the intracellular space seeking out and destroying DNA/RNA 
matching the CRISPR guide sequence (Wiedenheft et al., 2012). This 
system can be utilized for genome editing by designing specific, single guide 
RNA (sgRNA), consisting of 20 nucleotides targeting the DNA of interest. 
The sequence must be followed by a protospacer adjacent motif (PAM) 
sequence; for the S. pyogenes system used here the PAM is 5’NGG (Jinek 
et al., 2012, Ran et al., 2013). The Cas endonuclease will cause a double 
stranded DNA break approximately 3 base pairs ahead of the PAM. This 
break can be repaired through either non-homologous end joining (NHEJ) or 
homology directed repair (HDR) (Ran et al., 2013). NHEJ tends to introduce 
errors during the repair which can introduce a stop codon, leading to gene 
knockout. HDR, on the other hand, uses a specific template and can be 
manipulated to introduce specific modifications (Ran et al., 2013). In this 
way, complete knockout/in of a specific gene of interest can be made at the 




Figure 5-1 CRISPR/Cas9 genome editing. The green ‘X’ represents the double stranded break point.  
PAM= protospacer adjacent motif, DSB= double stranded break, NHEJ= non-homologous end joining, 
HDR= homology directed repair. Based on (Ran et al., 2013) 
 
 
5.2.4 Which knockouts are of particular interest? 
 
Having identified a potentially suitable cell line, and the technology to 
genetically manipulate it, the next task was to determine which knockouts 
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were of particular interest to test with rosetting parasites. Of the currently 
proposed rosetting receptors, heparan sulfate was no longer felt to be 
relevant given the finding in Chapter 3 that HS does not appear to be 
expressed on mature erythrocytes. Complement receptor 1 is relevant for 
some parasite lines, namely R29 (Rowe et al., 1997), and testing this 
receptor further with knockout erythrocytes would be useful. Glycophorin C 
has been investigated in a very limited fashion using knockdown cRBC and 
testing a knockout in a wider range of parasites could help confirm whether 
the findings of Lee et al. (2014) and Niang et al. (2014) can be replicated 
using different strains.  
 
However, given the results of my Fab rosette disruption experiments (section 
4.6.6.2), the key receptor to study was Band 3 and specifically the Wrightb 
antigen. The Wrightb antigen is encoded on the Band 3 gene, SLC4A1, on 
Chromosome 17q21-22, and results from a single nucleotide polymorphism 
at nucleotide 1972 (A>G) leading to Glutamic acid at residue 658 (Bruce et 
al., 1995). Individuals expressing the Wrighta antigen (with Lysine at residue 
658), or those heterozygous for Wright(a+b+) are very rare (Bruce et al., 1995). 
Importantly, the Wrightb antigen, but not Wrighta, is dependent on an 
interaction with  Glycophorin A (GYPA) for proper expression and function 
(Bruce et al., 1994, Bruce et al., 2004). The precise nature of this interaction 
is not fully understood, however it likely involves residues 61-70 of GYPA 
(Vengelen-Tyler et al., 1981, Ridgwell et al., 1984, Bruce et al., 1995, Huang 
et al., 1996). Evidence for this comes from Dantu and Miltenberger Class V 
(MiV) erythrocytes; both express GYPA/B hybrid molecules which lack these 
specific GYPA residues and do not display Wrightb, while another GYPA/B 
hybrid phenotype, Sta which does have this key GYPA amino acid sequence, 
does express Wrightb (Huang et al., 1996). Interestingly, the Dantu blood 
group was found in recent genome-wide association studies in Kenya to 
reduce the risk of severe malaria by 40% for heterozygotes and 70% for 
homozygotes (Leffler et al., 2017). There are other naturally occurring GYPA 
deficient cells (Table 5-2) which also completely lack Wrightb antigen 
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expression including the En(a-) (Issitt et al., 1976) and MkMk phenotypes 
(Huang et al., 1996). Of note, Rowe et al. (1997) had already tested MkMk 
erythrocytes and found no effect on rosetting.  
 
Table 5-2 List of naturally occurring phenotypes which show deficient Wrightb antigen expression  
 Phenotype Comments 
MkMk GYPA and 
GYPB null 
Cells apparently able to rosette (Rowe et 
al., 1997) 
Dantu Hybrid GYPA 
and GYPB 
The extracellular portion of the molecule is 
GYPB, while the cytoplasmic domain is 
GYPA (Bruce et al., 1995). Associated with 
protection from severe malaria (Leffler et 
al., 2017) 
En(a-) GYPA null Wright (a-b-) (Issitt et al., 1976, Huang et 
al., 1996) 
MiV Hybrid GYPA 
and GYPB 
Extracellular portion is a hybrid of both 
GYPA and GYPB amino acid sequences. 
(Bruce et al., 1995). Very rare.  
Wright (a-b-) (Vengelen-Tyler et al., 1981) 
Band 3 null Band 3 null but 
do express 
GYPA 
Generally not compatible with life. Few 
reported surviving cases (Ribeiro et al., 
2000, Perrotta et al., 2005, Toye et al., 
2008) 
 
While people with a GYPA null phenotype appear to suffer no major adverse 
clinical consequences (unlike Band 3 null phenotypes), there is evidence to 
suggest GYPA does have a role in Band 3 function (Bruce et al., 2004). 
Bruce et al. (2004) have shown that anion transport is lower in MkMk and MiV 
cells and trafficking of Band 3 to the cell surface is also reduced in the 
absence of GYPA (Young et al., 2000). A recently published computational 
analysis suggests that GYPA promotes clustering of Band 3 in the 
erythrocytes membrane (Figure 5-2) (Kalli and Reithmeier, 2018). 
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Conversely, the complete lack of Band 3 is usually fatal (Ribeiro et al., 2000, 
Perrotta et al., 2005, Toye et al., 2008). 
 
 
Figure 5-2 A computerized simulation model of the interaction between GYPA and Band 3, taken 
directly from (Kalli and Reithmeier, 2018). Band 3 monomers are shown in blue and red, while the 
GYPA is in green. The yellow spheres represent the GYPA Arg61 residue which is thought  to be key 
for the interaction and the Band 3 Glu658 residue is shown in orange.  
 
Therefore, both Band 3 and GYPA knockout cells will lack proper expression 
of the Wrightb antigen. Individually, it is not possible to dissect whether any 
change in rosetting in these cells is due to the lack of the Band 3 or GYPA, or 
the Wrightb antigen. However a comparison of the rosetting abilities of these 
cells could help clarify the essential rosetting receptor further. Both 
knockouts, along with a CR1 Knockout line, had already been created by the 
Duraisingh laboratory and were available for testing, however a GYPC 
knockout had not yet been generated.  
 
5.3 Hypothesis and aims 
 
Based on the results of the rosette disruption assays shown in Chapter 4, I 
hypothesised that the Wrightb antigen is a key, strain-transcending host 
rosetting receptor for P. falciparum. The aim of the current chapter is to 
confirm this hypothesis using knockout erythroid cells generated from the EJ 
immortalized erythroid cell line.  
 
Firstly, I intended to culture the EJ cells for the first-time outside the 
developing laboratory in Harvard, then characterise the wildtype and 
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knockout EJ cells in terms of their morphology and cell surface receptor 
expression. Following this, I aimed to test the rosetting ability of both wildtype 
and knockout matured EJ cells to determine which receptors are essential for 




Details of the culture methods for maintenance and differentiation of EJ cells 
are included in section 2.3. 
 
5.4.1 Characterisation of undifferentiated and mature EJ cells 
 
EJ cells were investigated for morphology and cell surface receptor 
expression in much the same way as cRBCs described in section 4.4. 
Modifications to the techniques are described below. 
 
5.4.1.1 Morphology by cytospin  
 
Cytospin slides were prepared in an identical way to that described in section 
4.4.2, however instead of straightforward staining with Giemsa, slides were 
first stained for 3 minutes with 10% May-Grünwald stain (VWR chemicals, 
10047018, made up with dH2O) rinsed in water for one minute, then stained 
with 10% Giemsa (filtered and made up with Giemsa buffer) for 15 minutes.  
 
5.4.1.2 Flow cytometry for cell surface receptor expression 
 
Preparation of cells for flow cytometry was identical to that described in 
section 4.4.3, including Heparinase III pre-treatment when looking for the HS 
stub molecules. However, the list of receptors investigated was curated to 
those of particular interest and a number of primary antibodies to different 
parts of the Band 3 antigen were included. The Band 3 antibodies used are 
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included in Table 5-3. Initially, BRIC 6 and BRIC 14 were of particular interest 
as BRIC 6 fails to react with erythrocytes with the South Asian ovalocytosis 
mutation, and BRIC 14 is specific for the Wrightb antigen. However other 
antibodies directed against other Band 3 epitopes were also used in later 
experiments. All were purchased from the International Blood Group 
Reference Laboratory in Bristol, UK, and were used at 14µg/ml. Isotype 
controls for the IgG1 antibodies were as described in Table 4-3, for BRIC 6 
an IgG3 isotype control was used (mouse IgG3k, clone MG3-35, Abcam, 
ab18392) and for BRIC14, a mouse IgG2a isotype control was used (mouse 
IgG2a, Clone MOPC-173, Biolegend, 400202). 
 
Table 5-3 List of Band 3 antibodies used in flow cytometry experiments on EJ cells, including their 






BRIC 6 9439PA Mouse IgG3 Probably extracellular 






(Pasvol et al., 
1989). Fails to 
react with SA 
ovalocytosis 
CD233 (Groves 
et al., 1983). 
BRIC 14 9413PA Mouse IgG2a, Wrightb, aa sequence 
at residue 658 (GLU) 
of Band 3, on 4th 
extracellular loop 
connecting TM 
domains 7 and 8 











9468PA Mouse IgG1 Probably extracellular 
loop between aa 545-
567 
 
BRIC 71 9472PA Mouse IgG1 3rd extracellular loop 
presumed to be 
different to others 
 
BRAC 17 9451PA Rat IgG2b, Probably extracellular 
loop between aa 545-
567 
Not used in this 
thesis 
IBGRL = International Blood Group Reference Laboratory 
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5.4.2 Rosetting assays with undifferentiated and mature wildtype EJ 
cells 
 
Rosetting assays with EJ cells were carried out as described in section 2.6.3. 
 
Pilot tests using ITvar60 and 11019 were conducted while visiting the 
Duraisingh lab in Harvard University and involved testing undifferentiated and 
matured EJ cells. As ethidium bromide was not available, Vybrant® 
DyeCycleTM Violet stain (Thermo Scientific, V35003) was used to stain 
parasites by centrifuging the required packed cell volume of parasite culture, 
resuspending in 10ml of incomplete RPMI and adding 1µl of the dye (to give 
1:10,000 dilution) followed by a 30 minute incubation. The parasites were 
then washed and MACS purified for use in the rosetting assay. For these 
pilot experiments, the EJ cells were stained with Vybrant® DyeCycleTM Green 
(Thermo Scientific, V35004) in the same manner. Otherwise, the methods 
were as previously described in section 2.6.3. 
 
On my return to Edinburgh, these experiments were repeated for matured EJ 
cells with both the lines previously tested and for R29, 9605, HB3 and 
TM284. Parasites were stained with ethidium bromide and EJ cells with 
CellTraceTM as detailed in section 2.6.3. Again, for practical reasons, the 
‘control’ mature erythrocytes were not matched to the original donor from 
whom the EJ cells were derived.  
 
5.4.3 Lentiviral transduction and CRISPR/Cas9 gene editing of EJ cells 
to generate knockout cells 
 
The Duraisingh laboratory in Harvard had already generated a number of 
knockout EJ cell lines, including GYPA, CR1 and Band 3, however these had 
not yet been characterised by flow cytometry. While I was visiting, I worked 
under the supervision of Dr Becca Lee to produce a GYPC knockout line. 
This line and the GYPA, CR1 and Band 3 knockouts were shipped to 
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Edinburgh on dry ice in late 2018. The methods used to generate the GYPC 
knockout line are detailed below.  
 
The LentiGuide-Puro two vector system derived from Streptococcus 
pyogenes was used (Figure 5-3) (Sanjana et al., 2014). This is a two-stage 
approach in which cells are first transduced with a lentiCas9-Blast and 
selected using Blasticidin which integrates Cas9 into the cell line (GeCKO 
lentiviral CRISPR toolbox (Sanjana et al., 2014, Shalem et al., 2014). This 
was done prior to my arrival in the Duraisingh lab.  
 
 
Figure 5-3 The two stage LentiGuide-Puro two vector system. Figure taken from (Sanjana et al., 2014). 
psi+= Psi packaging signal, RRE= Rev response element, cPPT= central polypurine tract, EFS= 
elongation factor 1 short promotor, Flag= Flag octopeptide tag, P2A= 2A self-cleaving peptide, Puro= 
puromycin selection marker, Blast= Blastocidin selection marker, WRPE= post-transcriptional 
regulatory element, EF1a= elongation factor 1a promotor. 
 
The next stage (detailed below and Figure 5-4) is the introduction of a 
LentiGuide-Puro vector containing the guide RNA of interest, which is then 





Figure 5-4 Schematic showing the production of KO EJ cells using the lentiGuide-Puro two vector 
system. pLKO= the CRISPR sgRNA plasmid designed to knockout the gene of interest 
 
5.4.3.1 Production of lentiviral particles 
 
The protocol for the production of lentiviral stocks from CRISPR plasmids 
was taken from The RNAi Consortium (TRC) laboratory protocols at the 
Broad institute (available from 
https://portals.broadinstitute.org/gpp/public/resources/protocols), with 
modifications by Dr Estela Shabani of the Duraisingh laboratory.  
 
Packaging 293T cells were seeded at 2x106 cells per 6cm Petri dish in 6 ml 
of seeding media (Table 5-4) giving a density of 1x105 cells/cm2 and 
incubated for 24 hours at 37oC in 5% CO2. After 24 hours the cells were 
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Table 5-4 Media for 293T packaging cells 















30% HI FBS 1% v/v Pen/Strep, 
Mediatech, 30-002-CI 
DMEM= Dulbecco’s Modification of Eagle’s Medium, Pen/strep= Penicillin/Streptomycin, FBS= fetal 
bovine serum, HI= heat inactivated 
 
The packaging (pCMV-R8.74psPAX2) and envelope plasmids (VSV-
G/pMD2.G ), required to encode the viral structural proteins and enzymes, 
had previously been obtained from the Broad institute and prepared by Dr 
Estela Shabani. The pLKO vector plasmid containing the GYPC targeted 
sgRNA (sequence AATGGTGGTAGTATGCATTG), was designed and 
synthesized by the Broad institute and transformed into Stbl3 bacteria which 
was cultured overnight from frozen plates. Plasmid DNA was isolated using 
the QIAprep® Spin Miniprep Kit (Qiagen) according to the manufacturer’s 
instructions; the bacterial culture was lysed, centrifuged and the supernatant 
passed through the QIAprep 2.0 spin column binding the plasmid DNA. The 
columns were then washed and eluted to obtain the plasmid DNA.  
 
The transfection mixture was made by first diluting 6µl of TransIT-LT1 
transfection reagent (Mirus Bio, MIR 2300/5/6) with 84µl of OPTI-MEMTM 
serum-free media (Invitrogen, 31985-070) dropwise with gentle mixing. This 
was incubated for 5 minutes at room temperature then added to the three 
plasmid mix (900ng of packaging plasmid, 100ng of envelope plasmid, and 
1µg of pLKO vector per 6cm petri dish), again dropwise with gentle swirling 
and finally mixing by inversion 5-7 times. The mixture was incubated at room 
temperature for 30 minutes then transferred to the 293T packaging cells. The 
cells were incubated for 18 hours at 37oC in 5% CO2, then the media 
changed to viral harvest media (Table 5-4) and the cells incubated for a 
further 24 hours. After this, the media containing the lentivirus was collected 
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and centrifuged for 5 minutes to pellet any remaining 293T cells. The 
resulting supernatant was stored at -80oC. 
 
5.4.3.2 Lentiviral transduction of Cas9 EJ cells 
 
Undifferentiated EJ cells with integrated Cas9 were transduced with the 
lentiviral particles prepared as above using a similar spinoculation method to 
that described in section 4.4.7 for cRBC. One hundred µl per well of PBS/1% 
BSA was pipetted into a 96-well plate and left at room temperature for 20 
minutes. Sufficient volume of undifferentiated EJ cell culture to give 5x104 
cells per transduction was centrifuged at 200g for 12-15 minutes and 
resuspended in pIMDM without serum (Table 2-4) at approximately 5x105 
cells/ml. The PBS/1% BSA block was removed from the 96 well plate and 
100µl of the resuspended cells pipetted per well (5x104 cells/well). A further 
20µl of pIMDM was then added along with 80µl of the lentiviral mixture 
(estimated to give a MOI of 0.5) and 8µg of polybrene (Santa Cruz 
Biotechnology, sc-134220, diluted to 1mg/ml with PBS). The plate was then 
centrifuged for two hours at 1000g. After centrifugation, the contents of each 
well were transferred to a 24 well plate to which was added 2ml of complete 
EJ media with additives, excluding puromycin (Table 2-5). After 24 hours, 
2µg/ml of Puromycin was added and from day 3 after transduction, the usual 
EJ maintenance protocol was followed with the addition of Puromycin at each 
media change.  
 
5.4.3.3 Post transduction  
 
After transduction, the EJ cells were maintained with Puromycin selection for 
2- 4 weeks then cloned by limiting dilution. As my visit to the Harvard 
laboratory was for 4 weeks only, this step was carried out by Dr Becca Lee. 
Clones were then Sanger sequenced by the Duraisingh laboratory. The 
selected GYPC KO line was shipped to Edinburgh on dry ice at a later date.  
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5.4.4 Characterization of knockout EJ cells 
 
Knockout EJ cells were characterised as regards their morphology and cell 
surface receptor expression as described in sections 5.4.1.1 and 5.4.1.2. 
 
5.4.5 Rosetting assays with knockout EJ cells 
 
The rosetting assays with the knockout EJ cells were conducted as 
described in section 2.6.3. Wildtype and knockout EJ cells were matured in 
parallel until day 8-10 when they were harvested for use in the rosetting 
experiments with MACS purified parasites (section 2.6.3). Each experiment 
also included a separate sample of mature peripheral erythrocytes from 
Scottish donors as a comparator and to ensure that the parasites were 
retaining their ability to rosette after MACS purification. Though the 
experiments were blinded, it should be noted that it was fairly easy to 
unintentionally determine between EJ cells and mature peripheral 
erythrocytes under the microscope as the vast majority of EJ cells still 
contained a nucleus, although it was not possible to differentiate between 
wildtype and knockout EJ cells. Wildtype and CR1 knockout EJ experiments 
were carried out separately to the wildtype, GYPA and Band 3 knockout 
experiments. For each parasite line, three independent experiments were 
carried out for each knockout line (i.e. different MACs purifications and 
different EJ samples), though some of the repeats were from the same 
maturation cycle of the EJ cells (e.g. tested on D8 and D9). Due to limited 
cell numbers and time constraints, parasite line 9605 was not tested with the 
Band 3 KO EJ cells, and the results for the Band 3 KO with parasite line 
11019 are those carried out while in the Duraisingh laboratory.  
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5.5 Results  
 
5.5.1 Expansion, differentiation and maturation of EJ cells 
 
After a variable period of recovery after thawing (ranging from 1-5 weeks), 
undifferentiated EJ cells tripled in number on average every 2-3 days, though 
day to day growth did vary. In a similar way to my cRBC and the 
HiDEP/HUDEP and BEL-A cells (Kurita et al., 2013, Trakarnsanga et al., 
2017), a significant number of cells were lost in the later stages of 
differentiation, however the cells did continue to divide and grow until around 
day 4 of the differentiation protocol. Initially, part of this cell loss was due to 
EJ cells adhering to the stromal cells and being left behind on day 7 when 
both the media and stroma were changed (see Figure 5-5), however this was 
improved by gently pipetting the EJ-containing spent media over the used 
stromal layer 2-3 times to collect adherent EJ cells before centrifugation and 












Figure 5-5 EJ cells adherent to MS-5 stroma cells after removal of the cell culture medium. Cells 
visualised using an Olympus CK2 inverted microscope and the x20 objective. Photograph taken with 
an iPhone 5 camera. 
 
As with the cRBC, the EJ cell morphology matured with differentiation (Figure 
5-6), however enucleation was very poor, around 1-3%, even when the 





Figure 5-6 Evolving morphology of EJ cells following the differentiation protocol. Wildtype EJ cells were 
prepared using cytospin and May-Grünwald staining. Cells were visualized using the x100 objective on 
an Olympus BX40 microscope and Olympus microscope camera.  
 
 
A modified differentiation protocol, without the use of supporting stromal 
cells, was also tried. This protocol is simpler and only requires media change 
on day 3 (plate at 5x105 cell/ml pIMDM with 5% serum and 3IU/ml 
erythropoietin) and day 5 (plate at 5x105 cell/ml pIMDM with 5% serum and 
0.3IU/ml erythropoietin) with harvesting of cells at day 8. While this avoided 
the need to co-culture with stromal cells, I found a significantly higher level of 
cell debris from dead and dying cells was present in the later stages of the no 
stroma cultures and cells appeared less healthy, therefore it was decided to 








Figure 5-7 A comparison of the morphology of maturing EJ cells cultured with and without stromal support. The cells shown are CR1 KO EJ cells as these were the first 
EJ available for use. Cultures without stroma had significantly more debris and increased cell death as the culture time was extended.  
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5.5.2 Cell surface expression of undifferentiated and mature EJ cells 
 
The cell surface expression of receptors of interest was investigated using 
flow cytometry. A significant amount of non-specific binding was seen as 
demonstrated in the IgG1 isotype control cells shown in Figure 5-8. Both the 
IgG/M secondary only samples and isotype controls showed high levels of 
background fluorescence, particularly the IgM secondary control. Despite 
this, specific signals could be seen above the background staining, and the 
overall receptor profile was similar to that of D8-10 cRBC cells (Figure 5-9, 
results for 3G10 have been shown in Figure 3-16). 
 
 
Figure 5-8 Undifferentiated EJ cells. Upper panels show flow cytometry plots demonstrating the FSC 
and SSC profile and gating strategies for the receptor expression profiles. Lower panels show “no 
antibody” samples (RED), IgG/M secondary antibody only (BLUE) and isotype control (ORANGE), 
demonstrating non-specific binding. IgG1 controls are on the left and IgM on the right. 
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Figure 5-9 Cell surface receptor expression on undifferentiated wildtype EJ cells. RED- isotype control 
(varies by receptor), BLUE- receptor. All plots have been normalised to mode. Note higher background 
fluorescence for Wrightb antibody 
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As the cells reached the end of the maturation process, three broad 
populations emerged; intact nucleated, enucleated, and disintegrating cells 
(Figure 5-10). After excluding the large proportion of dead cells and debris, 
gating based on nuclear staining revealed a very small number of enucleated 
cells, a population of intact, mature, nucleated EJ cells, and a population of 
brightly fluorescing, false-positive cells (Figure 5-10A). This third population 
represents cells which are disintegrating but not yet dead and can be also 
seen clearly by IFA (Figure 5-10B). The disintegrating cells could also be 
defined by a lower FSC and wide-ranging SSC (Figure 5-10C), and based on 
this, the final intact/live gating strategy shown in Figure 5-10C was used. 
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Figure 5-10 Flow cytometry profile of mature (D8) EJ cells. Cells shown are of the IgG1 isotype control 
samples, therefore positive fluorescence represents non-specific binding. A Far left- gating to exclude 
dead cells and debris based on FSC and Live/Dead stain. Centre- the three populations of cells 
described in the text based on FSC and nuclear staining with Hoechst. Far right- the FSC/Alexa488 
profiles of each of the cell populations, demonstrating the false-positive Alexa488 signal of the 
disintegrating cell population. LIGHT BLUE= live, intact nucleated EJ cells (live), RED = enucleated 
cells (Enc), ORANGE = disintegrating cells (Disin). B IFA image of three intact and one disintegrating, 
false positive cell. Taken using a Yenway microscope camera with the x100 objective on a Leica DM 
LB2 florescence microscope. BLUE= Hoechst nuclear stain, GREEN= Alexa 488. C demonstrates how 
the disintegrating cells can be gated out from the start using FSC and SSC. The final gates used to 
determine receptor expression (by FSC/SSC followed by Live/dead staining) are shown in the middle 
and left plots of C.  
 
The receptor profile based on gating for intact, live mature wildtype EJ cells 
is shown in Figure 5-11, the main difference from the undifferentiated cells 
being an increase in Wrightb expression and loss of HS. CR1 expression 
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remained very low, as seen with the cRBC (section 4.6.2); again, this could 
be due to low CR1 phenotype in the original donor, or a reflection of the 
immature nature of the EJ cells. 
 
 
Figure 5-11 Receptor profile of mature EJ cells (D8/9 of culture) by flow cytometry. RED= isotype 




5.5.3 Differentiated EJ cells are able to rosette with P. falciparum 
infected erythrocytes 
 
Mature wildtype EJ cells were capable of forming rosettes with the six tested 
parasite lines, however immature EJ cells were not. Examples of rosettes 
with ITvar60 and 11019 for mature and undifferentiated EJ cells are shown in 
Figure 5-12. The rosette frequency of mature EJ cells was comparable to 
that of unmatched peripheral erythrocytes (Figure 5-18, Figure 5-19,  
Figure 5-20).  
 
Figure 5-12 Mature EJ cells are able to form rosettes. Example images of rosette formation with 
mature, but not immature EJ cells with the parasite lines ITvar60 and 11019. EJ cells are stained 
green, infected cells are blue and unstained cells are peripheral erythrocytes. The three larger images 
were taken using a photometric evolve camera and the x60 objective on the Zeiss Imager fluorescent 
microscope at Harvard. The inset image for 11019 was taken using with x100 objective using a 
Yenway microscope camera on a Leica DM LB2 florescent microscope. In this image, the parasites are 
stained orange with ethidium bromide.  
 
5.5.4 Morphology and receptor expression of knockout EJ cells  
 
The morphology of the knockout EJ cells matured in a similar way to the 
wildtype cells (Figure 5-13). Some differences were noted including a more 
irregular outline and increase vacuoles within the cytoplasm seen in the Band 










Immature EJ cells Matured EJ cells
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3 KO cells. This is unsurprising as Band 3 has an important structural role 




Figure 5-13 Giemsa/May Grunwald staining of maturing Wildtype and KO EJ cells. Wildtype, CR1 and 
Band 3 KO images were taken using the x100 objective on an Olympus BX40 microscope and 
Olympus microscope camera.  GYPA KO and GYPC KO images were taken using the x100 objective 
on an Olympus BX45 light microscope and iPhone 5 camera. The GYPC cells have not yet been 
matured (see below). 
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5.5.4.1  GYPC KO EJ cells 
 
The GYPC KO cells generated as described in the methods were tested for 
receptor expression in the undifferentiated state. Sanger sequencing 
conducted by the Duraisingh lab had indicated that a stop codon had been 
introduced into the GYPC gene suggesting that these cells were genetically 
GYPC knockouts (Dr Becca Lee, personal communication). However, on 
thawing in Edinburgh and prior to selection, the EJ cells were found to 
express GYPC on the cell surface by flow cytometry (Figure 5-14). After 
selection with Puromycin, GYPC expression did reduce further, but did not 
disappear completely suggesting that these cells may be heterozygous for 
GYPC expression, rather than a complete knockout. For this reason, along 
with the minimal rosette disrupting effect of the GYPC Fab shown in section 




Figure 5-14 GYPC expression on immature selected and unselected GYPC and CR1 KO cells. RED- 
IgG isotype control primary antibody, ORANGE- puromycin selected GYPC KO cells with anti-GYPC, 
GREEN- unselected GYPC KO cells with anti-GYPC, BLUE- CR1 KO with anti-GYPC (WT cells were 
unavailable at this point). Gates are as described in Figure 5-8. 
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5.5.4.2 CR1 KO EJ cells 
 
The CR1 KO EJ cell receptor profile was very similar to that of the wildtype 
EJ cells, which expressed very little CR1 even in an unmodified state.  By 
flow cytometry and IFA, no obvious difference could be seen in CR1 









5.5.4.3 GYPA and Band 3 KO EJ cells 
 
In contrast to the GYPC KO EJ cells, both the GYPA KO and Band 3 KO did 
not appear to express any GYPA/Band 3 respectively when tested by flow 
cytometry (Figure 5-16).  As expected, the Band 3 KO cells also lacked the 
Wrightb antigen, however in the GYPA KO, some binding of Wrightb antibody 
did occur, though it was reduced compared to wildtype cells. The epitope for 
the Wrightb antibody used is thought to be on the Band 3 portion of the 
Wrightb antigen, and as the GYPA KO do express Band 3, this binding is to 
be expected. However, as discussed in the introduction, GYPA is required for 
the proper formation of the Wright antigen (Bruce et al., 1995), therefore it is 
unlikely that the Wrightb detected on the GYPA KO cells is of normal 
structure or function (Bruce et al., 1995). On IFA, Wrightb binding was 
noticeably reduced compared to wildtype with an altered pattern (Figure 
5-17). This is in keeping with the evidence that that GYPA has a role in 
trafficking Band 3 to the cell surface and promoting clustering of Band 3 
molecules (Kalli and Reithmeier, 2018). In my experiments Band 3 
expression on the GYPA KO cells appeared slightly reduced to the wild type 
cells on flow cytometry, though the differences were not obvious on IFA 
(Figure 5-16 and Figure 5-17). 
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Figure 5-16 Band 3, Wightb and GYPA expression on KO EJ cells. Three different Band 3 antibodies were used (BRIC 200, BRIC 71 and BRIC 6). RED- isotope control, 




Figure 5-17 IFA of Wrightb (A) and Band 3 (B) expression on WT and GYPA KO EJ cells. BLUE- 
Hoechst nuclear stain, GREEN- Alexa488. Images were taken using the x100 objective on a Leica DM 
LB2 florescence microscope with a Yenway microscope camera. The same exposure was used for 
Hoechst and Alexa488 images for each cell type. Composite images were made using ImageJ 




5.5.5 Rosetting of CR1, GYPA and Band 3 KO EJ cells 
 
5.5.5.1 Rosetting of CR1 KO EJ cells 
 
No significant differences were seen in rosette frequency between CR1 
knockout EJ cells, wildtype EJ cells and unmatched peripheral erythrocytes, 
though there was a trend towards decreased rosetting with R29 (Figure 
5-18). This is perhaps not surprising given the already very low level of CR1 
expression on wildtype EJ cells.  
 
 
Figure 5-18 Rosetting of CR1 KO EJ cells compared to wildtype EJ cells and unmatched peripheral 
erythrocytes. Each data point represents the results of one independent, blinded experiment (the mean 
of two technical replicates as described in the methods section 2.6). p-value <0.05 was considered 
significant. Error bars show the mean and standard deviation of the three results. 
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5.5.5.2 Rosetting of GYPA and Band 3 KO EJ cells 
 
The rosetting of both GYPA (Figure 5-19) and Band 3 KO EJ cells (Figure 
5-20) was reduced for all strains tested, though for the Band 3 KO with 
TM284 this did not reach significance, and 9605 was not tested with Band 3 
KO cells. Of note, unlike the cRBC, no difference was seen in the rosetting 
ability of wildtype EJ cells and peripheral erythrocytes. Also of interest, no 
significant differences were seen in the (reduced) rosetting frequencies 
between GYPA and Band 3 KO cells (Figure 5-21), indicating that neither the 
presence of Band 3 in the GYPA KO, nor GYPA in the Band 3 KO, are 
capable of rescuing the rosetting phenotype. This suggests that it is the 
Wrightb antigen, absent in both KO cells, that is key for rosetting. However, it 
is important to note that Band 3 structure and function is not entirely normal 
in the absent of GYPA and the absence of Band 3 will have a significant 
impact on the structure and function of the erythrocyte(Bruce et al., 1994, 




Figure 5-19 Rosette frequency is significantly reduced with GYPA KO EJ cells. Each data point 
represents the results of one of three independent, blinded experiments (the mean of two technical 
replicates as described in the methods section 2.6). p-value <0.05 was considered significant and were 
calculated using an ordinary one-way ANOVA with Tukey’s multiple comparisons test. Error bars show 





Figure 5-20 Rosette frequency is reduced with Band 3 KO EJ cells. Each data point represents the 
results of one of three independent, blinded experiments (the mean of two technical replicates as 
described in the methods section 2.6). The experiments for 11019 were carried out in Boston and did 
not include mature peripheral erythrocytes. p-value <0.05 was considered significant and were 
calculated using an ordinary one-way ANOVA with Tukey’s multiple comparisons test, with the 
exception of the Harvard data for 11019 which was analysed using an unpaired t-test. Error bars show 




Figure 5-21 Combined GYPA and Band 3 KO EJ cells. Data shown are the same as those in Figure 5-19 and Figure 5-20, the experiments were carried out in parallel 
(except for 11019 as described), using the same WT EJ cells and peripheral erythrocytes therefore are directly comparable. Each data point represents the results of 
one of three independent, blinded experiments as before.  Data were collectively re-analysed using an ordinary one-way ANOVA with Tukey’s multiple comparisons test, 




The data presented here support the hypothesis that the Wrightb antigen is a 
key, strain-transcending host rosetting receptor for P. falciparum, however 
there are important limitations regarding the use of GYPA/BAND 3 KO cells 
which are further discussed below.  In keeping with the rosette disruption 
demonstrated by anti-Wrightb antibodies, mature EJ cells lacking Wrightb had 
significantly reduced rosetting frequencies compared to wildtype EJ cells, 
suggesting that Wrightb could be a valuable anti-rosetting therapeutic target. 
In addition, the EJ cells have proved to be an extremely useful tool with great 
future potential. 
 
5.6.1 Further investigation into Band 3/Wrightb as a rosetting receptor 
 
While these data are encouraging, there are many questions that remain to 
be answered. In particular, are the effects of the Wrightb antibodies also seen 
in parasites grown in blood group A, or do the stronger and larger rosettes 
seen in some strains when cultured in their preferred blood group ameliorate 
the effect? A useful therapy would be required to work in all blood groups, 
particularly as the non-O groups are particularly associated with severe 
malaria (Rowe et al., 2007, Tekeste and Petros, 2010, Rout et al., 2012, 
Network, 2014). This phenomenon may also be relevant for the differing 
results seen in the existing literature in which Rowe et al. (Rowe et al., 1997) 
tested MkMK cells for rosetting as part of a rare erythrocyte panel and found 
that these cells were capable of forming rosettes, in contrast to that of my 
GYPA knockouts. The blood group of the tested cells is not certain (A. Rowe, 
personal communication) and it is possible that if they were of a non-O blood 
group (unlike my EJ cells), the blood group antigens could have 




As yet, I have not investigated the parasite side of the rosetting equation and 
it is not known which parasite-derived ligands bind to Band 3/Wrightb. Band 
3, along with GYPA and Wrightb, can be expressed in Xenopus oocytes and 
K562 cells (Groves and Tanner, 1992, Groves et al., 1993, Beckmann et al., 
1998, Young et al., 2000) Therefore these cells could be used in binding 
assays with P. falciparum infected erythrocytes, to assess whether Band 
3/Wrightb is sufficient for rosetting. The specific parasite ligands could be 
investigated further by mildly trypsinising the infected erythrocytes to remove 
PfEMP1, and monitoring the effect on binding (Kyes et al., 1999). If infected 
erythrocytes are still able to bind, this suggests trypsin-resistant parasite 
ligands, such as the RIFINs are the key binding molecule. If, however, 
PfEMP1 was found to be the key ligand, recombinant PfEMP1 domains could 
be used to determine the precise binding domains, bearing in mind the 
caveats to using recombinant PfEMP1 discussed throughout this thesis.  
 
Given the overall aim of rosetting research is to reduce the mortality and 
morbidity of severe malaria, thought must also be given to translating these 
findings into a potential anti-rosetting therapy, and the prospect of this will be 
further discussed in Chapter 6. 
 
5.6.2 Limitations of the EJ rosetting model  
 
Despite these promising findings, it must be acknowledged that the EJ cells 
are not a perfect proxy for mature peripheral erythrocytes. EJ cells are larger 
and, in the vast majority of cases, nucleated which has consequences for 
deformability (Guzniczak et al., 2017). Though Trakarnsanga et al. report that 
the BEL-A cells had similar deformability to peripheral erythrocytes, they only 
tested filtered, enucleated BEL-A cells (Trakarnsanga et al., 2017), while 
most of the cells I used in my rosetting assays still contained a nucleus. The 
difference in rosette morphology can be seen in Figure 5-22 which shows an 
EJ rosette with a 11019 parasite-infected erythrocyte, compared to a normal 
rosette. EJ cells do not appear to adopt the ‘plastered on’ appearance of 
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normal erythrocytes onto the infected cell and instead adhere over a smaller 
cell surface area.  
 
 
Figure 5-22 Comparison of rosette morphology for mature peripheral erythrocytes and EJ cells. In both 
cases, there is a central, infected erythrocyte, surrounded by three, uninfected cells. Images were 
taken using a Leica DM LB2 florescence microscope and have been cropped from a larger image 
taken using the x20 objective. Images have been changed from colour to monochrome using Image J 
software.  
 
The other major caveat which applies to the EJ cells specifically is that even 
the wildtype EJ cells do not come from a ‘normal’ donor, as the EJs were 
immortalised from the PBMC of a patient with haemochromatosis. While 
there is no obvious reason to suspect that this would affect the results, 
particularly as the knockout cells are compared to wildtype EJ cells from the 
same source, it would be useful to confirm these findings with the BEL-A 
cells which derive from a healthy original donor, when they become 
available.  
 
While the knockout EJ cells have been profiled for the receptors of particular 
interest in terms of rosetting, I cannot exclude the possibility of off-target 
effects arising from the CRISPR/Cas9 gene editing. In addition, pure Wrightb 
knockout cells were not available, and the conclusion that Wrightb is the key 
molecule has been inferred from cells which were abnormal in other respects 
(e.g. lacking GYPA and Band 3). However, the similarities in rosetting 
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frequency between the GYPA and Band 3 knockouts do suggest that the 
common factor, i.e. lack of Wrightb was crucial. 
 
Aside from the potential off-target effects of gene editing, the removal of 
either Band 3 or GYPA has significant structural consequences for the 
erythrocyte. The loss of Band 3 leads to disruption of the Band 3/Ankyrin 
macrocomplex and loss of additional proteins including protein 4.2, GYPA, 
Rh antigen, CD47, LW and GYPB (Kalli and Reithmeier, 2018). Band 3 null 
cells are spherocytotic and fragile (Toye et al., 2008), which likely accounts 
for the marked cell loss noted during the later stages of culturing. Similarly, 
GYPA null cells have altered Band 3, protein 4.1 and p55, with reduced cell 
volume (Bruce et al., 1994, Bruce et al., 2004). All of these features could, in 
theory, affect the rosetting ability of the KO cells, independent of their Wrightb 
status. Rather than wildtype EJ cells, more appropriate controls would be 
those which also had a disrupted macrocomplex but still expressed Wrightb,  
for example a RhAG KO as the Band 3 KO control or Protein 4.1 for the 
GYPA (Professor L Bruce, personal communication).  
  
I also fully acknowledge the lack of sequencing data for the knockout cells 
which could confirm the genetic, rather than just phenotypic, knockout of the 
cells. However, arguably, this is less important that the actual receptor profile 
which I have assessed through antibody binding and flow cytometry. As the 
GYPC knockout shows, an apparent genetic knockout by sequencing does 
not necessarily mean that no GYPC is expressed on the cell surface.  
 
There are other, technical, issues with the EJ cells, particularly the massive 
cell loss at the late stages of differentiation, however this may be an issue 
with many of the immortalised cell lines (see Trakarnsanga et al. 2017 
supplemental information figure 1). Culturing is also expensive, particularly 
when maintaining large cell numbers. 
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5.6.3 Generating multiple erythroid knockouts and screening for novel 
receptors 
 
Despite these limitations, the EJ cells, and other immortalised erythroid lines, 
offer a great range of opportunities for the malaria field as a whole, including 
research into host invasion and sequestration receptors. Of particular interest 
in the context of rosetting, the generation of multiple knockouts could help 
dissect the relative contribution of various rosetting candidates to better 
determine which are essential and which have a more accessory role. Such 
knockouts have been designed by the Bristol BEL-A team, though the focus 
of these cells was to create universal erythrocytes for blood transfusion 
(Hawksworth et al., 2018). Various combinations of knockouts of the known 
rosetting receptors could be tested to determine which receptors were 
necessary and/or sufficient. If a cell that lacked CR1, AB antigens, GYPA 
(and therefore Wrightb) and GYPC was capable of rosetting, this would 
suggest the existence of further, as yet undetermined, host rosetting 
receptors. The EJ cells are also potentially a tool for screening for these 
unknown rosetting receptors, in a similar manner to the invasion receptor 
screen undertaken by Egan and colleagues (Egan et al., 2015) and this will 
be discussed further in Chapter 6. 
 
To conclude, the data generated using the knockout EJ erythroid cells 
corroborates the results of the Fab experiments and both findings support the 
hypothesis that the Wrightb antigen is an important, strain-transcending host 
rosetting receptor. There is more work to be done in elucidating the parasite 
side of the rosetting equation and confirming that the same results apply in 
different ABO blood groups. However, this discovery represents an important 
new piece of the rosetting puzzle which has potential to lead to the 
development of a specific anti-rosetting therapy for use in severe malaria.  
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6. CHAPTER VI: CONCLUSIONS 
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P. falciparum malaria is a pernicious disease, affecting millions of children in 
some of the poorest countries of the world. Around 10% of children with 
malaria in Africa will develop severe disease, which has an unacceptably 
high morbidity and mortality. At present, we have no effective adjuvant 
treatments for severe disease and with the advent of increasing anti-malarial 
drug resistance, the scale of the problem is likely to worsen.  
 
The goal of my research is to better understand the pathological mechanisms 
of rosetting in severe malaria, with a view to informing the development of 
novel adjuvant therapies to reduce the mortality and morbidity of this deadly 
condition. I approached this challenging problem by first re-evaluating current 
assumptions regarding the role of the glycosaminoglycans, heparan sulfate 
and chondroitin sulfate, in rosetting. Having concluded that that neither of 
these molecules represents a specific host erythrocyte rosetting receptor, I 
then sought to overcome the limitations of existing experimental 
methodologies by establishing a new approach using immortalised knockout 
erythrocytes. During the development of these techniques, I identified a new 
potential rosetting receptor, Wrightb, and was able to confirm the importance 
of this molecule for rosetting across all strains tested, using two different 
experimental approaches; rosette disruption with anti-Wrightb antibodies and 
the use of CRISPR-Cas9 knockout erythrocytes.  
 
6.1 Translating my results to the clinic 
 
These results are tremendously exciting as they suggest that a therapy 
directed against Wrightb could possibly reduce rosetting in severe malaria 
and potentially alleviate some of the microvascular obstruction thought to 
contribute to the disease pathology. However, there are a number of 
questions to be addressed before such a therapy reaches the clinical 
research stage, and further work is required to better understand the 
mechanisms of this host-parasite interaction. These questions are 
summarised in Table 6-1. 
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Table 6-1 Questions to be addressed when considering the translation of my findings into an effective 
clinical therapy 
Clinical questions Mechanistic questions 
What are the potential pathological 
consequences of releasing 
rosettes? 
Can we demonstrate direct binding 
between Wrightb and infected 
erythrocytes? 
How would blocking Wrightb affect 
the erythrocytes? 
To which parasite ligand does 
Wrightb bind? 
At what stage of disease would the 
treatment be most effective? 
Is the same level of rosette 
disruption by anti-Wrightb seen in 
different blood groups? 
Would rosette disruption be 
sufficient for a therapeutic effect? 
Does blocking Wrightb have any 
effect on sequestration? 
Cost, availability, duration of 
treatment etc. 
Do rPfEMP1 co-localise with 
Wrightb? 
 
6.2 Clinical questions 
 
If one accepts the theory that rosetting is a causative factor in the pathology 
of severe malaria, possibly by contributing to microvascular obstruction, it 
seems logical that disrupting these rosettes would be beneficial to the 
patient. However, this assumption must be carefully considered, as it is also 
plausible that the sudden release of erythrocytes infected with mature 
parasites into the peripheral circulation may be detrimental. In particular, the 
spleen could become overwhelmed with infected erythrocytes leading to a 
splenic sequestration crisis as seen in sickle cell disease. Though this is 
perhaps less likely for a therapy which would specifically release rosettes, 
rather than causing generalised desequestration of infected cells. 
Encouragingly, Leitgeb et al. saw no such issues in their clinical trial of 
Sevuparin, despite demonstrating transient desequestration, though splenic 
size or ultrasound assessment of the spleen was not done (Saiwaew et al., 
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2017). Of note, this trial was in adults with uncomplicated malaria and 
relatively low parasitaemia (10,000-100,000/µl). Dondorp et al. (Dondorp et 
al., 2007) reported similar findings in patients with uncomplicated malaria 
using the anti-helminth drug, Levamisole, an alkaline phosphatase inhibitor 
which inhibits cytoadhesion. Patients treated with Levamisole had higher 
levels of erythrocytes infected with mature forms of the parasite in the 
periphery, again with no safety concerns. However when Levamisole was 
trialled in patients with severe malaria, no desequestration was seen (Maude 
et al., 2014), therefore the consequences of releasing rosettes in children 
with severe malaria remain unclear. Even if no adverse effects were seen, it 
is also uncertain whether simply disrupting rosettes would be sufficient to 
reverse the pathology of severe disease. However, field studies have 
demonstrated that a relatively small decrease in rosette frequency does 
impact on disease severity (Rowe et al., 1995, Rowe et al., 2007, Doumbo et 
al., 2009, Rout et al., 2012), and my results show that anti-Wrightb Fab were 
highly effective at disrupting the majority of rosettes.  
 
Perhaps more concerning is the potential effect of anti-Wrightb 
antibodies/Fab on the uninfected host erythrocytes. As whole anti-Wright 
antibodies cause significant agglutination and extravascular haemolysis 
(Squires et al., 2012), it would be necessary to use antibody fragments, 
however even Fab may have clinically important clinical consequences. Early 
work by Pasvol et al. (Pasvol et al., 1989) showed that the addition of anti-
Wrightb Fab at 50µg/ml (half the concentration used in this thesis) reduced 
the deformability of erythrocytes, though the physiological consequences of 
this are unknown and more work is required to explore this further. 
Interestingly, the anti-Wrightb Fab also significantly reduced parasite 
invasion, and, given that erythrocytes lacking Wrightb had previously been 
found to be fully susceptible to invasion (Hermentin et al., 1985), the 
mechanism was felt to relate to the decrease in cell deformability (Pasvol et 
al., 1989). It is therefore possible that an anti-Wrightb antibody, anti-rosetting 
therapy could have the additional benefit of reducing invasion. However, it is 
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also important to consider whether my rosette disruption results could be due 
to this reduced deformability mechanism. The additional evidence provided 
by the knockout EJ cells, which did not rely on the Wrightb antibody, suggest 
that this is not the case, however as discussed in section 5.6.2 there are 
important caveats to my finding as the wildtype EJ cells were not the most 
appropriate experimental controls. Therefore, there are alternative 
explanations for both the Fab and EJ KO results and it is not possible to 
definitively confirm that Wrightb is a specific host rosetting receptor. 
Nevertheless, Wrightb Fab do disrupt rosettes, just as Heparin does (albeit 
Heparin acts through a non-specific mechanism), and it these Fab are found 
to be safe, they could still represent and important and useful anti-rosetting 
therapy.  .  
 
On that note, before testing any potential anti-rosetting therapy in humans, a 
phase of animal testing must be completed. The literature regarding the use 
animal models of P. falciparum is large and much debated (Craig et al., 
2012), and as such will not be discussed in further detail here. However, 
advances in the development of humanised mouse models (Rahmig et al., 
2016, Foquet et al., 2018, Minkah et al., 2018) may address some of these 
issues and offer a useful method of testing an anti-Wrightb therapy in vivo.  
 
6.3 Mechanistic questions and future work 
 
I addressed the question of the role of Wrightb in rosetting using two different 
approaches; antibody mediated rosette disruption and the use of knockout 
cells. This allowed me to assess the therapeutic potential of using anti-
Wrightb to disrupt pre-formed rosettes and establish that Wrightb is a key host 
erythrocyte rosetting receptor. However, I have yet to demonstrate that 
Wrightb is sufficient for rosetting or determine to which parasite-derived 
ligand Wrightb binds. This latter question is particularly interesting as a recent 
study (Almukadi et al., 2019) has suggested that Plasmodium falciparum 
glutamic acid-rich protein (PfGARP) binds to Band 3 (though a different 
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epitope to Wrightb) which the authors suggest may be related to rosetting. In 
section 5.6.1 I have outlined plans to express Wrightb in alternative cell types 
and assess the binding of PfEMP1 and other parasite ligands. In addition to 
these experiments, recombinant PfGARP domains could also be used. I 
have also discussed the need to test the effect of anti-Wrightb in parasites 
cultured in blood group A, and encouragingly, preliminary experiments by 
Molly Carlier and Professor Rowe appear to show the same effect regardless 
of blood group (personal communication). 
 
Another potentially interesting avenue to explore could be the role of Band 
3/Wrightb in sequestration. Band 3/Wrightb is only expressed on erythrocytes 
and in the renal tubules, not on endothelial cells, therefore one would not 
expect to see a desequestration effect with anti-Wrightb. However, others 
have suggested that modified Band 3 may act as an adhesion molecule, not 
on the host erythrocytes, but on the infected cells (Winograd and Sherman, 
1989, Eda et al., 1999, Winograd et al., 2005). Sherman, Winograd and 
colleagues (Sherman et al., 1995, Sherman et al., 2003) propose that 
erythrocyte infection with P. falciparum induces conformational changes in 
Band 3 (Eda et al., 1999, Winograd and Sherman, 2004) which exposes an 
epitope, Pfalhesin, capable of binding to the endothelial receptors 
Thrombospondin (TSP) (Lucas and Sherman, 1998, Eda et al., 1999) and 
CD36 (Winograd et al., 2004). Binding to TSP and CD36 in cytoadhesion 
assays on plastic dishes is common in clinical isolates, but not particularly 
associated with severe disease (Heddini et al., 2001). This adhesion can be 
disrupted in vitro with antibodies or synthetic peptides of the Band 3 
sequence, HPLQKTY (found on the third extracellular loop) (Lucas and 
Sherman, 1998, Eda et al., 1999). In addition, the infusion of synthetic 
peptides based on residues 546-553 (GHPLQKTY) and 553-546 
(YTKQLPHG) causes desequestration in infected Aotus and Saimiri monkeys 
(Crandall et al., 1993). These sites are some distance from the Wrightb 
antigen, however an assessment of the ability of anti-Wrightb to interrupt 
binding to endothelial cells may be an interesting experiment to conduct. 
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6.4 A rosetting screen 
 
In addition to Wrightb, there may be other important rosetting receptors which 
have not yet been discovered. The development of immortalised erythroid 
cell lines, such as the EJ cells, will help remove many of the technical 
barriers which have hampered progress thus far, and a rosetting screen, 
similar to that of Egan et al. (Egan et al., 2015) could be a very useful 
experiment. In their quest to identify novel invasion receptors, Egan and 
colleagues transfected CD34+ cells with a pooled shRNA lentiviral library 
before selecting and differentiating the resulting knockdown cells. The 
transfected erythrocytes were then infected with GFP-expressing, 3D7  P. 
falciparum parasites or mock infected, and the shRNA between the infected 
erythrocytes (selected by GFP positivity) and mock infected cells were 
compared (Egan et al., 2015). In this way, CD55 was found to be an 
essential P. falciparum invasion factor. Such a screen for rosetting receptors 
would be more challenging, as isolating rosettes is not as simple as sorting 
by GFP expression. Flow cytometry has been used to detect multiplets as a 
surrogate measure of rosettes (Ch'ng et al., 2016), however the reliability of 
these methods and the relationship between multiplets and rosetting 
frequency has not yet been fully established. Alternatively, cells could be 
sorted by those which bind fluorescently tagged recombinant rosetting 
PfEMP1 domains. This would have to include the caveat, illustrated 
throughout this thesis, that PfEMP1 binding may not always be an accurate 
representation of binding to infected erythrocytes. Nevertheless, there is 
much potential in the idea of a rosetting screen of this kind, and we are in 
discussion with the Duraisingh laboratory on how to proceed with such an 





Many of the limitations of this work have been discussed in the relevant 
chapters. However, one overriding limitation to my findings is that all my 
experiments have been carried out using laboratory adapted parasite lines, 
some of which have been in culture for decades and may not have originated 
from Africa or from patients with severe malaria. The lines 11019 and 9605 
are more recently adapted and do come from African children with severe 
disease, but a key experiment which I have yet to carry out is testing fresh 
clinical isolates from the field. It is these such isolates which are clinically 
relevant and representative of the parasites causing severe disease in ‘real-
life’. My original plans to spend time studying such isolates in Uganda have 
been modified, mainly due to family reasons, nevertheless, I am conscious of 
the importance of establishing that my results are not simply an artefact of 
using laboratory parasites and are just as applicable to those in the field. 
 
I am also conscious that, while the EJ and cRBC have been a very useful 
tool, they are not a perfect representation of mature peripheral erythrocytes. 
In particular, the vast majority of the EJ cells remain nucleated and therefore 
can be expected to have altered physical properties in terms of size and 
deformability. Additionally, as has been demonstrated by myself and others 
(Wilson et al., 2016, Dankwa et al., 2017), the cell surface receptor 
complement of these cultured erythroid cells is not identical to that of mature 
erythrocytes. Therefore, the results of experiments using these cells must be 
interpreted with these differences in mind, and corroborating evidence using 
mature erythrocytes should also be sought.  
 
Finally, there remains another conflicting result from  the literature which I 
cannot fully explain. In section 4.2.2.1 I discussed a study by Rowe et al. 
(Rowe et al., 1997) in which multiple, rare red cell variants were tested for 
rosetting ability. One such variant, MkMk, lacks GYPA and GYPB, therefore, 
by extension presumably lacks Wrightb, however these cells were found to 
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rosette normally. Only one donor was used, and the blood group of the donor 
was not entirely clear (A. Rowe, personal communication), therefore it is 
possible (if the donor was non-O) that rosetting via the blood group A 
antigens is sufficient for rosetting, even in the absence of Wrightb.  As an 
alternative to my knockout EJ cells, a useful experiment would be to retest 
these cells, along with other rare variants, in particular those of the Dantu 
and En(a-), MiV and Wrighta phenotypes (Table 5-2). I have also not 
explored the potential involvement of the very rare Wrighta phenotype in 
rosetting. One might expect that if Wrightb is key for pathological rosetting 
then negative selection for this antigen would occur and Wrighta would be 
more common, particularly in African populations. Wrighta is extremely rare in 
Caucasian populations (Bruce et al., 1995), but comprehensive data on its 
prevalence in Africa is lacking, though the polymorphism has not been 
highlighted as a specific protective factor in large Genome Wide Association 
Studies (Leffler et al., 2017, Band et al., 2015). A useful further experiment 
would be to test and compare the rosetting abilities of various Wright antigen 
phenotypes including Wright(a+b+) and particularly Wright (a+b-).  
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6.6 Final thoughts 
 
Severe malaria is a complex phenomenon. Even after over a century of 
research the questions of why some people experience severe disease, who 
gets it and how the pathological processes develop remain, at least partly, 
unanswered. Rosetting has been associated with all types of severe malaria 
and represents a potential therapeutic target. The parasite ligands involved in 
rosetting are highly variable and as yet, the development of a strain-
transcending vaccine remains challenging (Ghumra et al., 2011, Ghumra et 
al., 2012). I have focused on the other side of the rosetting equation, in a 
quest to discover the host receptors essential for rosetting in severe P. 
falciparum malaria. Through re-evaluating the existing literature, I have 
challenged the dogma that heparan sulfate is an important rosetting receptor 
but have also identified a novel rosetting receptor which appears to be 
important across multiple strains. The next stage of my research is to delve 
deeper into the mechanisms of Wrightb mediated rosetting and explore the 
potential for an anti-Wrightb therapy. Ultimately, I want to translate my 
findings into an effective treatment which can be used to reduce the mortality 










7.1 Flow cytometry gating strategies 
 
7.1.1 Chapter 3 
 
7.1.1.1 Gating strategy for Figure 3-16 
 
 
Figure 7-1 Gating strategy for Figure 3-16 The IgG2bk isotype control labelled cells are showed and 
were gated by FSC and SCC to exclude debris. No live/dead staining was used for this experiment.  
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7.1.1.2 Gating strategy for Figure 3-17 
 
 
Figure 7-2 EJ cells gating strategy for Whole HS and HS stubs when undifferentiated and at D8. Note: 
the “Comp-APC-Cy7-A” is the Live/Dead strain, with high levels indicating dead cells.  
 
7.1.2 Chapter 4 
 
7.1.2.1 Gating strategy for Figure 4-12 
 
 
Figure 7-3 Gating strategy for day 4 CD34+ cRBC. Isotype control labelled cells are shown and gate 




7.1.2.2 Gating strategy for Figure 4-23 
 
 
Figure 7-4 Flow cytometry gates for flow plots shown in Figure 4-23, lentiviral transduction results. 
Plots shown are for control cells and are gated for intact cells by FSC and SSC (A) or FSC and 
live/dead stain (B) 
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7.2 Additional experiments 
 
7.2.1 Chapter 4 Comparison of different multiplicity of infections for 
GYPC transduction 
 
Cells were transduced as described in section 4.4.7, however three different 
multiplicities of infection (MOI) were used for both control and knockdown 
cells. The control lentiviral particles incorporate GFP expression into the cells 
while the GYPC shRNA do not. For MOI 0.5 (transducing units [TU] 5x104), 
10µl of virus was added, for MOI 1 (TU 1x105), 20µl of virus was used and for 
MOI 5 (TU 5x105), 100µl of virus was used. The corresponding volume of 
complete media was added to give a final volume of 200µl. Figure 7-5 shows 
the GYPC expression and GFP expression of control (GFP expressing) and 
knockdown cells using flow cytometry at day 18 of culture. No obvious 
benefit of a higher MOI was seen for either the GYPC knockdown or GFP 
expression.  
 
Figure 7-5 Effect of different MOI on GYPC and GFP expression. BLUE- GYPC shRNA transduced 
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